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SUMMARY
The present thesis is aimed at the characterisation of an unknown gene 
named DRAGO (DRugs Activated Gene Overexpressed), isolated in the 
Laboratory of Molecular Pharmacology at the Mario Negri Institute as a 
p53-inducible gene by differential expression analysis in cells following 
genotoxic insults. The structure of the human DRAGO has been 
molecularly characterised. The coding region contains exons 2, 3, 4, 5 
and the first 26 bases of exon 6 . The remaining bases of this exon (4 
Kb) constitute the 3’ untranslated region (3’UTR). Interestingly, the 
gene presents two large (45 -50  Kb) introns. Both the presence of 
such introns, and of the large 3 ’UTR suggest a strong gene regulation 
at transcriptional and post-transcriptional levels. This observation is 
also supported by the presence of several AU and CU rich regions, 
which are known to be involved in degradation/stability of mRNA. A 
fragment upstream the 5 ’ of the coding region of DRAGO was isolated 
and demonstrated to have promoter activity. In transfection 
experiments the promoter activity of the isolated region was two-fold 
increased by human p53. An even stronger promoter activity in 
response to p73 and its isoforms was observed. Moreover, DNp73 was 
able to induce DRAGO expression co-operating with p73 and its 
isoforms.
The presence of DNA mutations in the gene has been investigated by 
using single strand conformation polymorphism (SSCP) analysis and DNA
11
sequencing. For these studies, 12 human cancer cell lines of different 
origin and four cell sublines made resistant to anticancer drugs were 
analysed but no mutations were detected. The investigation was also 
extended to human tumor biopsies and again no mutations could be 
detected. The functional role of the DRAGO gene has been studied by 
ectopically overexpressing it in eukaryotic cells. An inhibitory effect on cell 
growth and the formation of a large number of vacuoles leading to the 
disruption of the plasmatic membrane could be observed upon its 
overexpression. The phenotypic changes induced by DRAGO 
overexpression were therefore evaluated using specific deletion mutants 
and it was demonstrated that cells can tolerate the expression of DRAGO 
mutant with deletion of a few aminoacids in the C-terminus. The 
computational analysis of the protein revealed that DRAGO protein is 
likely a transmembrane protein. The theoretical prediction was supported 
by immunofluorescence experiments using deletion mutants transiently 
expressed in cells and by the analysis of GFP (green fluorescent protein) 
-derived deletion mutants clones, showing that the fluorescence was 
localised in the membrane. DRAGO-null mice have been generated: they 
are viable and do not present any macroscopical alterations. Mouse 
embryo fibroblasts (MEF) were isolated from homozygously deleted mice. 
DRAGO - / -  MEFs were more resistant to drug treatment than wild-type 
MEF due to the inability of the cells to activate apoptosis. This newly 
isolated gene can be therefore considered as a novel potential target for 
the development of new therapeutic anticancer agents.
12
CHAPTER 1 
INTRODUCTION
1.1 Cancer and cancer genes
Cancer is a term covering a plethora of conditions characterised by 
uncontrolled cellular proliferation.
As the average age rises in many countries and consequently cancer- 
related deaths, cancer will be one of the most common causes of death in 
the 21st century. Cancer is a complex disease in which somatic cells 
evade normal restrictions to clonal expansion and autonomy. Normal 
somatic cells are, in fact, totally dependent for their proliferation upon 
extracellulary received mitogenic signals (1). The unregulated proliferation 
of transformed cells kills and invades normal tissues giving rise to a 
bewildering array of clinical outcomes. For these reasons cures for cancer 
must be as diverse as the diseases themselves making difficult to design 
effective treatments.
Although cancers are extremely diverse and heterogeneous, their 
development and progression are driven by a defined number of critical 
events whose convergence is required for cancer inception and evolution. 
These pivotal steps comprise aberrations in the regulations of a restricted 
number of key pathways that control cell proliferation and cell survival 
leading to the establishment of all tumors. Mutations have been generally 
found in genes governing growth control (2 ).
Those genes, defined “cancer-genes”, whose alterations enhance net cell 
growth, could be generally grouped into three types of genes: oncogenes, 
tumor-suppressor genes and stability genes.
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In genetic diseases, mutations in one gene can cause disease; 
conversely, in most human malignancies mutations in cancer genes 
contribute to the development of cancer since only when several genes 
are defective cancer invasion arises (3).
Under normal conditions, proto-oncogenes (oncogenes with regular 
functions) are the genes whose expression stimulates appropriate cell 
growth of somatic cells especially those required for the continued renewal 
and turnover of some tissues.
A mutation in a critical position in a proto-oncogene causes uncontrolled 
cell growth by activating persistent growth stimulatory signal transduction 
pathways even when cells are receiving no mitogenic signals. The oldest 
and best studied oncogene is c-Src (4). In normal cells, c-Src is a kinase 
involved in proliferation, maintenance of normal intercellular contacts and 
cell motility. Even though its role in tumor development and progression is 
not fully understood, it is known that whenever overactivated and 
overexpressed through mutations or stimulation by growth factors, c-src 
can induce increased proliferation, invasion and motility (5). 
Tumor-suppressor genes normally keep cell numbers down, either by 
halting the cell cycle and thereby preventing cellular division or by 
promoting programmed cell death. When these genes are rendered non­
functional through mutation, the cell becomes malignant. Among tumor 
suppressors the prototypic genes are the RB and p53 genes. At the top of 
the list is p53, being implicated in more than 50% of human cancers (6 ) 
and p53-related topics will be further discussed in this work.
15
The first tumor suppressor to be cloned was the retinoblastoma (RB) gene 
(7-10). It was identified as the gene carrying the mutations responsible for 
the onset of retinal tumors.
In familial cases of retinoblastoma, mutation in the RB gene is inherited 
through the germ line, and affected children develop disease early in life 
that frequently affect both eyes (11). RB was subsequently found to be 
mutated in other human cancers, such as small-cell lung carcinoma and 
osteosarcoma. The retinoblastoma protein has been implicated in many 
cellular processes, such as control of cell cycle, DNA-damage responses, 
DNA repair, DNA replication, apoptosis and differentiation, all of which 
could contribute to its function as tumor suppressor (12-16).
Defective proto-oncogenes and tumor-suppressor genes act similarly at a 
physiologic level: they promote the inception of cancer by increasing tumor 
cell number through the stimulation of cell birth or the inhibition of cell 
death or cell cycle arrest.
A third class of cancer genes, called stability or repair genes, do not 
control cell birth or death directly. They drive the neoplastic process in 
different way when they are mutated. They control the rate of mutation of 
all genes keeping genetic alterations at a minimum. When stability genes 
are inactivated, cells acquire mutations in other genes at an accelerated 
rate. All genes are potentially affected by genetic alterations. Only 
mutations in proto-oncogenes and tumor-suppressor genes or in general 
in critical genes affect net cell growth conferring a selective growth 
advantage to mutant cells driving thereby the initiation of tumors. The
16
class of stability genes includes genes associated with mismatch repair 
(MMR), nucleotide-excision repair (NER) and base-excision repair (BER) 
which are responsible for repairing subtle mistakes made during normal 
DNA replication or induced by exposure to mutagens. Other stability 
genes control processes involving large portions of chromosomes such as 
those responsible for mitotic recombination and mitotic chromosomal 
segregation.
1.2 DNA damage and cancer
As it has been underlined, cancer is a disease of our genes. DNA 
accumulates changes conferring either a gain of function by activating 
proto-oncogenes or a loss of function by inactivating tumor-suppressor 
genes (17). In this manner, cancer development can be viewed as an 
evolutionary process whenever somatic mutations in cellular genes, which 
are usually detrimental to the cell, produce cells that can escape the 
normal constraints of proliferation and death (18).
The causes of cancer are many and varied and include genetic 
predisposition, environmental influences, infectious agents and ageing. 
These events transform normal cells into cancerous ones by altering the 
cellular networks of molecular pathways responsible for the control of 
cellular proliferation.
Oxidizing and alkylating agents, ultra violet (UV) and ionizing radiations 
(IR) are just few representative examples of damaging agents. The
17
damage induced by these agents is responsible for determining biological 
consequences like mutations and cell death.
DNA repair activities are extremely important for the cell because 
unrepaired DNA damage has the potential to be mutagenic, cytotoxic and 
carcinogenic. Maintenance of genomic integrity is therefore the major 
challenge for a cell, which is continuously exposed to genotoxic stresses 
(19). Cells have thus evolved complex surveillance networks in order to 
safeguard the genome against the possible detrimental effects of 
mutations by detecting DNA breaks, replication arrest, or defects in mitotic 
spindle assembly. These networks comprise DNA repair and DNA- 
damage checkpoint pathways which are responsible for the recovery of 
the cellular damage through the mobilisation of DNA repair factor and the 
activation of pathways which slow down or arrest the progression through 
the cell cycle to provide time for the repair, thus preventing mutations from 
being propagated (20). The cell cycle is characterised by different phases 
during which the genetic information is accurately transmitted from one 
cell to its daughters. Such faithful transmission required an accurate 
replication of DNA (the “S” phase) during which chromosomes are 
duplicated. After DNA synthesis, DNA and cellular components are equally 
and precisely distributed between two identical daughter cells (“M” phase). 
Between the S and M phases two gap periods occur, G1 and G2 
respectively, which are intermediate phases and during which cell 
prepares itself for DNA synthesis (G1) and mitosis (G2). The term “cell 
cycle checkpoints” characterises monitored points of the cell cycle at
18
transitions between the different phases (2 1 ), and it refers to mechanisms 
by which the cell actively halts progression through different phases until it 
can ensure that an earlier process, such as DNA replication or mitosis has 
been completed properly. These cell-cycle checkpoints are believed to 
prevent the replication of damaged DNA (G1/S and intra-S checkpoints) or 
segregation of damaged chromosomes (G2/M checkpoints) (22, 23).
1.3 DNA damage response
The cellular response to DNA damage can be considered as a complex 
network of interacting signal transduction pathways consisting of sensors, 
transducers, and effectors (20) (Fig. 1.1).
The “stimulus” (DNA damage) is detected by “sensor proteins” that 
recognise the DNA lesion itself or eventual chromatin alterations that 
follow DNA breakage. Then the “transducers”, a system composed of 
upstream and downstream protein kinases together with adaptor proteins, 
are brought into action: they transmit the damage signal to a series of 
downstream “effector molecules” through a transduction cascade that 
amplifies the initial DNA-damage signal and triggers the mechanisms 
necessary for the repair.
DNA can be damaged in a variety of ways. Energy released by free 
oxygen radicals, generated by normal metabolic process or by exposure to 
IR, can break the phosphodiester bonds in the backbone of the DNA helix 
involving either a single strand or both strands. The latter damage, defined 
as double-strand breaks (DSB) is probably the most dangerous form
19
Genotoxic stress, UV, IR, chemotherapeutic agents
I 
m m
l
(Sensors
DNA damage sensingI
Transducers
Signal transductionI
Effectors 
Cellular responses
Figure 1.1
Schematic view of the general DNA damage response signal-transduction 
pathway.
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among the many types of damages that exist within the cell (24). Other 
damages can be inflicted by alkylating chemicals that can modify bases or 
cause inter- or intra-strand crosslinks. Furthermore, inhibitors of DNA 
topoisomerases can lead to enhanced single or DSB (25).
Even though cells can adapt to low levels of unreparable damages (26), 
one DNA DSB is sufficient to kill a cell if it is located in an essential gene 
(27). DNA DSBs are considered to be particularly biologically important 
because their repair is more difficult than that of other types of DNA 
damage. Incorrect repair of chromosomal breakage may cause gross 
chromosomal loss, amplification or rearrangement that can lead to cancer. 
Each type of DNA lesion requires specific cellular responses depending on 
the specific nature of the damage. Although cells use different signalling 
pathways, there are commonalities in the various networks that cells use 
to deal with DNA damage.
As mentioned above, the message (damage signal) is transmitted via a 
standard signalling mode of protein phosphorylation: a central role is 
played by two well characterised and highly conserved protein kinases, 
ATM (ataxia-telangectasia mutated gene) and ATR (ATM-related gene).
1.3.1 The PI3K and PIKK families
ATM and ATR belong to a conserved family of proteins most of which 
possess a serine/threonine kinase activity.
All the members contain a domain with motifs that are typical of the 
phosphatidylinositol 3-kinases (PI3Ks), which constitute a lipid kinase
21
family characterized by its ability to phosphorylate inositol ring 3 -OH group 
in inositol phospholipids, generating second messengers that regulate 
fundamental cellular processes such as cell growth, survival and motility. 
In human cancer, this pathway is frequently constitutively activated by 
genomic aberrations such as mutation, amplification, deletion and re­
arrangement (28).
The PI3K family is divided into three classes. Class 1A of PI3Ks is 
composed of heterodimer, the catalytic subunit p1 10  and its associated 
regulatory subunit p85. In quiescent cells, p85 binds to p110 inactivating 
its kinase activity. Upon growth factor stimulation, p85 binds to the 
phosphorylated tyrosine in receptor tyrosine kinases or in their substrate 
adaptor proteins. The binding relieves the inhibition of p110 which in turn 
can phosphorylate the phosphatidylinositol 4,5-bisphosphate (PIP2) to 
produce phosphatidylinositol 3,4,5-triphosphate (PIP3), a second 
messenger that binds to proteins containing a pleckstrin homology domain 
recruiting them to cellular membranes (29). Among these, the serine- 
threonine kinase AKT, once recruited by PIP3, is the predominant and 
essential mediator for the regulation of both growth and proliferation by 
PI3K. In cancer, the deregulation of the PI3K/AKT pathway, which causes 
its constitutive activation is involved in tumorigenesis by inducing cell 
survival thus inhibiting apoptosis (30, 31). The phosphorylation of PIP2 to 
generate PIP3 is reversed by the PTEN phosphatase. PTEN is a negative 
regulator of the PI3K signalling and functions as a tumor suppressor.
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Genetic inactivation of PTEN occurs in numerous human tumors and 
results in a constitutive upregulation of PI3K signals (32, 33).
There are three known isoforms of Class 1A p110 (p110a/p/5) and seven 
known p85 subunits generated by alternative splicing. Only p110a and 
p85a have been found to be mutated in tumors. Class I B PI3Ks consists 
of only one member, p110y, which associates with the p101 regulatory 
subunit and is directly activated by G-protein-coupled receptors and 
indirectly by other receptors. The single isoform of the class-ill PI 3-kinase 
and the three isoforms of the class-ll PI 3-kinase (PI3K-C2a, PI3K-C2(3, 
PI3K-C2y) are all capable of using phosphatdylinositol (PI) as a substrate 
to produce PIP3.
On the basis of their structural relation to the PI3K, the kinase family to 
which ATM and ATR belong to is named PI3K-like protein kinases (PIKKs) 
that also include other three members: ATX/SMG-1, mTOR/FRAP and 
DNA-PK (DNA-dependent protein kinase).
mTOR/FRAP is the only kinase of the family that is not directly involved in 
the response to damage.
Whereas ATM and DNA-PK respond primarily to DSBs (above all those 
induced by IR and radiomimetic drugs), ATR and SMG1 respond to both 
UV light damage and DSBs. ATM and ATR are the prototype actors in the 
DNA-damage signalling pathways (34).
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1.3.2 Sensors o f damage
In undamaged cells ATM kinase activity is low or minimal but it is rapidly 
engaged whenever cells have to deal with stress affecting DNA or 
chromatin structures. In unstressed cells ATM molecules reside 
predominantly in the nucleus and are held together as homodimers with 
the kinase domain of each molecule blocked and thus inactivated by the 
tight binding to an internal domain of the protein surrounding ser 1981.
The introduction of DNA breaks, and in particular DSB, causes specific 
chromatin alteration leading to the activation of ATM by conformational 
changes in the molecule. This stimulates the kinase to autophosphorylate 
the ser 1981, causing the dissociation of the homodimer (35). ATM can 
“sense” chromatin structure changes without binding DNA at the sites of 
damage. A possible role in sensing DNA breaks might be held by the MNR 
(Mre11, Rad50 and Nbs1) complex (36-39) which binds DNA at breaks, 
unwinds the ends and recruits ATM thus activating it (40).
By contrast, induction of the DNA-damage signalling pathway following 
UV-light irradiation seems to be triggered by blockage of either 
transcription or replication. The ATR kinase has been implicated as a 
sensor of replication blockage and might have a similar role in sensing 
blocked transcription complexes (41). Hence, whereas ATM seems to 
become engaged in signalling pathways primarily following the 
introduction of DNA breaks, ATR has a critical role in virtually all cellular 
stress responses that share inhibition of replication-fork progression as a
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common mechanism. ATR has been reported to be engaged also in 
cellular responses to DNA breaks.
SMG1 which is a recently discovered member of the PIKK family, might 
respond to both DNA damage and truncated mRNA species that arise as 
a result of blocked transcription (42).
DNA-PK, which is activated by DSBs, is a heterodimer containing a large 
catalytic subunit and two smaller accessory proteins that seem to function 
as sensor of DSB consequently recruiting the catalytic subunit. DNA-PK- 
dependent phosphorylation has been reported for two proteins, the WRN  
(Werner syndrome protein) DNA helicase and Artemis. Phosphorylation 
affects W RN’s helicase activity which might act in DSB repair (43, 44), 
whereas Artemis which normally possesses a single stranded 5’-3 ’ 
exonuclease activity, after phosphorylation becomes capable of opening 
hairpin structures that are typically formed at the ends of DSBs (45).
1.3.3 Tranducer phase
ATM and ATR cooperate closely with two other classes of proteins. These 
are the checkpoints mediators, also known as adaptors, and the 
transducer kinases CHK1 and CHK2.
The mediators are those proteins that are initially recruited to the sites of 
DNA damage and/or replication blockade.
The ATM-related mediators include MDC1 (mediator of DNA damage 
checkpoint 1), 53BP1 (p53 binding protein 1), BRCA1 (breast cancer 1), 
NBS1 (Nijmegen breakage syndrome-1), H2AX (Histone-2A family,
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member X) and SMC1 (structural maintenance of chromosomes 1). These 
proteins are phosphorylated by ATM and seem to facilitate ATM signalling 
and processing/repair of the lesions (38).
ATR exists in a complex with the ATR-interacting protein (ATRIP) both 
before and after exposure to stress such as UV irradiation. In vitro 
experiments showed that replication protein A (RPA) a single-strand DNA 
(ssDNA) binding protein involved in DNA replication would bind ATRIP 
(46-48). The accumulation of the RPA on the ssDNA would lead to the 
recruitment of ATRIP and hence of its partner ATR. ATR localisation at the 
site of DNA damage or the arrested replication fork are thought to be 
important (47). ATR also needs the recruitment of other protein complexes 
to the ssDNA sites to carry out its cellular functions.
Among these proteins, there are RAD17-containing complex, 9-1-1 
(RAD9-RAD1-HUS1) complex, claspin, BLM (Bloom syndrome protein) 
and H2AX which are phosphorylated in an ATR/CHK1-dependent manner 
(49-51). The 9-1-1 and RAD17-containing complexes, and the RPA 
protein have also been implicated as possible sensors of replication 
stresses and other type of damages (23, 41, 52, 53). The checkpoint 
transducer kinases, triggered by phosphorylation of ATM and ATR, are 
CHK2 and CHK1 respectively (53).
1.3.4 Effector phase
Once phosphorylated, CHK1 and CHK2, in turn can phosphorylate a 
plethora of downstream effector proteins comprising cell cycle regulators,
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such as CDC25 phosphatases, various DNA repair proteins, transcription 
factors such as p53 or E2F1, chromatin components and regulators such 
as histone H2AX and Tousled kinases (Tlk). Those effectors are 
responsible for cell cycle control, activation of DNA repair activities, 
apoptosis and senescence (20, 34, 53, 54). Among those effectors the 
tumor suppressor protein p53, which is phosphorylated at different, yet 
specific, residues by ATM, ATR, CHK1 and CHK2, has an important role in 
mediating part of the response of mammalian cells to DNA damage and 
other types of cellular stress thus determining the fate of the cells.
In the following chapters an overview over its functions and role in the 
cellular response to damage is presented.
1.4 P53 protein
The p53 gene product is a key player in the cellular response to stresses 
and DNA damage and for this reason p53 probably represents one of the 
major obstacles to tumor development and inception. It plays a pivotal role 
in regulating cell growth and death. It was one of the first tumor 
suppressor genes to be identified, even though it was initially considered 
an oncogene (55-57). Genetic and functional data collected afterwards 
showed it is a tumor suppressor (58, 59). Germline mutations of p53 gene 
result in Li-Fraumeni syndrome, which predispose individuals to a variety 
of cancer types (60). P53 null mice, generated by homologous targeting, 
are susceptible to spontaneous development of tumors at a young age 
(61). Additionally, the function of p53 as a tumor suppressor is further
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supported by the fact that the p53 protein does not function correctly in 
most tumor. In approximately 50% of human cancers p53 is directly 
inactivated as a result of mutations in p53 gene (62, 63). In the majority of 
the remaining cancer cases, p53 activity is compromised by alternative 
mechanisms. It can be inactivated through the binding to viral proteins, 
such as the E6 protein of human papillomavirus (HPV) after viral infections 
or by amplification or overexpression of MDM2 (mouse double minute 2), 
the negative regulator of p53 protein or as a result of silencing of key p53 
co-activators like p14ARF through deletion of the gene (64).
1.4.1 Structure of p53
The human p53 gene was shown to span about 20 Kb of DNA and to be 
localised to the short arm of chromosome 17 (17p13). The p53 gene 
comprises 11 exons with the translation start site located in exon 2 for a 
cDNA encoding a protein of 393 aminoacids with an apparent molecular 
weight of 53 kDa. P53 has several functional domains (Fig. 1.2). The N- 
terminal region contains the transactivation domain (TA) which is divided 
into 2 subdomains, named activator domains (AD). AD1 spans from 
residue 1 to 42 and provides the generic transactivation functions: it 
interacts with the basal transcription machinery by contacting TATA box- 
binding protein (TBP)-associated factor (TAF) components of TFIID  
(TFII70 and TFII37) (65, 66) whereas the activator domain 2 (AD2) which 
is located within residues 43 to 63, is required for p53-dependent 
apoptosis (67-70). The first domain also contains the binding sites for
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MDM2 (19-26), the main regulator of p53 stability. These two domains are 
followed by a proline-rich region (PRD, 64-92) that contains five copies of 
the sequence PXXP and is necessary for the induction of apoptosis and 
contributes to growth suppression (70-75). The central core domain of the 
protein is required for sequence-specific DNA binding. This region, also 
known as the sequence-specific DNA binding domain (DBD), comprises 
residues 102-292 and is crucial for the key role of p53 as a transcription 
factor (76-78). The tetramerisation domain (TD), within residues 324-355 
is necessary for formation of the p53 tetramer (79) which is the functional 
form of the p53 transcription factor (80-82). Upstream to the TD, within 
residues 316 and 325, there is the nuclear localisation signal (NLS) for 
p53 intracellular localisation. In addition, the C-terminus (residues 364- 
393) is involved in the regulation of the DNA-binding activity. Moreover, C- 
terminus itself possesses a nonspecific DNA-binding activity, which seems 
to be implicated in p53-mediated repair of damaged DNA and in DNA and 
RNA reannealing (83). The mechanism by which the C-terminus could 
regulate the specific DNA-binding of p53 is controversial. The C-terminus 
has been reported to exert repressive effects on DNA-binding activity 
through the control of p53 conformation (84). On the other hand, the C- 
terminus can mediate aspecific interactions with DNA and may interfere 
with sequence-specific DNA-binding through the central DBD (85, 86). 
Recent NMR analyses of p53 protein has suggested an overall 
conformational effect by the C-terminus (87). However the exact role of C- 
terminus in regulating p53 function is still poorly understood (88).
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Figure 1.2
Structure and domains of the p53 protein. The N-terminal domain 
contains the transactivation (TA) domain, which is divided in AD1 and 2, 
and the proline rich domain (PRD).
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1.4.2 Activation and regulation of p53
The p53 network is normally “off”. It is activated following stress such as 
IR, UV radiation, hypoxia, heat and cold shock, growth factor withdrawal, 
oncogene activation, ribonucleotides depletion, telomerase erosion, 
inflammation (and its associated nitric oxide signalling) and the treatment 
with cytotoxic drugs (89) (Fig. 1.3). The induction of p53 involves the 
stabilisation of the protein itself for many hours at a high intracellular 
concentration, the transformation of the protein from a latent to an active 
form (through a covalent modification of the protein) and the localisation of 
the protein to the nucleus, allowing p53 to carry out its major function as 
transcription factor. It binds to a particular DNA sequence thus activating 
adjacent genes (90). These genes directly or indirectly lead to DNA repair 
or to the inhibition of the cell cycle or to cell death.
The p53 tumor suppressor protein negatively regulates cell growth through 
the induction of cell cycle arrest or apoptosis (6). Thus, in dividing tissue, 
there are mechanisms acting to downregulate the function of p53. The 
principal mechanisms that govern p53 activity are exerted at the protein 
level. These include regulation of p53 stability, control of the subcellular 
localisation of the p53 protein, posttranslational modifications, and 
conformational changes that allow activation of the binding activity of p53. 
One of the central component of the regulation of p53 is the p53- 
interacting protein MDM2 E3 ubiquitin ligase (91). MDM2 binds tightly to 
p53 and renders it inactive. This inactivation is achieved through at least
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Figure 1.3
Schematic representation of activation of p53 network following stress.
two distinct molecular mechanisms: on the one hand, MDM2 interferes 
with the transcriptional activity of p53, by virtue of its binding to the N- 
terminal transactivation domain of p53; this blocks critical interactions with 
other protein necessary for p53-dependent regulation of gene expression. 
On the other hand, MDM2 plays a critical role in the degradation of p53. In 
normal proliferating cells the p53 protein is kept at a very low level due to 
a very short protein half-life (6-20 minutes), which is controlled in large part 
by the constant removal of newly synthesised p53 by mechanisms 
involving proteasome-mediated degradation. Through a cascade of 
enzymatic reactions several copies of ubiquitin are attached to the C- 
terminus of p53. The final ubiquitylation enables p53 to be detected by the 
protein degradation machinery. MDM2 is the enzyme involved in targeting 
p53 to this machinery. The process is regulated by a feedback loop since 
p53 itself binds to the regulatory region of the gene encoding MDM2 thus 
driving the expression of its own negative regulator (92). MDM2 binds to 
the N-terminus of p53 activating the addition of ubiquitin group to p53 
which is then degraded. This lowers the concentration of p53 and, in turn, 
reduces the transcription of the MDM2 gene, so closing the feedback loop 
and allowing p53 levels to rise again (93). While MDM2 is the prominent 
E3 ligase of p53, it is important to note that other E3 ligases have been 
shown to promote p53 degradation, including Pirh2 and COP1 (94, 95). 
The levels of p53 within the cell increase dramatically (3-20 fold) following 
stress or damage induction. This increase in protein level is attributed 
mainly to an increase in p53 stability and can be achieved through
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conformational changes in the protein resulting from chemical and 
covalent modification, such as the addition or the removal of phosphate, 
acetyl, glycosyl, ribose, ubiquitin or sumo chemical groups (summarised in 
figure 1.4). Recently, it has been found that p53 can be also methylated 
(96) and neddylated (97). Phosphorylation sites in p53 are clustered within 
the N- and C- termini. Phosphorylation of the N-terminus does not affect its 
DNA-binding ability but interferes with its affinity for MDM2 and hence for 
its subsequent degradation. Many stress signals, including some DNA- 
damaging agents, are able to activate kinases responsible for the 
phosphorylation of numerous sites within or near the N-terminal MDM-2 -  
binding region of p53 (98) hence increasing p53 stability.
The p53-MDM2 loop is, in fact, the focal point of many different types of 
stresses that activate the p53 pathway (99).
For instance, DNA strand breaks initiate a series of phosphorylation 
events through several stress-response kinases such as ATM, ATR, Chk1 
and Chk2 which have been shown to phosphorylate p53. Particularly, the 
ATM kinase has been implicated as the prime candidate for 
phosphorylating p53 at Ser15 in response to IR whereas ATR  
phosphorylates p53 on serine 15 and 37 after cellular exposure to UV 
light. ATM and ATR also activates Chk2 and Chk1, respectively, which 
phosphorylate p53 at ser20 (and possibly at other residues). Furthermore, 
ser15 phosphorylation triggers a series of subsequent post-translational 
modifications (phosphorylation or acetylation) on p53 that contribute to 
both its stabilisation and biochemical activation. These findings might add
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complexity in the regulation of p53 stability (100). Other kinases that have 
been shown to phosphorylate the N-terminus of p53 are casein kinase 
(CK) 1 and 2 , JNK (Jun N-terminal kinase) and DNA-PK, p38, CAK (CDK- 
activating kinase), protein casein C (PKC) (89, 101, 102). Nevertheless, 
DNA damage can also induce changes in MDM2 phosphorylation and this 
is thought to contribute to blocking the degradation of p53 (103). 
Stabilisation of p53 can be also achieved through the phosphorylation of 
residues at the C-terminus. Whereas phosphorylation of ser315 by Aurora 
kinase (AUR K) increases p53 stability (104), phosphorylation at Thr55 by 
TAF1 promotes p53 for degradation (105). The N-terminus of p53 is 
thought to contain a nuclear export sequence (aminoacids 11-27). DNA- 
damage induced phosphorylation of ser15 and ser20 may also block 
export of p53 mediated by nuclear exportation signal (NES) thereby 
maintaining p53 within the nucleus (106). Coupled with the stabilisation of 
p53, phosphorylation of ser15, thr18 and ser20 also stimulates recruitment 
of transcription factors including p300, CBP (both transcriptional co­
activators and histone acetyl-transferases HATs) P/CAF (a p300/CBP- 
associated HAT). These factors stimulate transcription from p53- 
responsive promoters and also promote acetylation of a cluster of C- 
terminal lysine residues (320, 372, 373, 382 and 381) in p53 that are 
normally targets for ubiquitylation (107) thus contributing to p53 
stabilisation.
Several studies have shown that negative regulation of the DNA binding 
activity of p53 depends on the C-terminus and this inhibitory activity can
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be relieved by a number of modifications within this region of p53. The C- 
terminus of p53 normally folds back and thus inhibits the DNA-binding 
domain located in the central part of the p53 protein. The N-terminus of 
p53 has also been shown to play a role in regulating dissociation from 
DNA, and it is likely that modifications at both ends of p53 are important in 
controlling the DNA binding function.
Acetylation of lysine residues is not the only modification that occurs to 
activate p53 function. Other modifications which are involved in switching 
on the activity of p53 include sumoylation (108-110), phosphorylation, 
glycosylation, of lysine residues or phosphorylation of serine residues near 
to the C-terminus: these modifications can favour the DNA binding of p53, 
presumably by interfering with the C-terminus folding.
Lysine modifications are complicated since, beside those forehead 
mentioned, they could be even subject to ubiquitination, neddylation and 
hydroxylation (111). Lysine methylation leads to addition of up to 3 methyl 
groups to the s-amino group and different methylation states have distinct 
functional consequences (112). For istance, methylation of p53 at Lys372 
by Set9 methyltransferase stabilises p53 and retains it in the nucleus, 
thereby increasing its transcriptional activity (96). A forehead mentioned 
modification of p53, neddylation, has been recently identified. Unlike 
methylation, modification of lysine residues of p53 by NEDD8 inhibits its 
transcriptional activity (97). Further studies will increase the knowledge 
about how other posttranslational modifications regulate the stability and 
activity of p53.
36
JNK
Chk2 DNA-PK
V S9S15S20 S37S46
| . ® ® ®  0(E)
7E)
S33 T55
TAF 1
CAK
Set9
P300/CBP
PCAF
K320 K372 K373 K38
©
S315 S376 S378
PKC
AUR K
Figure 1.4
Schematic representation of some post-translational modifications of p53. 
Phosphorylation of serine (S) and threonine (T) residues are represented 
as P. Acetylation (Ac) and methylation (Me) of lysines (K) are also 
indicated.
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1.4.3 Regulation of MDM2
Besides those events that lead to the posttranslational modification and 
the following stabilisation of p53, other stress such as hypoxia, high doses 
of UV and some cytotoxic drugs efficiently reduce MDM2 mRNA and 
protein levels (99, 113-116). Hyper-proliferation, induced by dominant 
oncogenes, can operate by inducing expression of p14ARF, which binds to 
MDM2 and blocks its ability to mediate the degradation of p53. 
Nevertheless, the transcription factors YY1 (Yi Yang 1) negatively 
regulates p53 by enhancing the MDM2-dependent proteasomal 
degradation (117, 118) whereas the de-ubiquitination enzyme HAUSP 
(herpesvirus associated ubiquitin-specific protease), also known as USP7, 
has been recently discovered to bind to p53 in cells and to deubiquitinate 
p53 both in vitro and in vivo (119). Conversely, it has subsequently 
demonstrated that HAUSP deubiquitinates MDM2 rather than p53, thus 
leading to the stabilisation of MDM2 which then destabilises p53 (120). 
Other proteins, such as Rb and L11, which is a ribosomal protein, bind to 
the acidic domain of MDM2 and prevent it from targeting p53 for 
degradation (121-124). 14-3-3 sigma increases p53 stability by binding its 
C-terminus and blocking MDM2-mediated ubiquitination (125)). 
Conversely, PML (promyelocytic leukaemia) protein can bind MDM2 and 
sequester it to the nucleolus (126).
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1.5 The p53 response: functions of p53
The p53 protein has been denoted “the guardian of genome” (127) for its 
role in preventing the accumulation of genetic alterations. This task is 
achieved through the induction of cell cycle arrest or senescence to 
prevent the replication of damaged DNA and playing a direct role in the 
repair of DNA through NER and BER. P53 is also called the “cellular 
gatekeeper” (6) being a critical player in the suppression of tumor 
development for its well-documented activity in apoptosis and contributing 
to the inhibition of angiogenesis (Fig. 1.5).
The best understood function of p53 is the ability to inhibit growth of 
aberrant or stressed cells. Inhibition of cell growth is thus associated with 
cell cycle arrest, differentiation, senescence or apoptosis. The ability to 
prevent growth of potential tumor cells is critical for its ability to function as 
a tumor suppressor.
1.5.1 P53 is a transcription factor
The growth and tumor suppressing activities of p53 are strictly related to 
its main function as a transcription factor (128-130) that binds as a 
tetramer to DNA in a sequence specific manner activating or repressing 
transcription of an increasing number of genes (131-134). Acting as a 
transcription factor, p53 activates vital damage-containment procedures to 
restrict aberrant cell growth in response to UV and IR, oncogene 
activation, hypoxia, heat shock, growth factor withdrawal, the loss of 
normal cell contact and the application of cytotoxic drugs (64, 89, 135).
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Summary of p53 functions.
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The criteria that influence p53 to stimulate cell cycle arrest or apoptosis 
are only partially understood and are under intensive study. General 
factors influencing the final choice between life and death of p53 include 
p53 expression level, the type of stress signal, the cell type and the 
cellular context at the time of cellular exposure to stress (136).
The idea that the function of a transcription factor is critical for the role of 
p53 as a tumor suppressor is supported by the observation that almost all 
naturally occurring mutations in the p53 gene are mostly localised in the 
DBD thus compromising its ability to bind cognate recognition sequences 
(64).
The active p53 in the tetrameric form binds to four palindromic copies of its 
consensus sequence which is a pentamer and has been precisely defined 
(5’-RRRCW -3’). The canonical consensus binding site for p53 (p53BS), 
also defined as responsive element (p53RE), is defined as two decamers 
5’- RRRCWWGYYY-3’ separated by 0-21 nucleotides (nt). In the motif, R 
is G or A, W  is T or A, Y is C or T (90, 137). The two pentamers in each 
decamer are arranged head-to-head (HH). The p 2 lWaf1/CIP1 (p21) gene 
promoter is the paradigm of this kind of base arrangement (90). These 
p53BS have been found both 5’ to a gene and in the first or second introns 
of a gene (138, 139). Nevertheless, p53 is also able to repress the 
transcription from various promoters and emerging evidence indicates that 
transcriptional repression by p53 is important for its ability to promote 
apoptosis (140-142). Transcriptional repression by p53 is mediated 
through several mechanisms. P53 can interfere with the functions of DNA-
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binding transcriptional activators such as SP1 and E2F (143, 144). P53 
may interfere with transcriptional activator not by preventing the binding to 
DNA, but by disrupting its interactions with other components of the 
transcriptional machinery (145, 146). The second mechanism involves 
interference with the basal transcriptional machinery by p53. P53 may 
interact with the basal transcriptional machinery, such as TBPs and certain 
TAF, at the gene promoter or in solution (66, 147-150). This may disrupt 
transcriptional processes such as pre-initiation complex assembly. Another 
mechanism of transcriptional repression could be that p53 recruits 
chromatin-modifying factors such as histone deacetylase (HDAC). 
Alterations in chromatin structure may reduce promoter accessibility to the 
transcriptional machinery or activator proteins (151-153). It is also possible 
that differences within the p53-binding site itself could have pivotal effects 
on the action of p53. A peculiar example is given by the gene MDR1. In 
this case, the p53BS harboured by the MDR1 promoter presents a 
particular orientation, with head-to-tail (HT) pentamer arrangement (154). 
The authors proposed that this conformation could affect p53 protein 
conformation leading to an inactive p53.
Recently an intriguing promoter arrangement of a p53-dependent gene, 
BTG2TIS21/PC3 has been reported. BTG2 function may play a role in cell 
cycle control, cell growth, differentiation and cellular response to DNA 
damage (155, 156). For this gene, the pentamer organisation of p53BS is 
again different from those reported for the canonical p53BS (HH) or MDR1 
promoter (HT). In fact, the arrangement of the pentamer has a tail-to-tail
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(TT) configuration. This specific arrangement could account for the 
particular response of the BTG2 promoter to the DNp73a protein (see 
ahead chapter 1.5.3) in a p53 dependent manner in neuroblastoma cells in 
contrast with other p53 target genes such as p21, which was completely 
repressed by DNp73 (157). P73 (see ahead chapter 1.5.1) shares 
structural and functional homology with p53. It is a transcriptional factor 
and can bind the canonical p53BS in the promoter of p53 target genes and 
thus transactivate them. This topic will be further discussed in depth. 
DNp73a is a p73 isoform lacking the transactivation domain. The authors 
proposed two models in order to explain the particular pentamer 
arrangement of BTG2 p53BS. On one hand they suggest that DNp73 and 
p53 form heterotetramers which are transcriptionally inactive on the 
canonical p53BS, but, through a conformational change, active on the 
BTG2 promoter. This is not according to previously published data (158) 
which demonstrated a weak interaction between p53 and p73. On the 
other hand, p73a being unable to bind BTG2 non canonical p53BS could 
suggest that DNp73a would not be able to compete with p53 in binding to 
its responsive element.
Furthermore recently collected observations could suggest an additional 
mechanism of transcriptional regulation of p53-induced genes. It has in 
fact been discovered that p53 can also activate target genes through a 
non-canonical sequence. The first such example is the p53-induced gene 
3 (PIG3), which has been implicated in the accumulation of reactive 
oxygen species and apoptosis induction (159). PIG3 can be induced by
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p53 through a microsatellite sequence, the pentanucleotide motif TGYCC  
repeated 10, 13 or 15 times within its translated region (160). Another 
recently described example is the gene encoding the pro-apoptotic 
phosphatase PAC1, which is induced through binding p53 to a novel 
palindromic binding site (161). It is a 12-base pair (bp) palindromic 
consensus sequence (5’-CCCCACGTGAGG-3’) mapping from -202 to - 
191 bp in the PAC1 promoter.
Several p53 responsive genes have been identified but intensive studies 
have so far established direct roles for only a small group as mediators of 
the p53 response.
In the following paragraphs p53 functions will be specifically discussed.
1.5.2 Cell cycle arrest
Among the target genes stimulated by p53 to halt the cell cycle, p21 is 
probably the most critical and well studied (162, 163). It is an inhibitor of 
cyclin-dependent kinases (CDKs). CDKs are key regulator of the cell 
cycle, working together with their partners, the cyclin proteins, to ensure 
the correct progression through different phases of the cell cycle. By 
inhibiting several CDKs, p21 can block both G 1-to -S  and the G 2 -to -  
mitosis transitions (164-166).
Another target of p53 that contributes to the p53-induced G2 arrest is 14- 
3-3 sigma. The 14-3-3 family proteins play a role in signal transduction 
and cell cycle control. 14-3-3 sigma binds to CDC25C and keeps it in the 
cell cytoplasm. CDC25C is a phosphatases that acts upon cyclin B-CDC2,
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a kinase essential for the G-2 to M-phase transition. Keeping CDC25C in 
the cytoplasm prevents it from activating cyclin B-CDC2 in the nucleus and 
these cells are blocked in the G-2 phase of the cell cycle. Further potential 
mediators of the G2 arrest include GADD45 (167) and Reprimo (168).
1.5.3 Apoptosis
P53 is implicated in the induction of the apoptotic signalling pathways, 
known as the extrinsic and the intrinsic pathways, that lead to the 
activation of the caspases, a group of cysteine proteases which, upon 
activation, destroy cellular machinery and lead to eventual cell death 
(169). The extrinsic pathway is mediated by particular “death” receptors 
(DR), that belong to the tumor necrosis factor receptor (TNF-R) family 
which form the death-inducing-signalling-complex (DISC) (170) thus 
leading to the activation of caspase dependent cell death. The intrinsic 
pathway is triggered by the release of apoptogenic factors from 
depolarised mitochondrial membrane, including cytochrome c and 
Smac/DIABLO (Smac, second mitochondria-derived activator of caspases; 
DIABLO, direct lAP-binding protein with low pi), Omi/HtrA2 (Htr2A, high 
temperature requirement A2), apoptosis inducing factor (AIF) and 
endonucleases G (EndoG), which lead to the eventual cell death through 
caspase-dependent and caspase-independent mechanisms.
Released cytochrome c allows the formation of the apoptosome complex 
which consists of apoptotic protease-activating factor 1 (APAF-1) and 
procaspase-9, which is actived after being recruited into the apoptosome.
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Active caspase-9 finally promotes the activation of caspase cascade by 
cleaving the effector caspases, caspase-3, -6 and -7, which execute the 
death program (171). Smac/DIABLO and Omi/HtrA2 bind to a group of 
apoptosis inhibitors called inhibitors of apoptosis proteins (lAPs), such as 
XIAP (x-linked inhibitor of apoptosis protein) and clAP1 (cellular inhibitor of 
apoptosis protein 1), thus relieving their inhibition on caspases (172-174). 
On the other hand, AIF and EndoG appear to promote DNA degradation 
through a caspase independent pathway (175, 176).
The release of mitochondrial apoptogenic factors is regulated by the pro- 
and anti-apoptotic Bcl-2 family proteins, which either induce or prevent the 
permeabilisation of the outer mitochondrial membrane. Several genes of 
the Bcl-2 family proteins are transcriptionally regulated by p53 thus 
encoding potential mediators of p53-induced apoptosis. The prototype of 
this class of mediators is the bax gene, a pro-apoptotic member, which 
governs the release of cytochrome c from the mitochondria (177-179). The 
Bcl-2 family members are classified on the basis of structural similarity to 
the Bcl-2 homology (BH) domains (BH1, BH2, BH3 and BH4) and to a 
transmembrane domain. The BH3 domain, which is present in all 
members and is essential for heterodimerisation among members, is the 
minimum domain required for the pro-apoptotic function (180, 181). The 
Bcl-2 family is subdivided into 3 classes: prosurvival proteins, structurally 
similar to Bcl-2 such as Bcl-X|_; pro-apoptotic proteins, Bax and Bak and 
the pro-apoptotic BH3-only proteins (182). Among the latter, a key subset
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of the Bcl-2 family genes are p53 targets, including Noxa, (183) PUMA 
(p53 up-regulated modulator of apoptosis) (181, 184) BID (185) and Bad. 
Some of this BH3 domain-only proteins function upstream of BAX/BAK to 
induce apoptosis in response to a different set of conditions in a tissue and 
cell type-specific manner (186). For instance, PUMA and Noxa are 
activated in a p53-dependent apoptosis after DNA damage. PUMA can 
also mediate apoptosis induced by p53, hypoxia, DNA damaging agents 
and endoplasmatic reticulum (ER) stress in human colorectal cancer cells 
(187, 188). Bad has been shown to regulate apoptosis induced by growth 
factors and nutrient deprivation (189). Bid mediates apoptosis transmitting 
apoptotic signal mediated by death receptors to Bax/Bak in hepatocytes 
(190) whereas Bim is required for apoptosis induced by cytokines in 
hematopoietic cells (191). These BH3-only protein receive the death 
signals transmitting them to Bcl-2 family members containing multiple BH 
domains (192, 193). Bax and Bak can be either directly activated by BH3- 
only proteins or indirectly through inhibition of Bcl-2 or Bcl-XL proteins 
(194, 195).
These proteins, as well as another p53 induced gene product, namely 
p53AIP1 (196), localise to the mitochondria promoting mitochondrial 
membrane potential perturbation with the consequent activation of the 
intrinsic apoptotic pathway. The mitochondrial membrane potential could 
be perturbed by other p53 target genes coding for redox-controlling 
enzymes and named PIGs, such as PIG3, POX2/PIG6 and ferredoxin 
reductase (159, 197, 198). The reactive oxygen species (ROS) produced
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by these PIGs cause damages to the mitochondria thus initiating the 
apoptotic pathway. p53 has been demonstrated to localise to the 
mitochondria following DNA damage or hypoxia, where p53 can interact 
with antiapoptotic proteins such as Bcl-2 and BcI-Xl. The binding of p53 to 
Bcl-2 and B cI-X l liberates Bak and Bax thereby allowing them to induce 
changes in the mitochondrial membrane leading to activation of the 
caspase cascade resulting in cell death. Since in this case p53-induced 
apoptosis does not involve its transcriptional ability, this represents the 
transcription-independent way of mediating apoptosis (199).
P53 has also been implicated in the membrane death receptor-induced 
pathway of apoptosis also known as the extrinsic pathway.
P53, in fact, upregulates the expression of at least three of the death 
receptors, FAS (AP01/Cd95), DR5/KILLER, DR4, PERP (p53 apoptosis 
effector related to PMP-22) and PIDD (p53-induced protein with a death 
domain) and one of the death receptor ligands FASL.
The cell-surface receptor FAS belongs to the TNF-R receptor family and is 
a key component of the extrinsic death pathway (200). Fas is activated by 
binding of its ligand, FASL, expressed mainly by T-cell (201), which 
induces the oligomerisation of the receptor with subsequent activation of 
the caspase cascade in the apoptotic pathway. Fas transcription is 
induced by p53 in response to gamma irradiation and in a tissue-specific 
manner (202). In addition to stimulating Fas transcription, overexpressed 
p53 may enhance cell surface expression of Fas by promoting the 
trafficking of the receptor from the Golgi to the membrane (203).
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Other members of this receptor family that are induced by p53 are 
DR5/KILLER and DR4, which are bound by the TNF-related apoptosis- 
inducing ligand (TRAIL). Both receptors contain a conserved death 
domain (DD) motif (an intracellular globular protein interaction domain) 
and signal apoptosis. Ligation of TRAIL to its receptors results in 
trimerisation of the receptors and clustering of the receptors’s intracellular 
DD, leading to the formation of the DISC and thus inducing apoptosis. 
PIDD, was initially identified as a prime target gene in an erythroleukemia 
cell line that undergoes G1 phase arrest and subsequent apoptosis after 
p53 expression (204). PIDD can form a complex with caspase 2, called 
PIDDosome and seems to involved in caspase 2 activation, in response to 
genotoxic agents (205). Another pro-apoptotic gene, PERP, is a putative 
tetraspan transmembrane protein that represents a new member of the 
PMP-22/gas3 family of proteins implicated in cell growth regulation. The 
presence of a p53-responsive element in the promoter and of higher levels 
of PERP mRNA in cells undergoing apoptosis than in arresting cells 
support the hypothesis that PERP contributes to p53-mediated apoptosis, 
even though details have to be defined (206).
1.5.4 P53 “choice” between life and death
Different type of cells often show different biological responses to a given 
stress (207). For example, thymocytes and splenocytes undergo p53- 
dependent apoptosis after IR, whereas fibroblasts arrest cell cycle after 
DNA damage but can undergo apoptosis following different stimuli. In
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most cases, cells can respond to DNA damage by activating either growth 
arrest or apoptosis. The ability of cells to execute a choice between life 
and death suggests that p53 pathway is able to sense whether or not 
recovery from DNA damage has been successful thus permitting the p53 
response to be attenuated or promote an irreversible and fatal outcome. 
The currently accepted model for the explanation of cellular choice 
involves a complex number of factors, not yet complete, that should direct 
p53 to differentially transactivate promoters of growth arrest or apoptosis 
genes.
Originally, intracellular levels of p53 were correlated with the outcome of 
p53 activation, since p53 has been shown to bind with higher affinity to the 
promoter consensus sequence of cell cycle arrest genes (e.g. p21, 
GADD45, MDM2). Whereas, death would be induced when high levels of 
p53 are present in the cell because promoters of apoptotic genes contain 
low affinity p53 binding sites (208). This model could suggest that 
increased level or activity of p53, after strong damages, can lead to the 
induction of the apoptotic pathway rather than growth arrest. Stronger 
damage induces more p53 and the persistence of damage would keep 
p53 active thus determining and leading to the induction of those genes 
whose promoters have low affinity for p53 (209). Furthermore, p53 
mutants with marginally altered conformations retain sufficient activity to 
induce arrest but not apoptosis (68, 210, 211).
Further studies have demonstrated exceptions to the proposed 
relationship between promoter binding and the induction of apoptosis
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(212, 213). It is now accepted that there are factors that are likely to play 
an essential role in determining the final cellular decision between cell 
cycle and apoptosis. Different post-translational modifications of p53 have 
been found to drive the p53 toward the activation of specific pro-apoptotic 
genes (AIP). In addition, there are cellular factors able to induce p53- 
dependent apoptosis such as JMY (214), ASPP (apoptosis stimulating 
protein of p53) 1 and 2 (215) and recently also p53 family members, p73 
and p63 which were also shown to be required for p53-induced apoptosis 
(216).
1.5.5 Senescence
Cellular senescence has been defined by Hayflick (217) as the irreversible 
loss of replicative potential occurring in primary somatic cell culture. 
Normal cells grown in vitro do not divide indefinitely but cell growth is 
arrested after a fairly reproducible number of cell divisions and this 
process has been defined as replicative senescence. Among mechanisms 
that have been suggested as putatively responsible for blocking cellular 
divisions, the erosion and eventual dysfunction of telomeres is the best 
established and investigated (218). During successive cellular divisions 
the telomeres in normal cells shorten progressively (219, 220). This 
erosion of telomeres length has been attributed to the inability of the DNA 
replication machinery to completely replicate the ends of chromosomes 
(221). Thus, proliferating cells experience progressive telomere shortening 
until the telomeres become critically short and dysfunctional. Dysfunctional
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telomeres signal normal cells to cease proliferation provoking a senescent 
phenotype (222, 223). Senescent cells remain metabolically active and 
undergo to characteristic changes in cell morphology, physiology and 
gene expression (224). They are unable to express genes required for 
proliferation in contrast with quiescent cells which are in a non-proliferative 
state promptly reversed if they are exposed to mitogens (225).
Mammalian telomeres consist of a long stretch of TTAGGG repeats 
followed by single-strand termini consisting of 10 to 300 bases (222) that 
end in a lariat-like structure called T-loop (226). Various telomere-specific 
proteins bind to the single- and double-strand regions. The T-loop and 
telomere-associated proteins form a protective cap that stabilises the ends 
of linear chromosomes preventing their degradation, recombination and 
end-joining reactions (227). When telomeric DNA sequence or structure is 
altered, cells undergo chromosome end associations and fusions leading 
to growth arrest or death.
Immortal cells which proliferate indefinitely are able to maintain telomeres 
at a stable length because they can express the enzyme telomerase, 
which can add the telomeric sequences to chromosomes ends de novo. 
Most human normal cells do not express the telomerase (222, 223, 228). 
Replicative senescence is an example of a more general process named 
as cellular senescence, which is a signal transduction program activated 
by normal cells in response to various stress and leading to irreversible 
growth arrest. These include telomere uncapping, DNA damage, oxidative 
stress, certain oncogene activity, specifically Ras and its downstream
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effectors and others (229-231). These stimuli are not independent of one 
another or mutually exclusive. Oxidative stress can cause DNA damage 
and also accelerate telomere shortening rates (232-234).
P53 together with Rb, another paradigmatic tumor suppressor protein, 
plays a critical role in the induction of senescence. Both proteins are in 
fact activated during senescence and in human fibroblasts the inactivation 
of both p53 and Rb is required to prevent the onset of senescence, 
whereas the inactivation of only one protein delay the entry into 
senescence (235). In MEF, p53 loss is sufficient to overcome senescence, 
whereas Rb has to be inactivated together with the related p107 and p130 
components of the Rb family to prevent senescence.
In the context of senescence, p53 seems to be controlled by two major 
pathways. One is the DNA damage-response pathway, mediated by the 
ATM/ATR and Chk1/Chk2 proteins, which cause the post-translational 
stabilisation of p53 through phosphorylation. The other pathway acts 
through the p14ARF or ARF (p19ARF in mouse). As already described, the 
ARF product activates p53 by sequestering MDM2 in the nucleolus 
thereby preventing the MDM2-mediated targeting of p53 to proteqlytic 
degradation.
Recent evidence from cell culture models clearly demonstrates that 
telomere shortening provides a DNA damage signal similar to that induced 
by DSBs. Human fibroblasts undergoing replicative senescence display 
nuclear foci containing phosphorylated H2AX and 53BP1 and the 
activation of checkpoint kinases CHK1 and CHK2, all hallmarks of DSBs
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(236, 237). P53 in its stabilised state (through post-translational 
modifications or prevented MDM2 targeting), increases the expression of 
p21, an inhibitor of cyclin E/cdk2 complexes thus causing cell cycle arrest 
(as discussed previously in the chapter 1.4.3.1). P21 expression levels 
rise in both growth arrested (for example quiescent) cells and senescent 
cells: however, p21 increases to its highest levels in senescent cells for a 
relatively long interval. Several weeks after human fibroblast cultures 
reach senescence, p21 levels gradually fall as p16INK4a (p16) levels rise. 
P16 is an inhibitor of cyclin D/Cdk4,6 complexes and is induced upon 
various situation of stress and is highly expressed in senescent cells. It is 
encoded by the INK4a/ARF locus, which encode as alternative transcript, 
the tumor suppressor p14ARF which share 2 exons but has a separate 
promoter and the first exon is translated in a different reading frame. Both 
p16 and p14ARF are induced in situations of stress (238, 239).
1.5.6 Genetic stability
As a tumor suppressor, p53 has also an important role in DNA repair and 
recombination. As recently described, during apoptosis, p53 can also have 
a transactivation-independent role in maintenance of genetic stability. In 
eukaryotic cells, the main DNA-repair processes are NER, BER, MMR, 
Non-Homologous End-Joining (NHEJ) and Homologous recombination 
(HR) (19).
NER is the process by which the cell recognises and repairs damaged 
bases and disrupted base pairings caused by UV light or oxidative
54
damage. P53 can affect NER in vivo both in a transactivation-dependent 
and independent manner. In fact, it can upregulate the expression of p48 
and xeroderma pigmentosum complementation group C (XPC) which are 
key components of the NER machinery (240, 241). P48 is one of the 
components of UV-damage DNA-binding proteins (UV-DDB) induced after 
UV damage. P48, whose expression is regulated by p53, may in turn 
directly affect p53 protein levels, which implies a mutual regulatory 
interaction between the two proteins (242). XPC together with RAD23B 
form a complex that is involved in identifying disrupted base pairings 
(243). P53 can also affect NER in a transactivation-independent manner. 
An example is the possible function of p53 as a chromatin-accessibility 
factor in NER. After recognition of UV-associated lesions, p53 seems to 
recruit the histone acetylase p300 to the NER site to acetylate histone H3, 
thereby relaxing chromatin and enhancing the detection of the lesion in the 
entire genome (244).
DNA base damage generated by IR, alkylating and methylating agents, as 
well as endogenous hydrolytic and oxidative processes is corrected by the 
BER pathway. Thus, BER is critically important for regulating spontaneous 
mutations (245). A recently published work (246) reported that BER 
intermediates could induce p53-independent cytotoxic and genotoxic 
responses, hence implying that p53 might not be involved in the process. 
However, Zhou et. al. (247) demonstrated that BER is stimulated by 
recombinant wild-type p53 in an in vitro reconstituted system, where p53 
might directly interact with some of the components of BER pathway. A
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direct interaction of the tumor suppressor with some of the proteins 
belonging to the BER machinery could suggest a transactivation- 
independent function of p53. P53 can in turn affect BER in a transcription- 
dependent fashion. An example is the effect of p53 on 3-methyladenine 
(3-MeAde) DNA-glycosylase gene (MPG) transcription. After exposure to 
nitric oxide (NO), p53 can repress the expression of MPG (gene belonging 
to the BER pathway) thus preventing the onset of a mutator phenotype 
resulting from the increased accumulation of point mutation after NO- 
induced DNA damage (248).
MMR is the DNA-repair process that removes mispaired nucleotides and 
insertion or deletion loops.
P53 affects MMR activating the expression of a MMR’s protein, MutS 
homologue-2 (MSH2), in a transcription-dependent manner by binding to 
the p53RE present in the MSH2 promoter. It has been reported that p53 
can synergise with the transcription factor Jun in the regulation of human 
MSH2 in response to UV exposure (249). This is one the several 
examples of the cooperation of p53 and MMR in DNA damage response. 
NHEJ is the mechanism by which most chromosomal DSB are repaired in 
somatic cells. It is error prone since it leads to the joining of the breaks 
without a template. As regards the regulation of NHEJ by p53 there are 
contradictory results. For instance, it has been reported that wild-type p53 
protein is able to rejoin DNA with DSBs, indicating a transactivation- 
independent role of p53 in NHEJ (250, 251). Conversely, it has been also
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shown, that DSB rejoining increases with loss of wild-type p53 (252) and 
also wild-type p53 was reported to inhibit NHEJ (253-256).
HR is a fundamental and error-free process, conserved in all organisms 
(257) and involved in genomic stability, chromosome segregation during 
meiosis and DNA repair (258). In mammalian cells, HR is strongly 
stimulated by DSB (259). During HR, the sequence lost in one ds-DNA 
molecule is replaced by exchanges with an intact homologous DNA 
partner (19), which can be found on the sister chromatid, leading to sister 
chromatid exchange (SCE) in the homologous chromosomes or on 
ripetitive sequences that are dispersed through the genome (260). The 
most documented model is the DSB repair model which accounts for DSB 
repair after genotoxic stress, during meiotic recombination or gene 
targeting. RAD51 is perhaps the most essential component of the pathway 
because it catalyses the strand exchange reaction (261). RAD51 binds to 
ssDNA and after having polymerised, upon RAD52 stimulation, searches 
the homology on sister chromatid with the help of the helicase rad54 
(262). Once the homology search is successful, the homologous duplex is 
captured and the ssDNA filament bound to RAD51 aligns and invades it to 
form heteroduplex structure allowing the exchange between the aligned 
chromatids (263). This step form cruciform junctions, known as Holliday 
junctions (HJ) which can migrate along the chromosomal branch leading 
to the elongation of the heteroduplex molecule. DNA polymerases use the 
intact copy to re-synthesise the deleted DNA sequences, DNA ligase join 
the newly synthesised fragments and the HJ are resolved by specific
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endonucleases that are known as resolvases (264). P53 seems to 
physically interact with proteins involved in the HR machinery, 
heteroduplex structures or holliday junctions together with helicases. W ild- 
type p53 alone might check the fidelity of HR events by either specific 
mismatch recognition in the heteroduplex intermediates correcting them 
exonucleolytically or by halting DNA exchange between imperfectly 
homologous sequences (265). The mechanism through which p53 
influences the HR process seems to be transactivation-independent. It 
interacts with RAD51 thus likely affecting RAD51 activity. P53, in fact 
seems to abrogate the polymerisation of RAD51, thus limiting its activity 
(266). It is necessary to finely control the HR machinery to allow the 
process to proceed at optimum efficiency thus preventing hyper­
recombination. Uncontrolled hyper-recombination, in fact, leads to 
genomic instability, including chromosomal deletions, translocations and 
gene amplifications. It is not known whether p53 loss alone can lead to 
hyper-recombination or whether p53 mutation lead to an increase in HR. 
However, it has been shown that the abrogation of wild-type p53 results in 
an increase of chromosomal aberration and frequency in spontaneous 
mutations (267-269). Furthermore, p53 can also interact with helicases, 
such as WRN and BLM belonging to the RecQ helicase family. This family 
is highly conserved in evolution and is required for genomic stability 
maintenance. Mutations in three of the RecQ-helicase genes in humans, 
BLM, WRN and RecQ4, lead to cancer predisposition disorders, Bloom 
syndrome (BS), Werner syndrome (WS) and Rothmund-Thomson
58
syndrome (RTS) respectively (270). There are several example of inter­
regulation between p53 and the RecQ helicases. (271). For istance, p53 
can form a complex with Sp1 thus preventing Sp1 to bind to the promoter 
of WRN helicase, which is transcriptionally regulated by Sp1. Another 
example is given by the interaction between p53 and BLM helicase. p53 
and BLM cooperate affecting HR and sister chromatid exchanges. BLM 
and p53 co-localise and physically associate with each other and RAD51. 
In particular, BLM is required for efficient p53 accumulation and 
association with RAD51 during HR response to damage (272).
Further evidence for a role of p53 in DNA repair comes from the induction 
of a new ribonucleotide reductase gene, designated p53R2, by p53 after 
damage. Ribonucleotide reductase is a rate limiting step enzyme for DNA 
synthesis as it catalyses the conversion of ribonucleoside diphosphates to 
their corresponding deoxyribonucleotides. P53R2 gene is inducible by 
DNA damage suggesting that this enzyme has a crucial role in supplying 
precursors for DNA repair. P53, once activated by ATM in response to 
DNA damage, directly induces p53R2, suggesting that p53 could 
participate in DNA repair activity also by direct induction of p53R2 
following to DNA damage (273).
1.5.7 Inhibition of blood-vessel forma tion
During the progression from normal to malignant phenotype, the cells 
have to recruit new blood vessels to ensure sufficient nutrient-bringing 
blood for tumor growth. To prevent neovascularisation, p53 can stimulate
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the expression of the thrombospondin-1 (TSP-1), a potent inhibitor of 
angiogenesis. In cultured fibroblasts from patients with Li-fraumeni 
syndrome the loss of the wild-type allele for p53 can also result in the 
reduced expression of TSP-1 (274). In various neoplastic cell lines, the 
levels of TSP-1 expression show an inverse correlation with malignant 
progression (275-278). A p53-inducible gene, named BAI-1 (brain-specific 
angiogenesis inhibitor 1) encodes a product that contains 5 
thrombospondin type 1 repeats and is specifically expressed in the brain 
(279): this gene has been shown to inhibit in vivo the neovascularisation 
induced by bFGF (basic fibroblast growth factor) in rat cornea, thus 
suggesting that this gene can play a significant role as a mediator of p53 
inhibition of angiogenesis. Other genes involved in suppression of tumor 
metastasis have been identified. Among them KAI-1 (280), maspin 
(mammary serine protease inhibitor) (281) and PAI-1 (plasminogen 
activator inhibitor 1) (282) have been found to be up-regulated by p53 thus 
emphasizing the role of p53 in the negative regulation of cell invasion and 
metastasis.
1.6 P53 and its family members
1.6.1 Structure of p53 family member gene and their products
Even though p53 discovery has been in 1979, two novel proteins 
belonging to the p53 family of transcription factors were identified only 20
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Figure 1.6
Structure and homology between p53, p63 and p73.
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years afterwards. The first homologue to be discovered was p73 (283) and 
then the other homolog, p63 (also named KET, p51, p40, p73L) appeared 
(284-288). P53, p73 and p63 share a remarkable structural similarity. The 
three most conserved domains in all three genes are the NH2-terminal TA, 
the central DBD and the oligomerisation domain (OD) in the COOH- 
terminal. The highest level of homology is reached in the DBD (63%  
between p53 and p73 and 60% identity between p53 and p63) suggesting 
that the three genes can transactivate the same target promoters (Fig. 
1.6 ). The high conservation of the OD suggests that these family members 
can form hetero-oligomers as well as homo-oligomers, although published 
data show that homo-oligomers are favoured (158, 283, 289, 290). Both 
p63 and p73 contain in their long C-terminus a protein-protein interaction 
domain known as “sterile alpha motive” (SAM). Up to now, TP53 has a 
single promoter encoding both the full length p53 and the alternative splice 
variant of 40 KDa called DNp53. This splicing occurs at the 5’ end of p53 
RNA thus affecting the N-terminus of the protein. This N-terminally 
truncated form has been described in literature and termed p53/p47 and 
DNp53 (291, 292). DNp53 retains the intron 2 by alternative splicing and 
its translation starts at codon 40 (291). DNp53 oligomerises with full-length 
p53 ad interferes with its transcriptional and apoptotic functions. DNp53 
does not respond to DNA damage.
For TP63 and TP73, two promoters have been identified: P1 in the 5’ 
untranslated region upstream to the non coding exon 1 and P2 within the 
23 kb spanning intron 3. P1 and P2 promoters produce two distinct
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Structure of TA and of DN isoforms of p73 and p63.
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classes of proteins: those containing the TA (TAp73 and TAp63) and 
those lacking it (DNp73 and DNp63) (Fig. 1.7). In addition, alternative 
exon splicing of the P1 transcripts of TP63 and TP73 gives rise to other 
isoforms lacking the transactivation domain (DN’p73, Ex2Delp73, and 
Ex2/3Delp73 ad DNp63) (283, 293, 294). Alternative splicing generates 
additional complexity at the C-terminus: TP73 and TP63 undergo multiple 
C-terminal splicing generating nine transcripts for TP73 (a, p, y, 5, z, £, rj, 
rji and c|>— a being the full-length) (Fig. 1.8) (283, 295, 296) and three for 
TP63 (a, p, y) (284).
1.6.2 Function o f p63 and p73 and role in cancer development
Only a small percentage of human tumors have been shown to harbor p63 
and p73 mutations (297), in contrast to p53 whose functional loss through 
mutation is a pre-eminent finding in most human cancers. TA proteins 
resemble p53 functions transactivating many p53 target genes. Therefore, 
these proteins can regulate cell cycle and apoptosis after DNA damage. 
Despite their functional and structural similarity with p53, p63 and p73 play 
important and unique roles in human and mouse development and 
differentiation. P63 and p73 knock-out mice exhibit severe developmental 
abnormalities (298-300) and this is in contrast to p53-null mice, which are 
highly tumor prone but lack a development-defective phenotype. The 
literature on p63 and p73 is complex and controversial, and their role in 
tumor suppression has been much debated. Irwin and Kaelin (297) have 
been reported that only in a small percentage of human tumors p63 and
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C-terminal splicing variants of p73.
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p73 were mutated. However, recent studies have shown that some 
isoforms of p63 and p73 are overexpressed in human tumors (301, 302) 
whereas certain tumors exhibit loss or reduced expression of p63 and/or 
p73 (303-308). Recently, heterozygous knock-out mice for either p63 or 
p73 (p63+/‘ and p73+/') showed shorter life span than wild-type mice and 
develop spontaneous malignant lesions. All these data seem to 
demonstrate that these genes could act as tumor suppressors (309).
1.6.3 Function of DN isoforms
DN isoform proteins, lacking of the transactivation domain should not 
induce the transcription of target genes. Several studies have 
demonstrated that DN isoforms (in particular those manuscripts dealing 
with DNp73) act as dominant negative inhibitors of the TA proteins and of 
the other family members in cell culture (293, 296, 310). Acting as a 
dominant negative inhibitor, DNp73 can interfere with the p53 binding to its 
downstream responsive elements and can inhibit the transcription of the 
TA isoforms (TAp73 and TAp63). This effect can be mediated either by 
competition through its DNA binding domain, as for p53-responsive 
elements, and/or by protein-protein interaction through its oligomerisation 
domain. Recent data show that upon strong DNA damage DNp73 is 
rapidly degraded, releasing the block exerted on p73 and p53, thus 
allowing cell cycle arrest and apoptosis to proceed. Therefore the relative 
accumulation of DNp73 in human tumors could be an important 
determinant of cellular response to treatment. In several manuscripts it
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has been reported that the level of DNp73 is higher in those patients with 
a poorer prognosis. However the levels of TAp73 in those tumors were still 
in excess (311-313). Nevertheless, in a recent paper, using a tet inducible 
expression of DNp73 in cells, it has been found that although the DNp73 
levels were well above those of TAp73 and wild-type p53 there was no 
effect on the malignant phenotype. Furthermore, DNp73a does not induce 
a higher resistance to drug treatment in vitro or a more aggressive tumor 
in vivo (314).
Recently DNp73 has been strikingly shown, despite the lack of the TA 
domain, to be able to transactivate gene expression (315). Other studies 
have reported that both DNp73a and TAp73a were able to induce the 
accumulation of the endogenous wild-type p53 in various cell lines (316, 
317). Recently, as reported in chapter 1.4.3, DNp73a was shown to 
induce the p53-dependent activation of bTG2TIS21/PC3 expression at the 
promoter level in a neuroblastoma cell line. These findings together would 
strongly suggest that DN isoforms can have other functions, distinct from a 
simple antagonism on the TA isoforms and on p53.
1.7 Identification of a new p53-dependent gene
Despite being discovered 25 years ago, the tumour suppressor p53 
continues to be highly studied, receiving most of the attention in the field of 
cancer research. Since its discovery in 1979, the number of publications 
centred on p53 are even more than 35,000 and it is considered the
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common denominator in human cancer. P53 is, in fact, the most induced 
gene in response to cellular stress signals.
As a transcription factor, p53 can transactivate and transrepress many 
target genes; more than 1 0 0  have been identified through gene array 
analysis. Bioinformatic studies also predict more than 4,000 human gene 
containing putative p53 binding sites although the presence of a p53 
binding site does not necessary mean that the gene containing this 
binding site is efficiently transactivated by p53. Moreover, p53 can repress 
the expression of many genes without these binding sites (318).
For this reasons and considering that p53 is highly mutated in cancers, it 
can serve as “nodal” point for the integration of a large number of different 
signals (64). This could suggest that there have to be numerous 
downstream genes acting as mediators of the different p53-dependent 
functions. Despite many of those functions of p53 have been elucidated, 
there are yet functions not completely explainable through the available 
p53 network. Either the search of other genes activated by p53, and 
therefore acting downstream to p53, or of genes having a complementary 
but p53 independent activity, is one important area of research which 
could help in better understanding the “behaviour” of cancer cells and 
possibly in future better rationalise the therapy for patients suffering from 
cancer.
Starting from this consideration, a program aimed at discovering new p53 
dependent genes activated following damage started in the Laboratory of 
Molecular Pharmacology at the Mario Negri Institute. By using the
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differential-display technique, a cDNA fragment expression was increased 
after treatment the cells with a synthetic derivative of distamycin A able to 
interact with the DNA minor groove. In figure 1.9 a representative 
differential display experiment is reported showing the cDNA fragment 
overexpressed 24 hours after treatment of the wild-type p53 expressing 
ovarian cancer cell line A2780.
This fragment has been cloned and sequenced and was found to match to 
a sequence (named KIAA0247) deposited in gene bank together with 80 
new cDNAs (KIAA0201 to KIAA0280) deduced by analysis of cDNA 
clones from a cDNA library (319). The referenced publication does not 
contain any information regarding either the structure or the function of 
those genes whose cDNA sequence has been deposited. However, the 
authors reported the expression profiles for each cDNAs. In particular, the 
KIAA0247 cDNA has been found to be ubiquitously expressed at low 
levels in all human tissues tested. The isolated cDNA has been named 
DRAGO (DRug Activated Gene Overexpressed).
In order to isolate the complete cDNA containing the isolated fragment 
corresponding to the DRAGO gene, a cDNA library, prepared from human 
fibroblasts using Agt10 vector was hybridised with the isolated fragment as 
a probe in order to isolate the clone containing the full length cDNA of 
DRAGO. The positive clones were isolated and sequenced. In the 
meantime, during the sequencing of the isolated clones, the full-length 
cDNA (5,338 bp) subcloned in a pBluescript-SKII+ (pBS) vector was
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kindly given by Nagase from Kazusa (Japan). The complete cDNA has 
5,338 base pair and putatively codes for a protein of 303 amino acids.
To verify whether the increase was mediated by p53, the effects of 
antitumour drugs were evaluated in isogenic model-systems differing for 
p53 expression. For this purpose, the HCT-116 colon carcinoma cell line 
with wild-type p53 (clone 40.16, p53 +/+) or disrupted by targeted 
homologous recombination (clone 379.2, p53 - / - )  have been used. An 
increased transcription of the isolated cDNA could not be observed by 
either RT-PCR or real time PCR in cells where the p53 gene had been 
inactivated (clone 379.2), suggesting that the activity of the gene under 
investigation is regulated by p53.
1.7.1 DRAGO induction by anticancer agents
The mRNA induction of DRAGO was further investigated by real-time PCR 
experiments after the cellular treatments with several cytotoxic compounds 
differing from distamycin A by their mechanism of action, such as cisplatin, 
taxol, doxorubicin and fluorouracil, obtaining in each case an increased 
production of the same fragment. However, after UV and topotecan 
treatments, no increase in the expression of DRAGO was measured (Fig. 
1 .1 0  and table 1 .1 ).
Drugs were selected among conventional anticancer agents in order to 
use at least one compound from each group into which they are classified 
and that are known to induce the expression of p53.
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Conventional chemotherapy included a number of families defined by both 
their chemical structure and mechanism of action: alkylating agents, 
antibiotics, antimetabolites, topoisomerase I and II inhibitors, mitosis 
inhibitors and others. These conventional treatments have basically 
evolved over the DNA molecule as its main molecular target (320). 
Alkylating agents were the first compounds identified to be useful in 
cancer. These drugs add methyl or other alkyl groups onto target 
molecules. The most common site of alkylation is the N-7 position of 
guanine, but it varies depending on the family of drugs. The alkylating 
agents can act by attaching alkyl groups to DNA bases. This alteration 
results in the DNA being fragmented by repair enzymes in their attempts 
to replace the alkylated bases. Another mechanism by which alkylating 
agents cause DNA damage is the formation of cross-links, bonds between 
atoms in the DNA. In this process, two bases are linked together by an 
alkylating agent that has two DNA binding sites. Cross-linking prevents 
DNA strands from being separated for synthesis or transcription. Finally 
the action of alkylating agents causes the mispairing of the nucleotides 
leading to mutations.
Alkylators belong to one of several families: nitrogen mustards, 
nitrosoureas, triazenes, platinum compounds and antibiotics. These 
compounds can also be classified into either minor or major groove 
alkylating agents (320).
The platinum compounds such as Carboplatin and Cisplatin (cDDP) are 
alkylating agents of the DNA major groove. These related drugs covalently
71
bind to DNA with preferential binding to the N-7 position of guanine. They 
are able to bind to two different sites on DNA producing cross-links, either 
intrastrand or interstrand resulting in inhibition of DNA synthesis and 
transcription (320).
Brostallicin (PNU-166196) is a novel compound which is able to alkylate 
mostly N3-position of adenine on the DNA minor groove. These agents, 
which belong to the generally classified minor groove binders (MGB) have 
been shown to be highly effective in in vitro and in vivo preclinical tumour 
models unresponsive to other antineoplastic agents (321). The main 
representatives of this class, which reached the clinical trials, are the 
Brostallicin ad the antitumour agents derived from CC-1065, that is, 
Adozelesin, Carzelesin, and Bizelesin (322).
A number of antibiotics such as anthracyclines, dactinomycin, bleomycin, 
adriamycin, mithramycin, bind to DNA and inactivate it. Thus the synthesis 
of RNA is prevented. General properties of these drugs include: interaction 
with DNA in a variety of different ways including intercalation (squeezing 
between the base pairs), DNA strand breakage and inhibition with the 
enzyme topoisomerase II (320).
Most of these compounds have been isolated from natural sources and 
antibiotics. However, they lack the specificity of the antimicrobial 
antibiotics and thus produce significant toxicity.
The anthracyclines (doxorubicin and their analogs epirubicin and 
idarubicin) inhibit topoisomerase II and form free radicals.
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The main epipodophillotoxin, etoposide (VP-16), also inhibits 
topoisomerase II.
Topoisomerase I transiently breaks a single strand of DNA during DNA 
replication, thereby reducing torsional strain. Inhibitors of this enzyme 
derive from camptothecin, such as topotecan and irinotecan (323).
The antimetabolites interfere with enzymes that contribute to DNA 
synthesis. In this group there are antifolates, fluoropyrimidines, raltitrexed, 
cytarabine, gemcitabine, and adenosine analogs (fludarabine, pentostatin, 
cladribine). 5-Fluorouracil (5-FU; Adrucil®, Fluorouracil, Efudex®, 
Fluoroplex®) is an effective pyrimidine antimetabolite. Fluorouracil is 
synthesized into the nucleotide, 5-fluoro-2-deoxyuridine. This product acts 
as an antimetabolite by inhibiting the synthesis of 2 -deoxythymidine 
because the carbon - fluorine bond is extremely stable and prevents the 
addition of a methyl group in the 5-position. The failure to synthesize the 
thymidine nucleotide results in little or no production of DNA (324).
Mitotic spindles are essential when a cell starts to divide itself into two new 
cells. These spindles are very important because they help to split the 
newly copied DNA such that a copy goes to each of the two new cells 
during cell division. Spindles are microtubular fibers formed with the help 
of the protein "tubulin". The antimitotic drugs disrupt the formation of these 
spindles and therefore interrupt cell division. Among them, Vincristine is a 
mitotic disrupter since it binds to tubulin, thus preventing the formation of 
spindles and cell division. In contrast to other microtubule antagonists, 
taxol disrupts the equilibrium between free tubulin and mircrotubules by
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shifting them in the direction of assembly, rather than disassembly. As a 
result, taxol treatment causes both the stabilization of microtubules and 
the formation of abnormal bundles of microtubules. The net effect is still 
the disruption of mitosis (325).
1.7.2 Mouse DRAGO expression
Analogously to human, a mouse cDNA library has been screened using 
the same human cDNA fragment of DRAGO gene as a probe for the 
isolation of the murine cDNA coding the murine homologue of human 
DRAGO gene product.
The full length murine cDNA analog consists of 5,338 bp coding for a 
putative protein of 302 aminoacids. The comparison between the human 
and murine sequences revealed a striking 80% similarity both at 
nucleotide and aminoacid level.
The mRNA induction of DRAGO was further investigated in isogenic 
murine systems differing for p53 status by semi-quantitative RT PCR 
experiments. MEF expressing a wild-type p53 or lacking it was treated 
with several cytotoxic compounds and total RNA was extracted from 
treated and untreated cells. Semi quantitative RT-PCR experiments 
confirmed that the murine homologue to human DRAGO gene is induced 
upon cytotoxic treatments in a p53-dependent manner.
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Figure 1.9
Representative differential display experiment showing the induction of a 
cDNA fragment 24 hours after treatment in A2780 cell lines.
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Figure 1.10
Expression of DRAGO induced after cytotoxic compounds and UV 
treatments.
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PNU 166196 (200nM x24h) ++
DDP (25 mM x1 h R=24) * +
DDP (25 mM x1h R=6) -
MNNG (25 mM x2h R=24) * -
MNNG (100 mM x2h R=24) +7V
TAXOL (5 nM x24h) * -
TAXOL (25 nM x24h) -
TAXOL (50 nM x24h) +++
UV 20j * -
UV 40j -
UV 60j -
5-FU (50 nM x24h)* -
5-FU (100 nM x24h) +
5-FU (200 nM x24h) -
5-FU (400 nM x24h) -
5-FU (50 nM x 48h) ++
5-FU (100 nM x 48h) ++
5-FU (200 nM x 48h) ++
5-FU (400 nM x 48h) ++++
DOXO 30 ng/ml (24h)* 
DOXO 60 ng/ml (24h)
+
DOXO100 ng/ml (24h) -
DOXO 1000 ng/ml (24h) +
DOXO 30 ng/ml (48 h) -
DOXO 60 ng/ml (48h) +
DOXO100 ng/ml (48h) +
DOXO 1000 ng/ml (48h) +
CC-1065 (0,05 ng/ml x1h R=24h) ++
Table 1.1
Summary of level of DRAGO mRNA induction upon treatments at 
indicated doses
1.8 AIMS
Tumorigenesis can be viewed as an evolutionary process that allows 
somatic cells that evade normal controls of cell proliferation and cell death 
to promote their unlimited clonal expansion.
As outlined in chapters 1.1 and 1.2, cancer evolution can be fueled by 
genomic instability caused by faulty cell division or defective DNA repair. 
However, cells are efficiently protected from tumorigenesis by several 
failsafe mechanisms and checkpoints. One of the most important 
components of the systems that keep us relatively safe from cancer is p53 
which is arguably the most well-known tumor suppressor gene (see 
chapter 1.4). Despite the considerable amount of knowledge that has been 
accumulated on p53, the p53 network is not yet fully understood. 
Furthermore, the available sequences of the human genome have allowed 
the identification of genes that are theoretically transcriptionally activated 
by p53. The main outcome of p53 activity in controlling tumor growth is cell 
cycle arrest and apoptosis. Among these functions, much less is known 
about the mechanisms by which p53 induces apoptosis. For this reason, 
an ongoing program in the Molecular Pharmacology Laboratory at the 
Mario Negri Institute is aimed at identifying new gene downstream of p53 
with particular emphasis on those involved in apoptosis. By using the 
differential display technique DRAGO, a new gene, has been isolated, the 
expression of which is induced following cellular damage. Preliminary data 
suggest that DRAGO is a new gene activated following induction of DNA
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damage in a p53-dependent way (see chapter 1.7.1). The present studies 
have been undertaken with the overall aim to provide a preliminary 
characterisation of the DRAGO gene. The work described here had the 
following specific objectives:
i. The initial aim was to characterise the structure of the gene at a 
molecular level. Thus, the full length cDNA has been compared with 
the available sequences of human genome.
ii. As DRAGO is a p53 downstream gene, a genomic fragment 
comprising a region upstream the first exon has been isolated with the 
aim to characterise the promoter region putatively containing the p53 
canonical responsive elements. The promoter activity of genomic 
fragments isolated and the responsiveness to p53 induction have been 
examined using the luciferase reporter gene assay in transient 
transfection experiments in the absence or presence of p53. Given that 
p53 belongs to a family of genes including p63 and p73, the hypothesis 
has been tested that these functionally homologous family members 
might induce the expression of DRAGO in analogy to p53. The effect of 
DNp73a on p73 isoforms transactivation of DRAGO gene expression 
was also evaluated.
iii. Many human genes with tumor suppressor activity, like p53, have been 
found to be mutated or altered in human tumors. So another aim of the 
present study has been the search for any mutations of the DRAGO  
gene at a nucleotide level. To this end, on the basis of the molecular 
structure SSCP analysis, followed by DNA sequencing, have been
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performed in human cell lines, cells with acquired resistance against 
cytotoxic drugs and human tumor sample.
iv. In order to understand the putative secondary structure of the protein, 
a computational analysis of the sequence of protein, derived on the 
basis of the cDNA, have been performed.
v. To understand the evolutionary conservation of DRAGO, the human 
sequence has been compared with cDNA sequences from different 
organisms for which the genome was available from the public gene 
bank.
vi. Another important objective of the study was the characterisation of the 
function of the gene under investigation. To that end, the effects of the 
overexpression of the gene were evaluated in stable and transient 
transfections experiments. The full length cDNA, the coding region of 
the gene and different deletion fragments have been subcloned in an 
expression plasmid under a strong promoter ensuing the constitutive 
expression of the gene in an in vitro model. Furthermore, the function 
of the DRAGO gene was explored by investigating and characterizing 
mice in which the gene was knocked out (KO). KO fibroblasts have 
been isolated from mouse embryos and used for in vitro experiments to 
evaluate of the response to DNA damage.
80
CHAPTER 2 
MATERIALS AND METHODS
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2.1 Cell culture
2.1.1 Culture condition
All the cell culture procedures were carried out aseptically in laminar flow 
hoods. Cells were maintained in a humidified incubator at 37 °C with 5% 
C 0 2.
The human cancer cell lines used in these studies were: the human 
ovarian carcinoma cell lines A2780, SW626, COS-7, IGROV-1 and SKOV- 
3, the human colocarcinoma cell lines HCT-116 and SW620, the human 
acute lymphoblastic leukaemia (ALL) cell lines ALL-PO, Reh, Tom-1, the 
human osteosarcoma cell lines U 20S  and Saos-2, the metastatic prostate 
carcinoma cell line DU145, the human lymphoblastoids cell line CEM, the 
human promyelocytic cell line HL-60 and the murine fibroblast cell line 
Swiss 3T3. Drug-resistant cell lines were: A2780/cp70, an A2780 cellular 
clone resistant to DDP (326); 1A9PTX22 resistant to paclitaxel, were 
generated from 1A9 (327) and kindly given by NCI; CEM-VM1 (328), 
generated from their drug-sensitive parental CEM cells, were selected for 
their resistance to VM26; LoVo/DX were selected from LoVo cells for their 
resistance to doxorubicin (329) and also to other chemotherapeutic 
agents, such as etoposide and vincristine (330).
All the ovarian cancer cell lines (except COS-7), the ALL cell lines, SW620 
and U 20S cells were grown in RPMI 1640 supplemented with 10% (v/v) 
fetal calf serum (FCS) and 2 mM of L-Glutamine.
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DU 145, CEM and HL-60 were grown in RPMI 1640 supplemented with 
10% (v/v) heat-inactivated FCS and 2 mM of L-Glutamine.
Saos-2, Swiss 3T3 and C O S-7 cells were maintained in DMEM 
supplemented with 10% of FCS and 2 mM of L-Glutamine. To the culture 
medium of Swiss 3T3 and C O S-7 cells, 1 mM Na-pyruvate (Mascia 
Brunelli, Milan-ltaly), 1% non-essential amino acid (Mascia Brunelli) were 
added. C O S-7 medium also required 20 mM Hepes Buffer solution 
(Mascia Brunelli). LoVo/DX were grown in Ham’s F12 medium 
supplemented with 10% of FCS and 2 mM of L-Glutamine. The different 
media were purchased from Sigma (Milan-ltaly) and contained all the 
minerals and supplements necessary for the growth of the cells except for 
the serum (Sigma) and the L-glutamine (Sigma), which were added when 
needed.
Cells were passaged routinely to maintain them in the growth logarithmic 
phase. The cells were renewed every four-five months of culture.
Passage procedures for leukemia cell lines provided for seeding cells at a 
suitable density after counting the cell at the cell culture counter (Coulter 
Channelyser® 256, Beckman Coulter, Milan-ltaly). The other cell lines were 
washed twice with warm sterile phosphate buffer saline (PBS, Bio- 
Whittaker, Milan-ltaly) and detached with a solution of 1x trypsin/EDTA 
(Bio-Whittaker). The trypsin activity was stopped by adding calf serum- 
containing medium. After centrifugation at 1,200 rpm for 10 minutes, cells 
were resuspended in the appropriate medium, counted and seeded at the 
desired concentration.
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2.1.2 Long term storage o f cultured cells
To cryopreserve batches of cells, exponentially growing epithelial cells 
were washed twice with PBS, detached and centrifuged at 1,200 rpm for 
10 minutes at room temperature. Cells growing in suspension were only 
centrifuged as reported above. The cell pellet was resuspended in culture 
medium containing 50% of cryoprotective medium (Bio-Whittaker) and 
20% of calf serum to a density of 5 x 106 cells/ml. Aliquots of 1 ml were 
cooled slowly on ice 30 minutes, pre-frozen in nitrogen liquid stream for 3 
hours and then immersed in liquid nitrogen. To recover from the cell bank, 
each vial of cells was thawed rapidly to 37 °C in a water bath, transferred 
in fresh medium and centrifuged at 1,200 rpm for 10 minutes. Pellets were 
then resuspended in the appropriate culture medium and moved to a 
tissue culture flask. The day after cells were washed and new, fresh 
medium was added.
2.2 Generation of cellular clones 
2.2.1 Subcloning o f the full length cDNA
To transfer the gene of interest in the genome of host cells, the DNA was 
excised from the plasmid of origin by restriction endonuclease digestion 
and subcloned in the appropriate expression vector. The expression 
vector used was the PCDNA3 (Invitrogen, Milan, Italy). The principal 
features of this plasmid are: the presence of a strong viral promoter 
(cytomegalo virus, CMV) driving the transcription, a polylinker sequence
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(also known as multiple cloning site -  MCS) the DNA recognition 
sequence for many restriction enzymes to facilitate the subcloning of the 
gene of interest, a bacterial resistance gene (ampicillin) for selection of 
recombinants and an eukaryotic resistance gene (neomycin) for selection 
of cells containing the plasmid. To subclone the gene of interest, the 
general molecular biology techniques reported in Sambrook and Russel 
(331) were followed. Briefly, the gene of interest was excised from the 
plasmid of origin by digestion with the appropriate restriction enzymes for 
1 hour at 37 °C in a buffer supplied with the enzyme. The entire reaction 
was loaded on 1% agarose gel (see section 2.7.1). The appropriate band 
containing the cDNA was excised from the gel and the DNA extracted 
from the agarose (section 2.7.2). The cDNA thus obtained was stored at -  
20 °C. The PCDNA3 plasmid was digested with the same restriction 
enzymes used to excise the cDNA from the original plasmid, loaded on 
agarose gel and purified from it. The linearised pCDNA3 plasmid was 
ligated with the excised cDNA insert in a 1:3-1:5 proportion in 10 pi of a 
solution containing 3 U of T4 DNA ligase (Promega, Milan-ltaly) and 1x 
Rapid Ligation Buffer (30 mM Tris-HCI, pH 7.8, 10 mM MgCh, 10 mM DTT 
and 1 mM ATP, supplied with the ligase) for 4 hours at room temperature. 
Five pi of this solution were then used to transform competent bacteria.
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2.2.2 Subcloning of the coding sequence
The coding region (nucleotides 269-1180) of DRAGO was obtained by 
PCR (see section 2.4) amplification using as a template the construct 
pBS-DRAGO. The coding region was subcloned in three vectors 
pCDNA3HA (see Results chapter 6.2), pEGFP-C1 (BD Bioscience 
Clontech, Milan-ltaly) and pG EX-3X (Amersham Biosciences, M ilan- 
ltaly). Briefly, the pEGFP-C1 vector has the same features of the pCDNA3 
vector described above except for the bacteria selection which is a 
kanamycin resistance. The main characteristic is the presence of the 
cDNA encoding the GFP with the MCS at the 3’ end of the GFP cDNA. 
Therefore the genes cloned into the MCS are expressed as fusions to the 
C-terminus of the GFP protein as they are in the same frame as GFP and 
there are no intervening stop codons. The pG EX-3X vector is designed for 
inducible, high-level intracellular expression of genes or gene fragments 
as fusions with Schistosoma japoncum Glutathione S-transferase (GST). 
This vector has a tac promoter for chemically inducible (using the lactose 
analogue isopropyl p-D-thiogalactoside, IPTG), high level expression of 
exogenous protein in E. coli hosts. The MCS is located at the 3’ end of the 
cDNA encoding the GST protein. Therefore, genes therein cloned are 
expressed as fusions to the C-terminus in frame with the GST protein. 
The factor Xa protease recognition site for cleaving the desired protein 
from the fusion product is between the GST coding sequence and the 
MCS. Bacterial cells carrying the pG EX-3X vector are selected for 
ampicillin resistance.
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Forward and reverse primers were designed to contain the restriction 
enzyme specific sequence at their 5’ termini in order to further allow sub­
cloning in the vectors. The sequences of the forward and reverse primers 
are listed in figure 2.1 for each construct. Underlined are the recognition 
sites for restriction enzymes in the forward and reverse primers, which are 
Xho\ and Xba\, BamHl and EcoRI, Kpn\ and HindiII for subcloning in the 
pCDNA3HA, pG EX-3X and pEGFP-C1 vectors, respectively. PCR 
amplification conditions were as follows: 95 °C for 40 seconds; annealing 
for 30 seconds; 72 °C for 1 minute and 30 seconds, for a total of 30 
cycles, followed by an additional step at 72 °C for 7 minutes. The 
annealing temperature (AT), specific for each set of primers is indicated in 
figure 2.1. The PCR products were analysed through 1% agarose gel. The 
size of the PCR amplified fragments was compared with the marker’s run. 
The DNA band of the expected size were extracted from the gel, 
subcloned in the pGEM -T easy vector for TA cloning (see section 2.2.4), 
excised by restrictrion endonuclease digestion with appropriate enzymes 
to be subcloned in the suitable vector. The procedure with respect to the 
restrictions and to the vectors was followed as described in section 2 .2 .1 .
2.2.3 Subcloning o f the deleted mutants
N - and C-terminus deleted mutants of DRAGO coding region were 
generated by PCR and subcloned in the pCDNA3HA, pG EX-3X and 
pEGFP-C1 vectors. The entire coding region subcloned in the same
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pCDNA3HA
Forward >XHOI
5’-CICGAGTGCCATGGCAGGATAGCACC-3’
Reverse >XBAI
5’- T  CT AG AT CATGCTT CTTT CAACAGT G -3 ’
AT 60 °C
pGEX-3X
Forward -  Gex S
5’-GGATCCCCTGCCATGGCAGGATAGCACCA-3’
Reverse Gex A
5’-G  AATT CTGCTT CTTT CAACAGT G G AAT- 3 ’
AT 6 0 °C
pEGFP-C1
Forward KIA1
5 -AAG CTTGCCATGGCAGGATAGCCACCAAA-3’
Reverse KIA2
5 -G G T  ACCT CATGCTT CTTT CAACAGT G-3*
AT 60 °C
Figure 2.1
Primers for subcloning the coding sequence of DRAGO in the vectors here 
reported. The sites specific for restriction enzymes were underlined.
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vector was used as template. Primers were designed to contain the 
restriction enzyme specific sequence at their 5’ termini in order to further 
allow sub-cloning in the vectors. For N-terminus deleted mutants, the 
reverse primer was the same (XBAI and GexA respectively for PCDNA3HA 
and pGEX-3X constructs, see figure 2.1) as that used for the entire PCR  
amplified coding region. Similarly, for the C-terminus deleted mutants, the 
forward primer was the same as for the entire coding region (XHOI, GexS 
and KIA1 for pCDNA3HA, pG EX-3X and pEGFP-C1 constructs). The 
sequences of the primers and the corresponding annealing temperatures 
are listed in figure 2.2 for each construct. PCR conditions for amplification 
and the subcloning procedure were the same as described in 2 .2 .2 .
2.2.4 TA cloning
This technique provides a one step cloning strategy for a direct insertion of 
PCR product into a vector (T-vector), taking advantage of the Taq enzyme 
non-template dependent activity of adding an adenenine (A) to the 3’ ends 
of PCR products. The T-vector contains in its MCS complementary an 
unpaired 3’ thymidine (T). PCR products were ligated at a ratio 1:5, 1:10 in 
the pGEM-T easy vector from the cloning kit (pG EM -T easy vector 
systems) purchased from Promega and following the manufacture’s 
instructions.
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pCDNA3HA-deletion mutants
Forward XHOI 5 -C T C G A G T  G CC A T G G C AG G AT AG C A C C -3 ’
Reverse HA-C1 5 ’- T  C T  AG AT C ATG AC G TG  AG G G A T AAAAG G C TT T  G -3  ’ 62  °C
HA-C2 5 ’- T  C T AG AT C A TG C A G TTT C TTT  G T G T G C -3 ’ 60 °C
HA-C3 5 ’- T  C T AG AT C A CC  AG G AAG AG G T G G TT G C -3 ’ 60 °C
HA-C4 5 ’- T  C T  AG AT C AG G C AG AG C C C C  AG G C T T  C AC A T A G -3 ’ 62 °C
HA-C5 5 ’- T  C T  AG AT C AAT C TT  C T  CC A C C T G C  AG AG G A -3  ’ 60 °C
HA-C6 5 ’- T  C T  AG AT C A TTG C T C C C TT G G C A C G C T  C C T-3 *  62 °C
Forward HA-N1 5 ’-C T C G A G T C A G T G T T T G C C G T G G C C T C C -3 ’ 58 °C
HA-N2 5 ’-C T C G A G G T G T T C C T T C C G C T A G T G -3 ’ 58  °C
HA-N3 5 ’-C T C G A G G G A G A C G G A C T T G C T T C C -3 ’ 58 °C
HA-N4 5 ’-C T  CG AG GAG AAT G G TG G  C T AC A T C T G C C  A C C C C -3  ’ 58 °C
HA-N5 5 ’-C T C G A G T G C A G A G A C C C C C T G A C A G C A G G C -3 ’ 58 °C
HA-N6 5 -C IC G A G T  G T G C T G A A G G C T A C A T G TT G A A G -3 ’ 58 °C
Reverse XBAI 5 ’- T  C T  AG A T C AT G C TT C TTT  C AA CA G T G - 3 ’ 
pGEX-3X deletion mutants
Forward GEX S 5 -G G A T C C C C T  G CC A T G G C A G G  A T AG C A CC  A -3  ’
Reverse GEX-C1 5 ’-G A A T T C T C A TG A C G T G A G G G A T A A A A G G C T TT G -3 ’ 61 °C
GEX-C2 5 ’- G  AATT C T C A TG C A G TTT C TTT  G T G T G C -3 ’ 59 °C
GEX-C3 5 ’-G A A T T C T C A C C A G G A A G A G G TG G T T G C -3 ’ 61 °C
GEX-C4 5 ’-G A A T T C T C A G G C A G A G C C C C A G G C TT C A C A T A G -3 ’ 62 °C
GEX-C5 5 ’- G  A A TTC T CAAT C TT C T C C A C C T G C A G A G G A -3 ’ 61 °C
GEX-C6 5 ’- G  A A TTC T C A TTG C T C C C TT  G G C A C G C T C C T -3 ’ 62 °C
Forward GEX-N1 5 -G G A IC C C C T C A G T G T T T G C C G T G G C C T C C G -3 ’ 59 °C
GEX-N2 5 ’-G G  AT C C C C G T G TT  C C TT  C C G C T  A G T G - 3 ’ 53 °C
GEX-N3 5 ’-G G A T C C C C G G A G A C G G A C T T G C T T C C -3 ’ 59 °C
GEX-N4 5 ’-G G A T C C C C G A G A A T G G T G G C T A C A T C T G C C A C C C C -3 ’ 59 °C  
GEX-N5 5 ’-G G A T C C C C T G C A G A G A C C C C C T G A C A G C A G G C -3 ’ 57 °C
GEX-N6 5 ’-G G  AT C C C C T G T G C T  G A A G G C T A CA T G T T  G A A G -3 ’ 59 °C
Reverse GEX A 5 ’-G A A T T C T G C T TC T TT C A A C A G T G G A A T -3 ’ 
pEGFP-C1 deletion mutant
Forward KIA1 5*-A A G C T T G C C A TG G C A G G A TA G C C A C C A A A -3 ’
Reverse HA-C2 5 ’- T  C T AG AT C A TG C A G TTT C TTT  G T G T G C -3 ’ 61 °C
Figure 2.2
PCR condition (primers sequences and AT) for the amplification of N -  and 
C-terminus deletion mutants of DRAGO coding region.
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2.2.5 Preparation of competent bacterial cells for transformation
Bacterial strains in the experiments reported in this thesis were XLIBIue 
(Stratagene) and JM110 (Stratagene). The latter, an E. coli strain which 
lacks both dam (DNA adenine methylation) and dcm (DNA cytosine 
methylation) gene was used for PCDNA3HA constructs, being the Xba\ 
restriction enzyme site, used for cloning, methylation sensitive (see section 
2.2.3). The methylation avoids the cleavage by means of the enzymes. 
From a sterile bacterial cellular suspension, 10 pi of suspension were 
spread to an agar plate containing LB (Luria-Bertani) agar and incubated 
overnight at 37 °C.
Complete LB agar (Sigma) (which is constitute by LB broth and agar-1.5% 
w/v) and LB broth (Sigma) where purchased as lyophilised powder to be 
reconstituted in a suitable volume of deionised water per grams of powder 
as indicated by the manufacturer. The solution was then autoclaved at 120 
°C for 10 minutes and poured on 90-mm dish (Corning-Costar, Milan-ltaly) 
and allow to dry under sterile hood.
Whenever required to the medium the antibiotic of selection (for PCDNA3 
and pG E X -3X  derived plasmids, ampicillin at the final concentration of 50 
pg/'ml; for pEGFP-C1 derived plasmids, kanamycin at the final 
concentration of 10 pg/ml was added after autoclaving once it had cooled 
to 55 °C).
A single colony was picked-up with a sterile disposable loop, and 
resuspended in a sterile 50 ml conical tube, with 10 ml of sterile LB
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medium and allowed to grow in a 37 °C heated shaking incubator (Folabo, 
Milan-ltaly) at 225 rpm overnight. One ml of such liquid bacterial culture 
was then transferred into 100 ml of sterile LB medium and placed into the 
37 °C heated shaking incubator at 225 rpm.
To harvest bacterial cells in logarithmic growth phase, 2 hours later, 1 ml 
of liquid culture was transferred, under a laminar flow in a disposable 
cuvette and the absorbance at 600 nm wave-length was read on the 
spectrophotometer. E. coli concentration in the liquid culture was 
calculated by considering that 1 Aeoo nm unit corresponds to about 109 
bacterial cells/ml. When the 600 nm absorbance reached A 0.3 units 
(corresponding to roughly 2.4 x 108 cells/ml;) the bacterial suspension was 
transferred in two ice-cold sterile 50 ml conical tubes and the cell growth 
was stopped by placing the tubes on ice for 15 minutes. E. coli cells were 
pelleted by centrifugation at 3,000 rpm for 10 minutes at 4 °C and, after 
removing the LB medium, cell pellets were pooled in the same tube by 
gentle resuspension in 10 ml of ice-cold sterile 0.1 M CaC^ solution 
(obtained by dilution of a 2 M  CaCI2 solution, prepared by dissolving 14.7 g 
of CaCI2 in 100 ml H20  and fiitering the solution with a syringe equipped 
with a 0.2 jam filter). After addition of 40 ml of ice-cold sterile 0.1 M CaCh 
solution, bacterial suspension was incubated on ice for 30 minutes and 
subsequently centrifuged at 3,000 rpm for 10 minutes at 4 °C. The 
supernatant was then removed and the cell pellet was carefully 
resuspended in 5 ml of an ice-cold sterile 0.1 M CaCL containing 15% 
(v/v) glycerol (Sigma). This bacterial suspension was dispensed in 1.5 ml
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Eppendorf tubes (Eppendorf, Milan-ltaly) (400-500 jllI aliquots for each 
tube) and kept at 4 °C for 24 hours after which the tubes were quickly 
frozen in liquid nitrogen and stored at -8 0  °C. The cells maintained their 
competence for transfection for 1-2 months when kept at -8 0  °C.
Fifty pi of freshly prepared competent cells were transformed with 50 ng of 
a DNA vector able to confer ampicillin resistance and 1/100,000 (dilution 
factor, 105) of the bacterial suspension was plated as described in agar 
plates. Transformation efficiency, calculated on the basis of the formula 
(NUMBER OF COLONIES) x (103) X (DILUTION FACTOR) / 50 ng, was 
expressed as the number of colony forming units (CFU) per jig of plasmid 
DNA. Generally, 106-108 CFU per pg of plasmid DNA were indicative of a 
good preparation of competent bacterial cells.
2.2.6 Transformation of bacteria
In an ice-cold 10 ml Falcon 2059 tube (Falcon, Becton Dickinson), 50 pi of 
competent bacterial cells were diluted to a final volume of 100 pi with 0.1 
M CaCb and either 50 ng of purified plasmid or half of the volume of the 
ligation reaction. The mixture was gently mixed and the tube was chilled 
on ice for 30-40 minutes, incubated for 2 minutes at 42 °C in a water bath 
and for 2 minutes again on ice. After a 5 minute incubation at room 
temperature, 900 pi of LB medium were added and tube was placed into a 
37 °C heated shaking incubator at 225 rpm for 1 hour. The tube was then 
centrifuged at 3,000 rpm for 5 minutes at room temperature, most of the 
supernatant LB removed and the bacterial cell pellet resuspended in the
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remaining fluid and spreaded into 90-mm dish, containing LB agar medium 
plus the antibiotic of selection and incubated overnight at 37 °C without 
agitation.
2.2.7 Identification of recombinant clones and purification o f DNA 
from bacteria
Each colony, representing antibiotic-resistant/transformed growing 
bacterial cells, was picked-up with a sterile disposable loop and dissolved 
in a 15 ml falcon tube containing 3 ml of liquid LB medium supplemented 
with antibiotic and allowed to grow overnight at 37 °C with shaking at 225 
rpm.
Plasmidic DNA was purified from bacterial suspension using the Quiagen 
mini-prep kit (Quiagen, Milan-ltaly). The procedure, starting from 1.5 ml of 
bacterial suspension was exactly as described by the manufacturer. The 
recovered DNA, in 50 pi of water, was subjected to restriction digestion 
with appropriate restriction enzymes to verify that the insert was indeed 
present in the colony isolated. After digestion and separation on agarose 
gel, the fragments of DNA were visualised by using an UV transilluminator. 
The positive colonies containing the right insert were stored at -8 0  °C after 
the addition of 0.5 ml of 50% sterile ultra pure glycerol (Sigma) to 0.5 ml of 
the bacterial suspension used for the enzyme digestion. When necessary, 
the remaining DNA was used for confirmation by DNA sequencing, which 
was performed through custom sequencing services (through a core 
facility available at Mario Negri Bergamo, Bergamo, Italy). Once verified 
that the plasmid contained the right insert and sequenced, if necessary, a
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large scale preparation of DNA was performed, using the Qiagen Plasmid 
Midi Kit (Qiagen) following the procedures reported in the instruction 
manual.
The DNA recovered from the midi preparation was quantified at the 
spectrophotometer by reading the absorbance at 260 nm and 280 nm. The 
quality of the DNA prepared was determined by the ratio between 260 nm 
and 280 nm absorbances, which should be 1.8.
For quantification the extinction coefficient was used. The amount of DNA 
was calculated considering that a solution of 50 pg of DNA/ml would give a 
reading of 1 at 260 nm.
2.2.8 DNA-Transfection
DNA was transfected in different cell lines by using the calcium phosphate 
precipitate method. Sterile water-dissolved DNA was mixed with a 0.25 M 
CaCI2 solution (obtained solution from a stock solution 2 M CaCh, see 
3.2.5) in a volume of 250 pi. In a 4 ml transparent tube (Falcon), 250 pi of 
a 2X HEPES-Buffered Saline (HEBS 2X) were placed:
HEBS 2x final concentration
1.6g N a d  280 mM
0.074g KCI 10 mM
0.027g Na2H P 0 4*H20  1.5 mM
0.02g Dextrose 12 mM
1g HEPES 50 mM
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The salts are dissolved in 50-70 ml of distilled water and the pH of the 
solution is then adjusted to 7.2 with 0.5 N NaOH and then brought to 100 
ml with sterile water.
With the use of a 1 ml sterile pipette fixed to an automatic pipettor placed 
in the tube containing the HEBS solution, the air was forced inside the 
tube. To the bubbling solution, the DNA-CaCb mixture is added dropwise, 
then, vortexed for 20 seconds and kept in a tube holder for 30 minutes. 
The solution is then added dropwise to the cells seeded in a 25 cm2 flask 
and incubated 16 hours at 37 °C. The day after, cells are visualised under 
the microscope to verify the presence of small precipitates of CaPC>4 on 
the cell surface. The cells are then extensively washed with sterile PBS at 
least three times and resuspended in complete culture medium.
2.2.9 Isolation o f cell clones stably expressing the gene o f interest
Forty-eight hours after the end of transfection, the cells were detached 
with trypsin/EDTA solution. After counting, the cells were seeded in 9 mm 
plates at a density of 5,000 cells/ml in medium containing the selection 
antibiotic (500 pg/ml of G418 for neomycin resistance gene containing 
plasmids). At these antibiotic concentrations parental cells were killed and 
the only cells growing were likely to be those which have integrated in their 
DNA the transfected plasmid. The plates were then incubated at 37 °C 
and the medium renewed every two-three days. Once the colonies were 
formed as visualised under the microscope, they were isolated from the 
other by using plastic rings which were stuck to the plate by using
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vaseline. Twenty pi of a trypsin/EDTA solution were added to the single 
colony isolated to detach the cells which were then placed in a 24-wells 
plates containing 1 ml of medium plus selection antibiotic. The different 
clones picked up from the original plates were grown and passed in 
duplicate in 6 well plates. One plate was used to maintain the cell clone for 
further studies and for long term storage. The other was used to verify the 
overexpression of the mRNA of the gene of interest by screening the 
clones thus obtained by Northern blotting. The clones selected were then 
expanded and stored in different aliquots in liquid nitrogen.
2.3 Luciferase reporter assay
These experiments were performed to evaluate the promoter activity of 
DNA fragments subcloned in the promoterless plasmid pGL2-Enhancer 
vector (Promega), carrying a non mammalian gene luciferase followed by 
a viral enhancer and a multiple cloning site at its 5 ’. The genomic 
fragments to be analysed for promoter activity are subcloned in the 
multiple cloning sites of pGL2 vector using restriction enzymes-based 
ligations. In same cases fragments were excised from the DNA region in 
which it was contained by restriction enzymes reaction. Otherwise 
fragments were PCR amplified to introduce the sequence site for cleavage 
of suitable restriction enzymes for subsequent cloning in the pG L2- 
enhancer vector. Primers are listed in figure 2.3 and underlined is the 
restriction enzyme sequence introduced by PCR. Once verified the exact 
insertion and orientation of the fragment using the procedures reported in
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964 bp
Forward Kpnl 5’-CCCGGGAGGTACCTGGCCCGGCCGGCGGCGCGT-3’ 
Reverse Xhol-rev 5’-GTTTTT GAG ATTAAAG AG C ACTCGAG G CG CGG G -3’ 
AT: 62 °C 
2.5-Kb
Forward Xhol-fwd 5’-G  AAAAGTTACCCTCGAG G AATTTAG GAG C-3’ 
Reverse Hindlll 5’-TT G AGCG AACACCCT CTAACAAG CTTT C-3*
AT: 58 °C
Figure 2.3
PCR conditions (sequence primers and AT) for amplification of promoter 
fragments 964-bp and 2.5-Kb. The sequence for the restriction enzymes 
is underlined.
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2.2.5, the plasmids are transfected in mammalian cells growing in culture. 
The luciferase activity was evaluated in transient transfection (following 
the procedure described in 2.2.8). The transient expression of this plasmid 
in mammalian cells results in a very low level of luciferase (due to the 
absence of a promoter), which was detected in cell lysates using a 
commercially available kit (Dual luciferase system, Promega). Forty-eight- 
72 hours following transfection, the medium was removed and the cell 
processed as reported in the manual of instruction of the kit. The 
luciferase levels were measured in a luminometer and the values 
corrected for the expression of a control plasmid co-transfected with the 
plasmid under examination, which encoded a renilla luciferase 
distinguishable from the fire-fly luciferase utilised in these experiments.
2.4 PCR
The polymerase chain reaction (PCR) follows the principles in which a pair 
of primers (forward and reverse) defines the region to be amplified. After 
denaturation (generally at 95 °C), primers are allowed to anneal to their 
complementary strand by lowering the temperature to their optimal 
annealing temperature which is specific for each set of primers and is 
linked to the oligonucleotides sequence. AT can be calculated on the basis 
of the following formula: AT=Tm-t, where Tm = 4x (G+C) +2x (A+T) is the 
melting temperature and 3 °C>t>5 °C. An elongation step allows the Taq 
DNA polymerase to start the polymerisation reaction downstream of the 3’ 
ends of the primers (generally at a temperature of 72 °C). These three
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steps are then repeated for “n” (usually 30) cycles to allow exponential 
amplification of the target sequence. A final step, at 72 °C for 7 -10  
minutes allows the Taq polymerase to conclude the polymerisation step. 
Amplification is measured by resolving products through agarose gel 
electrophoresis. Whenever necessary, PCR products were then purified 
from gel.
PCR reaction mix was made using as a Taq purchased from Takara 
(Gennevilliers, France) with which all the components necessary for the 
reaction (except for the primers and DNA template) are provided. PCR 
reaction mix was made following manufacturer's instructions. Generally, 
nucleotides (dNTPs) are used to a final concentration of 0.2 mM, MgCI2 to 
a final concentration of 1.5 mM, and 0.5 U of Taq. Forward and reverse 
primers were added to a final concentration of 500 nM. Primers were 
designed on the basis of the sequence reported in the Genbank database. 
The “GeneFisher” software free available online (web address: 
http://bibiserv.techfak.uni-bielefeld.de/qenefisher/) was used to design the 
best set of primers to be used for each gene. Synthesis of oligonucleotides 
used as primers was performed by Sigma.
To the reaction mix, DMSO (dimethyl sulfoxide) was also added to a final 
concentration of 5%. To the final reaction mixture, a quantity of DNA 
template was added, (20 ng of plasmidial DNA, 100 ng of genomic DNA) 
then quickly spinned in a microfuge to recover all the fluids at the bottom 
of the tube and placed in PTC-200 thermal cycler (MJ research, 
Watertown, MA). Amplification conditions and cycle numbers were
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selected each time according to the AT of the pair of primers and the 
length of the PCR product to be amplified.
2.5 SSCP analysis
This analytical method was developed for detecting a single point mutation 
in a DNA sequence.
The SSCP technique comprises amplification of DNA by PCR, 
denaturation and electrophoresis in a neutral polyacrylamide gel.
2.5.1 Sample preparation
Exons 1 -5  of human DRAGO gene were amplified by PCR (see 2.4) using 
as a template, genomic DNA extracted from either human cancer cell lines 
or human tumors using the Wizard genomic DNA purification kit 
(Promega) following the instruction manual provided by the manufacturer. 
Tumor tissues were obtained at first laparotomy before any chemotherapy, 
freed of necrotic, hemorrhagic and connective tissue and immediately put 
in liquid nitrogen, then stored at -8 0  °C until processed. Ovarian tumors 
were kindly given by Prof. Costantino Mangioni (Ospedale San Gerardo, 
Monza, Italy). DNA samples from other tumor types were kindly given by 
Prof. Cappella (Ospedale di Circolo, Varese). PCR procedure was 
performed as described in section 2.4, except for the reaction mix, which 
was the PCR master mix purchased from Promega following the 
manufacturer’s instruction. The primers are listed in figure 2.4 and the AT 
is indicated. The final volume of each reaction was 50 pi: 10 pi of the
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Forward Exon 1 5-TACAGCTGGGTCAGTGACGCGG-3’ 
Reverse Exon 1 5-ACTCACCCGGG AG CCGG C-3’
AT: 60 °C
Forward Exon 2 5-AGCCACTTCTGTG CTTGCCTCT-3’ 
Reverse Exon 2 5-CTCCAGGTGACTCATTAGAC-3’
AT: 52 °C
Forward Exon 3 5’-AATGGACGATACATTAGAGA-3’ 
Reverse Exon 3 5 -T T  CCT GTAG AG G CCTT C AG A -3 ’
AT: 52 °C
Forward Exon 4 5'-AGTAATGCTTGCACCTGCCT-3’ 
Reverse Exon 4 5-ATGTCTGTATTGCACCATTC-3’
AT: 52 °C
Forward Exon 5 5’-AGCAAGGACCCTAAGCAGCTA-3’ 
Reverse Exon 5 5-GAATCCAGCATGATAAGGTG-3’
AT: 52 °C
Figure 2.4
PCR conditions (primers sequences and AT) for amplification of human 
exons of DRAGO gene.
amplification product were loaded on 1% agarose gel to be checked as 
specifically amplified. Ten pi were destined for sequencing, 20 pi were 
mixed with 40 pi of denaturing buffer (see receipt below) and heat 
denatured at 95 °C for 5 minutes and then chilled on ice for 2 minutes. 
Denaturing buffer Final concentration
9,5 ml deionised formamide 100% 95%
20 pi NaOH 5M 10 mM
250 piXylene cyanol 10% 0.25% (w/v)
250 ijI Bromophenol blue 10% 0.25% (w/v)
to a final volume of 10 ml.
2.5.2 Gel preparation and electrophoresis
A 16x20 cm gel electrophoresis apparatus with 0.8 cm thick spacers was 
used. SSCP analysis was performed loading the denatured PCR fragment 
on 0.7x polyacrylamide gel prepared as follows:
Final concentration
11.27 ml MDE gel solution 2x 0 .75x
3 ml TBE 10x 1x
300 pi APS 10% 1%
30 pi TEMED 0.1%
to a final volume of 30 ml with deionised water.
The MDE (FMC BioProduct, Vallensbaek Strand, Denmark) gel solution is 
a polyacrylamide like matrix highly sensitive to DNA conformational 
differences.
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Gel electrophoresis was carried out at 150V at room temperature for at 
least 12 hours.
2.5.3 Gel staining
The gels were stained with silver. Before staining, they were immersed in 
a fix solution and kept in horizontal rotation for 6 minutes. The gels were 
then washed twice in deionised water for 2 minutes.
Fix solution was prepared diluting a stock solution of Nitric acid 10% in 
deionised water. Nitric acid 10% was prepared as a dilution in deionised 
water of starting nitric acid 65% solution.
The gels were stained in a staining solution for 30 minutes in rotation and 
at the end of the incubation they were washed rapidly in deionised water. 
Staining solution final concentration
1 g AgNC>3 0.2% (w/v)
500 pi Formaldehyde 37% 0.037% (v/v)
to a final volume of 500 ml with deionised water. This solution was
prepared just prior to be used.
After staining, the gels were immersed in a developing solution for 5 -1 0  
minutes in agitation, until the electrophoresis pattern was detectable 
(visible).
Developing solution final concentration
12.5 g Na2C 0 3 2.5% (w/v)
500 pi Formaldehyde 37% 0.037% (v/v)
4 mg Na Thiosulphate 0.002%(w/v)
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to a final volume of 500 ml with deionised water. To this solution, 
formaldehyde and Na Thiosulphate were added just before use.
After developing, a Stop solution, Glacial Acetic acid 10%, was added to 
the developing solution, agitated for 3 minutes and then washed in 
deionised water for 2 minutes.
2.6 RNA analysis
2.6.1 Isolation o f total RNA
To isolate total RNA, the SV total RNA isolation Systems (Promega) was 
used. RNA was then prepared following exactly the manufacture’s 
instructions except for the final elution volume containing the purified RNA 
which is smaller (generally 50 pi) than that suggested by the 
manufacture’s instructions. An aliquot of this solution was then used to 
determine the RNA concentration, as described above. Samples were 
stored at -8 0  °C until use.
2.6.2 Northern blotting analysis
Northern blotting is electrophoresis and transfer of RNA to a membrane 
followed by hybridisation to a specific probe. It provides the quantification 
of the levels of RNA species within a cell.
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2.6.2.1 Sample preparation and gel analysis
During gel electrophoresis a denaturing agent, formaldehyde, completely 
unfolded RNA molecules by reacting with amine groups preventing the 
formation of G-C and A-T base pairs. A formaldehyde agarose gel was 
prepared in MOPS (Sigma) buffer as reported here:
Formaldehyde Agarose Gel final concentration
0.8 g ultra pure agarose 1%
8 ml MOPS buffer 10x 1x
14.4 ml formaldehyde 37% 6.66%
57.6 ml water
The agarose is dissolved in water by boiling. The other reagents are 
added when the gel reached approximately 60 °C.
MOPS Buffer (1 Ox) final concentration
93 g MOPS 0.2 M
20.51 gN aAc 0.5 M
1.86 g EDTA 10 mM
to 500 ml with deionised water. The pH  was adjusted to 7 with NaOH and
the solution autoclaved.
The gel was poured in a chemical hood and let until solidified.
Equal amounts of RNA (generally 10 pg) were mixed with 3 volumes of a 
RNA denaturing solution prepared just prior to use as follows:
RNA Denaturing Solution final concentration
2.5 ml deionised formamide 50%
0.5 ml MOPS 10x 1x
106
806 pi formaldehyde 37% 6%
to a final volume of 5 ml with sterile water.
Formamide is deionised to remove ionic contaminants which could 
hydrolyse RNA. To do this commercially available Formamide was added 
to mixed-bed resin (BioRad) (5 g resin/100 ml formamide) and stirred for at 
least 1 hour in the dark. Formamide was filtered from the resin with 
whatmann paper; aliquoted and stored at -20 °C.
RNA samples were denatured at 65 °C for 15 minutes and quickly chilled 
on ice. Then 1/6th of the volume of loading buffer was added to the mixture 
immediately before loading.
RNA loading buffer final concentration
500 pi glycerol 50%
25 pi bromophenol blue 10%> 0.25%
475 pi of water
1 pi of ethidium bromide (10 mg/ml) is added to 29 pi of this solution. The 
solution is aliquoted and stored at -2 0  °C.
The gel run was carried out in MOPS buffer (1x) at constant voltage of 80 
V, for 2-3 hours. At the end of the run of the gel, two distinct, abundant, 
ribosomal bands (18S and 28S) were visualised under UV-light as 
indication of a good separation and absence of degradation. The RNA was 
then blotted onto a membrane.
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2.6.2.2 Blotting procedure
A capillary blot was set up using a solution of 20x SSC (175.3 g NaCI,
88.2 g sodium citrate in 1 I of water) as transfer buffer.
The wick was made up of 2 pieces of 3MM paper with each end dipping 
into the transfer solution. The gel was placed on the wick with wells facing 
down, and air bubbles were gently removed. A nylon membrane 
(GeneScreen Plus, PerkinElmer, Boston, MA) of exactly the same size of 
the gel was soaked in 20x SSC for at least 10 minutes and carefully 
placed on top of the gel and gently squeezed to remove air bubbles. Three 
sheets of 3MM paper where then added over the membrane followed by 
Kleenex towels. The blot system was left for 16-24 hours after which the 
membrane was removed, washed by immersion in deionised water, left to 
dry at room temperature for approximately 30 minutes and examined 
under UV light to mark the position of the RNA 18S and 28S fragments. 
The membrane was then baked at 80 °C for 2 hours to remove any 
residual formaldehyde from the RNA, as this could affect the efficiency of 
the hybridisation. The blot was stored at 4 °C until ready for hybridisation.
2.6.2.3 Preparation of probes for Northern blot analysis 
Radioactive probes suitable for determining the level of the mRNA of the 
gene of interest were prepared by using PCR amplified fragments and a 
klenow fragment of polymerase I -  based method. In particular, a 
commercially available kit (Rediprime, Amersham Biosciences) was used 
to label 50 ng of DNA following all the steps described in the manual. The
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radioactive nucleotide was the 32P-labeled dCTP (Amersham Biosciences, 
3,000 Ci/mmole). Purification of the probe from unlabelled nucleotide was 
performed using Sephadex G50 columns (Roche Diagnostics, Milan-ltaly) 
exactly following the manufacturer instructions. The incorporated 
radioactivity was detected by cherenkov counts and the probe was diluted 
to a final concentration of 500,000 cpm/ml in the hybridisation solution.
2.6.2.4 Hybridisation
Before hybridisation with a probe, the membrane was pre-hybridised for at 
least 4 hours at 42 °C in a glass bottle with 10-15 ml of hybridisation
solution:
Hybridisation solution final concentration
2 ml NaCI 5M 2 M
5 ml deionised formamide 100% 50%
2 ml dextran sulphate 50% 10% (w/v)
250 pi Salmon sperm DNA 10 mg/ml 100 pg /ml
The salmon sperm DNA was prepared by boiling the solution for 10 
minutes, chilling on ice and storing in aliquots at -2 0  °C.
The radiolabeled probe was denatured by boiling for 5 minutes and quickly 
chilling on ice for 5 minutes again. The denatured probe was added 
directly to the hybridisation solution without touching the membrane and 
the mixture was gently mixed. The blot hybridisation was performed by 
overnight incubation at 42 °C. The membrane was washed twice at room 
temperature for 10 minutes with 2x SSC, followed by two 2 washes of 15
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minutes each at 65 °C with 2x SSC + 1 % SDS and a final wash in 2x SSC  
for 10 minutes. The blot was kept humid by wrapping it in Saran wrap and 
either exposed to film overnight at -80 °C or exposed to a phosphorimager 
screen (Amersham Biosciences, formerly Molecular Dynamics) for at least 
5 hours at room temperature.
When necessary, the probe was stripped from the membrane by boiling 
the blot for 10 minutes in 0.5% (w/v) SDS solution. The blot was again 
kept humid, checked for radioactivity and either stored at 4 °C or 
hybridised with another probe.
2.7 Agarose Gel
2.7.1 Gel preparation and gel electrophoresis
Agarose gel of different percentages (w/v = grams of powdered agarose 
per 100 ml of TAE running buffer) was prepared by dissolving desired 
grams of ULTRA pure agarose (Sigma) in a suitable volume (ml) of 1x 
TAE buffer:
TAE Buffer (50x) final concentration
242 g Tris base 2 M
100 ml EDTA 0.5M, pH 8 50 mM
57.1 ml glacial acid acetic
to 1 1 with deionised water. The solution was stored at room temperature.
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The solution was heated in a microwave and boiled until all the agarose 
was dissolved. The solution was then cooled to approximately 50 °C 
before pouring in a casting tray.
To be loaded on the gel, DNA/RNA were mixed with 1/6th of the volume of 
loading buffer 6x.
Loading Buffer 6x final concentration
1 ml E D T A 0 .5 M  0.1 M
2.5 g sucrose 50% (w/v)
100 jji bromophenol blue 10% 0.25% (w/v)
100 pi xylene cyanol 10% 0.25% (w/v)
to a final volume of 5 ml of deionised water. Ten pi of ethidium bromide
(10 mg/ml) were then added and the solution was stored at 4 °C.
Samples were electrophoresed at 100 V for approximately 30 minutes in 
TAE 1X buffer. DNA bands were visualised under UV light with UV 
transilluminator. The assessment of the expected DNA fragment length 
was possible thanks to the available molecular weight markers solutions 
(Fermentas, Burlington, Ontario-Canada) which were loaded in a lane 
parallel to that of the samples and electrophoresed together with the 
samples.
2.7.2 DNA extraction from agarose gel
PCR products or bands of desired length obtained after restriction 
enzymes reaction were removed from the gel under the trans-illuminator.
111
The DNA was then extracted from the agarose slice using the “MiniElute” 
gel extraction kit (Qiagen) exactly following the manufacturer’s instruction.
2.8 Screening of genomic libraries
Both human and mouse genomic clones containing the genomic DRAGO 
sequences were isolated by screening either a human or a mouse 
genomic library spotted on filters obtained through the UK Human 
Genome Mapping Project Resource Centre (UK-HGMP-RC).
The human PAC library RPCI1 has been constructed in the vector, 
pCYPAC2N. The source is a normal male blood donor, and the insert size 
is about 110 kb. The mouse PAC library RPCI21 is subcloned in pPAC4 
vector. The source is a female 129/SvevTACfBr mouse spleen genomic 
DNA. Both libraries consist of approximately 120,000 clones spotted on
22.2 x 22.2 cm Hybond N nylon membranes (Amersham Biosciences). 
Each clone has been spotted twice to give 36,864 (18,432 x 2) spots on 
each membrane. 7 filters cover the whole library. The 7 filters were 
prehybridised at 65 °C in 25 ml of a solution containing 6x SSC, 100 jig/ml 
of salmon sperm, 0.5% SDS and 5x Denhardt’s solution ( a 50x 
Denhardt’s solution is prepared by dissolving 1 g of Ficoll 400, 1 g of 
polyvinylpyrrolidone and 1 g of BSA (bovine serum albumin) fraction V in 
100 ml of water; the solution is then filtered and stored at -2 0  °C) with 
gentle, continuous agitation. To this solution, radiolabeled human 
DRAGO-derived cDNA probes (prepared as reported in 2.6.2.3) was 
added and the incubation continued for further 16 hours at 65 °C. The
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filters were then washed twice at room temperature in 2x SSC, followed by 
two 2 washes of 15 minutes each at 65 °C with 2x SSC + 1% SDS and a 
final wash in 2x SSC for 10 minutes and exposed to autoradiographic 
films. Once developed, the films were oriented with the grid supplied with 
the filters and the positive clones identified. This procedure was facilitated 
by the double spotting of each clone. The identified, positive clones, where 
requested to the UK-HGMP-RC and obtained as E. coli colonies carrying 
the clone of interest streaked on LB agar containing kanamycin (25 pg/ml). 
Each clone was restreaked onto the same agar type and incubated 
overnight at 37 °C to obtained single colonies. One of those per each 
clone was then picked up and inoculated into LB broth containing 
kanamycin and let grow overnight at 37 °C. From the bacterial culture, the 
PAC clones were isolated using the Qiagen midi preparation kit. To isolate 
shorter genomic fragments containing the DRAGO gene, an aliquot of the 
genomic DNA isolated was digested with different restriction enzymes in 
their appropriate buffer, supplied together with the enzyme, for 16 hours at 
37 °C and the entire reaction loaded on 0.8% agarose gels. After 16 hours 
running at 30 V, the gel was visualised under UV and a picture collected 
for subsequent identification for the positive bands. The restriction 
fragments of genomic DNA thus separated by agarose gel run were 
blotted as regards the Southern blotting procedure to a nylon membrane. 
The transfer of the DNA to a membrane was carried out as described for 
Northern blotting in section 2.6.2.2 and hybridised with a radiolabeled 
human DRAGO-derived cDNA probe (the radiolabelling conditions were
113
the same as described in section 2.6.2.3). For human genomic DNA, a 
160bp-PCR fragment corresponding to the 5’ region of the DRAGO cDNA 
was used. PCR conditions were those described previously (section 2.4). 
The forward primer was 5-CCGAAGCCG GCGACCGCCCC-3’ and the 
reverse primer was 5-GGCGCTCACAGCTTCCACGC-3’, and the AT 
was 60 °C. For the mouse genomic DNA human exon 1, 3 and 5 were 
used and obtained by PCR as described in 2.5.2. Hybridisation and 
washing conditions were the same used for the screening of the genomic 
filters. The autoradiograph was compared to the ethidium bromide picture 
and the bands which hybridised with the probe identified. A second 
digestion was performed on the remaining genomic DNA maintaining 
exactly the same conditions previously used. Once separated on gel, the 
bands corresponding to the previously selected positive bands were 
excised and isolated as described in section 2.7.2. The band containing 
the fragment from human genome was ligated in the MCS of pGL2 vector 
using the same restriction enzyme used for the digestion of the human 
genomic clone and sequenced using the primers available from the 
manufacturer. The positive clones were further amplified and the DNA 
isolated from them was used in transient transfection experiments for the 
determination of luciferase activity. The fragment from mouse genome 
isolated from gel agarose as described in 2.7.2 was subcloned in the MCS 
of pBS vector using the same enzymes used for digestion of the mouse 
genomic clone. The construct was verified by sequencing using the T7 
primer.
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2.9 Induction of GST-fusions in bacteria and purification
To recover GST fusion proteins produced in E. coli cells containing a 
recombinant pGEX-3X plasmid (see sections 2.2) the GST Gene Fusion 
System, purchased from Pharmacia Biotech, was used, following the 
procedure suggested by the manufacturer’s instruction manual.
From a glycerol stock stored at -8 0  °C, each E. coli pG EX-3X  
recombinant was streaked onto a LB medium agar plate in sterility and 
incubated overnight at 37 °C.
One colony was picked up and inoculated into 5 ml of LB medium 
containing the antibiotic of selection (see 2.2.5) then incubated for 12-15  
hours at 37 °C with vigorous shaking. The grown culture was then diluted 
1:100 into fresh pre-warmed LB medium with the antibiotic and let grow at 
37 °C with shaking. Then the steps followed were exactly the same 
described in the instruction manual provided with the purification system 
previously mentioned. Briefly, the bacterial culture was grown until the Aeoo 
reached 0.5-2, then by the addiction of 0.1 mM IPTG the culture induced 
to produced fusion proteins with a 2 -6  hour-incubation. The bacterial 
culture was centrifuged to sediment the cells and the pellet resuspended 
in a final volume of ice-cold PBS corresponding to 1/20 of volume of the 
starting bacterial culture. The cells were disrupted with a sonicator on ice 
and fusion proteins were solubilised by addition of 1% Triton X -100  to the 
sonicated cells and gently rotation for 30 minutes. Then the solution was 
centrifuged and to the supernatant was loaded on the Glutathione 
Sepharose 4B. This agarose matrix carried glutathione molecules which
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bound the fusion proteins through the GST-tag. After washes to remove 
non specifically bound proteins, the fusion proteins were eluted with 10 
mM of GSH from the matrix. The eluates were monitored for GST-fusions 
protein by either SDS-PAGE or Western blotting (see section 2.10). 
Moreover, to identify the fraction in which the fusion protein was located, 
aliquots of supernatants after solubilisation cell debris pellet were saved 
after solubilisation. Aliquot of supernatant after the addition of the 
sepharose matrix was saved.
2.10 Western blotting
Western blot analysis involves separating proteins using sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE), transferring 
them to nitro-cellulose electrophoretically and then using specific 
antibodies to detect the protein of interest.
2.10.1 Calibration curve preparation
Solutions of BSA (ranging between 1 and 20 pg/200 pi) were prepared 
from a stock solution of BSA obtained by dissolving powdered BSA 
(Sigma) in water. In a 1.5 ml tube, 200 pi of each BSA solution were mixed 
with 600 jlxI of distilled water and 200 pi of BioRad protein assay dye 
(BioRad). In the blank sample, 800 pi of distilled water was mixed with 200 
pi of BioRad Protein assay dye. Samples were rapidly transferred into 
disposable cuvettes (PBI International, Milan-ltaly) and the absorbance at
116
595 nm was measured in the spectrophotometer. The absorbance value 
corresponding to the blank sample was subtracted from the values 
obtained in the BSA-containing samples. Each calibration sample was run 
in triplicate. The calibration curve obtained in such a way, allows 
extrapolation of the exact absorbance value corresponding to 1 pg of 
proteins present in the solution.
Protein concentration in the total cellular extract was determined according 
to Bradford protocol.
The concentration of proteins in the samples was determined by mixing in 
a 1.5 ml tube 10 jil of protein samples (see section 2.9) with 200 jil of 
BioRad protein assay dye and distilled water in a final volume of 1 ml. 
Samples were processed as for the calibration curve and the amount of 
proteins calculated from the absorbance value corresponding to 1 jig of 
proteins (obtained from the calibration curve).
2.10.2 SDS-PAGE
An equal amount of protein of each sample was mixed with the same 
amount of 2x SDS loading buffer and was boiled for 5 minutes :
SDS Loading Buffer (2x) final concentration
200 ijI Tris 1 M, pH 8.8 100 mM
400 pi DTT 1 M 200 mM
800 pi SDS 10% 4%
400 pi glycerol 20%
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40 fjl bromophenol blue 10%
to a final volume of 2 ml with sterile water
0.2%
Samples were loaded onto 5% stacking gel and 12% separating gel: 
Stacking Gel final concentration
1.25 ml Tris-HCI 0.5 M, pH 6.8 125 mM
0.1 ml SDS 10% (w/v) 0.1%) (w/v)
1.25 ml 40%> acrylamide/bis 29.1:0.9 5% (w/v)
To a final volume of 10 ml with deionised water.
50 pi ammonium persulphate 10% (w/v) 0.05% (w/v)
5 pi TEMED 
Separating Gel
2.5 ml Tris-HC11.5 M, pH 8.8 
0.2 ml SDS 10% (w/v)
3 ml 40%o acrylamide/bis 29.1:0.9 
To a final volume of 10 ml with deionised water.
100 pi ammonium persulphate 10%> (w/v)
7.5 pi TEMED
Stacking and separating gels were prepared shortly before pouring. 
Ammonium persulphate catalyses polymerisation and TEMED accelerates 
the reaction and so these two reagents were added last.
Proteins were resolved on a minigel apparatus (BioRad) and run for 2 
hours at 50 V in 1x TGE buffer:
final concentration 
750 mM  
0.1%o (w/v) 
12% (w/v)
0.05% (w/v)
Running Buffer (TGE 5x) 
15.15 g Tris base
final concentration
25 mM
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72 g glycine 192 mM
5 g SDS 0. 1% (w/v)
to a final volume of 5 1 with deionised water. The buffer was stored at room 
temperature.
Electrophoresis progress was followed using pre-stained molecular weight 
markers prepared following the manufacturer’s instructions (Fermentas).
2.10.2.1 Coomassie Blue staining
Coomassie Blue R250 (0.25 g Coomassie Blue, 45 ml methanol, 45 ml 
glacial acetic acid, to a final volume of 100 ml with deionised water. Filter 
the solution through paper) was used to colour the polyacryilamide gels 
after SDS-PAGE by incubating the gel immersed in the coomassie 
solution for 60 minutes and washing it overnight in a de-staining solution 
(30 ml methanol, 5 ml glacial acetic acid, to a final volume of 50 ml with 
deionised water).
2.10.3 Protein transfer and detection
The separated proteins were transferred onto nitro-cellulose (at 60 V for 3 
hours) using BioRad Mini transfer blot equipment in 1x transfer buffer:
Transfer Buffer 1x final concentration
24.2 g Tris Base 50 mM
28.5 g glycine 100 mM
4 ml SDS 10% 0.01%
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800 ml methanol 20%
to a final volume of 4 I with deionised water. The solution was stored at
room temperature.
Filters were stained with Ponceau red solution (Sigma) to check sample 
loading. Blots were placed in TBS-T 0.1% with 10% non-fat dried milk:
TBS-T 0 . 1% final concentration
2.42 g Tris base 20 mM
8 g NaCI 137 mM
1 g Tween 20% 0.1% (w/v)
to a final volume of 1 I with deionised water. The pH was adjusted to 7.6
with concentrated HCI and stored at 4 °C.
and shaken overnight at 4 °C to block non-specific binding. All following 
procedures were carried out at room temperature on a shaker. Blots were 
exposed for 1 hour at room temperature to the desired antibodies diluted 
to the optimal working solution in TBS-T 0.1%. After incubation, the blots 
were washed twice with TBS-T 0.1% and incubated with the appropriate 
horseradish-peroxidase linked anti-mouse IgG secondary antibody 
(Amersham) for 1 hour using 1:3,000 dilution. Blots were washed as 
previously described, and detection was performed with enhanced 
chemiluminescent detection system (ECL, Amersham-Life Science). 
Briefly, the horseradish peroxidase acts as a catalyst for the oxidation of a 
luminol substrate, which subsequently emits small but sustained quantities 
of light. This chemiluminescence is specifically enhanced allowing an
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image to be recorded on photosensitive film. Blots were exposed to film for 
different time ranging from 15 seconds to 3 minutes and developed using 
X-o graph compact x-2 developer with Kodak GBX developer and fixer.
2.11 In vitro synthesis of proteins
To synthesise a polypeptide in vitro, the TNT T7 Quick Coupled 
Transcription/Translation system (Promega) was used following the 
manufacturer’s instructions. This system provides a convenient single­
tube, coupled transcription/translation reaction for in vitro translation of 
eukaryotic genes subcloned downstream from the T7 RNA polymerase 
promoters. One pg of circular expression vector carrying the coding 
sequence of the protein of interest and a T7 primer sequence was used as 
cDNA template.
The polypeptide in vitro synthesised was then analysed by SDS-PAGE.
2.12 Immunofluorescence
Cells were seeded and grown for 24 hour or to confluency on glass 
coverslip. They were washed once with PBS and fixed with 4% 
paraformaldehyde overnight at 4 °C. During three PBS washes at room 
temperature, residual paraformaldehyde cross-linking activity was 
quenched by adding a drop of 1 M glycine, pH 8.5, to the second and third 
PBS washes and leaving it 5 and 10 minutes respectively. The samples 
were permeabilised with 0.5% Triton X -100  in Hepes buffer (20 mM
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Hepes, 300 mM sucrose, 50 mM sodium chloride, 3 mM magnesium 
chloride) 4 minutes at 4 °C, then washed twice with PBS and twice with 
PBS-0.1%  BSA. Primary monoclonal antibody anti-DRAGO (dilution 
1:100 from cellular surnatant) was then added in PBS-1%  BSA for 30 
minutes at 37 °C. Coverslips were washed in PBS and Alexa-Fluor 488 
antibody anti-mouse (Invitrogen) (1:500 dilution) for 30 minutes at 37 °C. 
After further washes with PBS, glass coverslips were mounted in Mowioll 
4 -8 8  (Hoechst, Frankfurt/Main, Germany) and observed in a Zeiss 
Axiophot photomicroscopy equipped for epifluorescence (Carl Zeiss, 
Oberkochen, Germany).
2.13 Animal procedure
Procedures involving animals and their care are conducted in conformity 
with the institutional guidelines that are in compliance with national (D.L. 
n.116,G.U., suppl.40, 18 Febbraio 1992, Circolare No. 8, G.U., 14 Luglio 
1994) and international laws and policies (EEC Council Directive 86/609, 
OJ L 358,1, Dec 12, 1987; Guide for the use of Laboratory Animals, 
United States National Research Council, 1996).
2.14 Isolation and handling of primary mouse embryonic 
fibroblasts (MEF)
Primary MEFs were isolated from wild-type and DRAGO - / -  embryos at 
embryonic day 12-15. Timed pregnant female at 12 to 15 days gestation
122
were sacrificed and individual fetuses were removed and washed 
repeatedly with sterile PBS. After removing the head and red organs (liver, 
heart and kidney) each embryo was broken (cut) into small pieces and 
then incubated with trypsin/EDTA at 37 °C for 15 minutes. After removing 
the trypsin by centrifugation at 1,200 rpm for 10 minutes, the tissue 
homogenate was resuspended in MEFs culture medium, DMEM 
supplemented with fetal bovine serum (Hyclone, Logan, UT) and 2 mM of 
L-Glutamine and placed in 100 mm culture plates (one plate for each 
embryo sacrificed). The plates were incubated at 37 °C overnight. The day 
after, the fibroblasts were visualised under the microscope. The medium 
was removed and replaced with fresh culture medium. These cells were 
considered passage 0. When the cells on the passage 0 plates became 
confluent, they were detached as described in chapter 2.1.1 except that 1x 
trypsin diluted in PBS (without EDTA) was used (from a stock 10x 
purchased from Bio-Whittaker). The cells were then counted and seeded 
at a density of 6 x 104/ml (9 x 105 in a tissue culture T75 flask). Cells were 
passaged at the same density as standard 3T3 protocol (332). To 
determine the cellular growth rate of DRAGO - / -  MEF culture relatively to 
the growth rate of wild-type (WT) MEFs, in a 6-wells plates both 
genotypes were seeded in triplicate at a density of 1.5 x 104/ml. One 
plates a day was then used to harvest the cellular growth of MEFs in order 
to determine the cell number in each culture every day.
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2.15 MEF treatments
2.15.1 Preparation of drug solutions
The drugs used in the experiments were cisplatinum (DDP, Sigma), taxol 
(obtained through the NCI), doxorubicin (DX, Nerviano Medical Centre, 
Milan-ltaly), campthotecin (CPT, Sigma) 5-Fiuorouracil (5-FU, Sigma), 
PS341 (CTI, Milan, Italy), VP-16 (Sigma).
DDP was prepared fresh for any experiment by preparing a solution of 0.5 
mg/ml in medium and allowing this solution to equilibrate with proteins 
present in the serum at 37 °C for 30 minutes before treatments. Taxol, 
CTP, 5-FU , V P -16 and PS341 were prepared in DMSO as respectively 2 
mM, 20 mM, 5 mM (both 5 -FU  and VP-16) and 10 mM stock solutions 
and subsequently diluted in fresh medium the day of treatment. The stock 
solution was maintained at -2 0  °C. DX was prepared as a 5 mM solution 
in water and stored at -2 0  °C in the dark. After treatment, the medium 
containing the drugs and the remaining solutions were properly discarded.
2.15.2 Cell growth inhibition
To investigate the effects on cell growth of either drug or UV and X rays 
treatment, both MEFs W T and MEFs DRAGO - I -  were seeded at a 
density of 1 x 104 cells/ml in either 24-wells plates whether treated with 
drugs or 6-wells plates whether exposed to UV or X rays. When treated 
with drugs, 48 hours after seeding a concentration range of drug was 
added into 2 replicate wells. Treatment was performed for 24 hours and
124
after 72 hours cells were washed with sterile PBS and stained with crystal 
violet. Control untreated cells were stained in the same manner. 
Otherwise, 6-wells plates of MEFs were entirely exposed to a range of UV 
or X rays and after 72 hours washed with PBS and stained with crystal 
violet. The degree of growth inhibition induced by UV and X rays was 
evaluated comparing the absorbance of treated cells stained with crystal 
violet with that of untreated ones (control cells). Basically, the stained cells 
were resuspended with 500 pi of a solution of 0.1 N HCI in isopropyl 
alcohol. The absorbance of each well was then read using a Titertek 
equipped with a filter for 550 nm.
2.15.3 DAPI/sulphorhodamine staining
Cells were seeded on glass coverslips and after 24 hours, they were 
treated with anticancer drugs. Forty-eight hours after treatment, cells were 
washed with PBS and fixed with 95% Ethanol for 1-2 hours. Cells were 
washed with PBS twice and in de-ionised water. Cells were incubated 
with a DAPI/sulphorhodamine solution for 15-30 minutes in the dark (3.5 
mg DAP! was dissolved in 100 ml in deionised water; to 0.5 ml of DAPI 
solution diluted in 100 ml of, 3 mg of sulphorhodamine was added. The 
volume was brought to 300 ml by adding the Na-Tris HCI pH8 solution:
Tris base 12 g 
NaC! 6g
HCI 1'M 54 ml
H20  to a final volume of 1 L.
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After futher washes with deionised water glass coverslips were mounted in 
Entellan (Merck, Milan-ltaly) and observed in a Zeiss Axiophot 
photomicroscopy equipped for epifluorescence (Carl Zeiss, Oberkochen, 
Germany).
2.16 Genotypic screening of heterozygous mice breeding
For routine genotyping of the litters from breeding of heterozygous (HE) KO 
mice, two PCR reactions were built up using three primers. One set of primers 
(GW723 5-TTC C T GCTAGT CAGACACGCCT GTG-3’, GW722 5 -
TACACAGGTGGCAGTTAGGCATCC-3’ AT: 61 °C) was designed by 
Genoway laboratory for screening test to detect the excision of the targeted 
region. The forward and the reverse primers of this set were designed at the 5’ 
and the 3’ end respectively of the targeted region which comprised the 
genomic fragment between exon 3 and 5. Therefore the PCR reaction might 
expect the amplification of either 10-Kb fragment for WT mice or a 3.6-Kb 
band for HO KO mice. For HE mice both bands of 10 Kb and 3.6 Kb were 
expected. However, among those bands, only the smaller one was detected, 
being the 3.6-Kb band more efficiently amplified. Therefore, in order to 
discriminate HE and KO mice, a second set of primers, formed by the same 
forward primer (GW723) of the previous set and a reverse primer (K0725 5 -  
GCCTTCTGCACACAGGTACTCG-3’ AT: 63 °C) mapping a region in the 
exon 3 which is deleted in the HO KO mice was designed. In this manner a 
1.3-Kb band was expected with HE KO and W T mice, conversely no band 
amplification was expected with HO KO mice.
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RESULTS
CHAPTER 3 
MOLECULAR CHARACTERISATION 
OF DRAGO GENE
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3.1 Introduction
As reported in the Introduction (Chapter 1.7), DRAGO is a new gene 
which has been isolated as a cDNA fragment overexpressed in cell lines 
after treatment with several cytotoxic agents. The cDNA fragment, once 
isolated and sequenced, perfectly matched to the sequence KIAA0247 
already present in gene bank. Beside the nucleotide sequence referred to 
the cDNA of this isolated gene, no functional and structural information 
has been reported. To start with the characterisation of this challenging 
gene, the determination of molecular structure has been posed as the 
initial steps to undertake.
3.2 Molecular characterisation
The description of the exon-intron organisation of the gene is a necessary 
prerequisite for most of the subsequent investigations and 
characterisations carried out in the present work. Using the information 
available with the full-length cDNA, the structure of the human DRAGO  
gene was molecularly characterised. The entire cDNA sequence 
(5,338bp) was compared with the sequences of human genome available 
from the public gene bank by using the BLASTN program at the NCBI 
database. The comparison led to the identification of two human genomic 
clones (BAC R-1046B16 clone of library RPCI-11 and BAC C-2216L1 
clone of library CalTech-D) from chromosome 14 which together comprise
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the full length cDNA. These results allow to build the genomic structure of 
the gene, which is composed of 6 exons, with canonical exon-intron 
junctions (GT..AG). The first exon (188 bp) spans nucleotide 1-188 
comprising most of the 5 ’ untranslated region (5’UTR) which overlaps part 
of the second exon. The coding region starts from the base 269, located in 
the second exon (189-389). Exons 2, 3 (390-587), 4 (588-726) and 5 (727- 
1,154) (201, 198, 140 and 427 bp respectively) correspond to the coding 
region which contains the first 26 bases (1,155-1,180) of exon 6 (4,184 
bp). Therefore the coding region results to be comprised between 
nucleotides 269 and 1,177 (1,180 including the stop codon “tga”), 
whereas the remaining 4,158 nucleotides form 3’UTR which is entirely 
located in the last sixth exon. Interestingly, the gene presents two large 
introns (45-50 kb) between exons 1-2 and 2-3, respectively (Fig. 3.1).
3.3 Isolation of DRAGO genomic sequences
To confirm the sequence of the genomic DNA regions of DRAGO and to 
isolate the region containing the gene, a human genomic library spotted in 
duplicate in seven different filters, obtained through the UK-HGMP-RC  
was used. These filters contain genomic DNA clones and can be 
hybridised with different probes derived from the human DRAGO cDNA to 
isolate the genomic sequence of interest. For the purpose of this study, a 
160 bp-fragment obtained by PCR (see chapter 2.4) and corresponding to
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ATG (269 bp) TGA (1,177 bp)
Exon 1 Eicon 2 Exon 3 Exon 4 Exon 5
188 bp 2|01 bp 198 bp 140 bp 427 bp
Exon 6
4,184 bp
46,684 bp 4,681 bp 1,011 bp 3,934 bp 1,849 bp
Figure 3.1
DRAGO gene structure. The length of exons and introns is indicated 
together with the position of the start (ATG) and the stop (TGA) codons.
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the 5’ region of the human DRAGO cDNA was used as a probe.
Figure 3.2 shows an example of an autoradiograph indicating the 
presence of two positive spots. On the whole set of seven filters, the use 
of this cDNA probe led to the identification of two positive clones which 
could be univocally identified through the coordinates of the filters and 
requested to the UK-HGMP-RC. The two positive clones (67A24 and 
92D20 from the RPCI human PAC library 1) thus obtained were grown in 
LB media and the DNA was isolated from the overnight culture using 
procedures described in the materials and methods chapter (chapter 2.8). 
Since each of these clones contained approximately 100 Kb of DNA, it 
was necessary to pinpoint smaller DNA fragments containing the DRAGO 
gene for further characterisation. To do this, DNA was digested with 
different appropriate restriction enzymes and half of it loaded on 0.8% 
agarose gels to separate the fragments of different length. At the end of 
the run, the gel was stained with ethidium bromide and the bands 
visualised under UV light. Figure 3.3A shows fragments of the two clones 
digested with the restriction enzymes BamHl, EcoR\ and Hind\\\. The gel 
was blotted overnight to a nylon filter and hybridised with the same probe 
used for the screening of the genomic PAC library and corresponding to 
the 5’ region of the cDNA DRAGO sequence to identify the fragments 
inside the genomic sequence present in the clone which contains the 
DRAGO gene. The results of the hybridisation are shown in figure 3.3B, 
from which one can deduce that few digested fragments gave positive 
hybridisation and hence contained the sequence of DRAGO used to
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Figure 3.2
Screening of the RPCI human genomic PAC library 1.
The figure shows a representative autoradiography obtained from a filter 
containing the genomic DNA that was probed with a 32P-labelled DRAGO 
cDNA fragment. Each clone is spotted in double on the filter. The arrow 
points the DRAGO positive clone (67A24) which has been selected based 
on screening.
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M1 H B
23 kb -  
9.4 kb -  
6.56 kb -  
4.36 kb -
Figure 3.3
Southern Blot of digested genomic 67A24 clone obtained from the RPCI 
human PAC library 1.
Panel A. Ethidium bromide staining of the gel. DNA isolated from the clone 
was digested with Hind\\\ (H), BamH\ (B) and Ecoftl (E) and resolved on 
agarose gel. M1 is the A DNA/H/ndlll marker 2, M2 is the 1 Kb DNA 
molecular weight marker.
Panel B. Autoradiography of the gel transferred to a nylon membrane and 
hybridized with 32P-labelled DRAGO probe. Numbers on the left are 
derived from M1 molecular weight markers. The arrow point to the 10 Kb 
fragment of the DRAGO clone digested with Hind\\\ isolated for further 
study.
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10,735 bp
5 ’ - 3- 3 ’
Exon 1
Figure 3.4
Schematic representation of the Hind\\\ 10,735-bp fragment isolated from 
agarose gel (see figure 3.3). The sequence of the fragment compared with 
genomic sequences present in the NCBI gene bank database resulted to 
match with a genomic sequence containing a large portion of about 7 Kb 
genome located upstream to the first exon of DRAGO gene, the first exon 
and about 3 Kb region mapping the first intron of the gene.
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hybridise. From these experiments a DNA fragment of approximately 10 
Kb (10,735 bp), obtained from the 67A24 clone after digestion with the 
restriction enzyme HindlW was isolated for further characterisation.
This DNA fragment was subsequently subcloned in the HindlW site 
contained in the multiple cloning site of the pBluescript SKII plasmid. This 
recombinant plasmid was used to sequence the DNA inserted. The 
sequences were obtained using the sequences contained in the plasmid 
as primers. The obtained sequence was compared with the human 
genomic sequences present in the NCBI gene bank database which 
resulted to completely match with the genomic sequence from the BAC R- 
1046B16 clone of library RPCI-11 and to overlap the first exon. This 
sequence, in fact, starts about 7 kp upstream to the 5 ’ end of DRAGO 
cDNA sequence (Fig. 4.4), contains the exon 1 and about 3 kb 
downstream the same exon, thus located in the first intron.
3.4 Discussion
One of the aims of this thesis has been to molecularly characterise the 
newly identified DRAGO gene. Previous experiments performed in the 
laboratory of Molecular Pharmacology at the Mario Negri Institute where 
the present thesis has been realised, showed that the sequence of full 
length cDNA of the newly isolated DRAGO gene corresponded to the 
cDNA of the deposited gene KIAA0247 (accession number D87434). The 
comparison between the cDNA sequence with the human genomic 
sequences present in the NCBI gene bank database allows the description
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of the molecular organisation which reveals the presence of six exons, two
-TV
long introns of respectively 46,684 and 44,681 bp, and a large 3’UTR  
(4,153 bp). All these large portions of non-coding regions suggest a strong 
gene regulation both at transcriptional and post-transcriptional level. In 
fact, the analysis of the 3’UTR sequence revealed the presence of AU- 
and CU-rich regions, which are known to be motives recognised by factors 
acting on the mRNA stability of genes like those coding for proto­
oncogenes, transcription factors, cytokines, lymphokines, growth factors 
and their receptors (333). Nevertheless, two introns of about 50 Kb could 
contain the binding sites for transcriptional factors involved in the 
transcriptional regulation of the gene expression or cryptic ATGs as start 
codons for hypothetic DRAGO isoforms. Anyway, those aspects regarding 
the regulation of DRAGO gene will be studied in the future but it will not be 
the object of this thesis. The alignment of the cDNA of DRAGO with the 
human genomic sequences from NCBI databases led to the identification 
of two clones from chromosome 14 which comprise the intronic and exonic 
sequences of DRAGO gene. These findings have been confirmed by the 
isolation of the genomic clone containing the gene of interest from a 
genome library. The isolation of this clone allows the following 
investigations regarding the promoter isolation of DRAGO which will be 
discussed further in this chapter.
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CHAPTER 4 
CHARACTERISATION OF THE 
PROMOTER REGION
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4.1 Introduction
As outlined in the introduction chapter (1.7), the activity of DRAGO gene is 
regulated by p53 as suggested by either the semi-quantitative RT-PCR or 
the real time PCR experiments. On the basis of these observations, two 
questions have been addressed. The first set of experiments described in 
this chapter was aimed at the identification of the promoter region possibly 
containing the p53 consensus sequence. Secondly the focus was on the 
evaluation of the possible role of the different p73 isoforms in determining 
the transcriptional activation of DRAGO. This question is particularly 
pertinent considering that the p73 gene shares relatively high sequence 
homology with p53 in the central DNA binding domain, thus enabling it to 
bind and activate the same downstream genes which are activated by p53 
(see introduction chapter 1.6.1-1.6.2). The investigation has been also 
addressed at elucidating the role of DNp73 which, lacking the 
transactivation domain, has been mostly considered to antagonise the TA 
isoforms of p73 and p53. As discussed in the Introduction chapter recent 
findings suggest that DNp73 can have other functions. Starting from these 
evidences, the effect of DNp73 has been also evaluated in the 
experiments reported here.
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4.2 Promoter activity of the 10,735 bp-Hindlll DRAGO
genomic region
Once it had been verified that the H/ndlll-digested 10,735 bp cloned 
sequence was indeed a sequence corresponding to the genomic region 
around the exon 1, containing the initial non coding cDNA of the DRAGO 
gene and a genomic region immediately 5’ to this non coding part, the 
isolated DNA region was then investigated for the putative promoter 
activity. The full length fragment of 10,735 bp was entirely subcloned in 
the HindlW site of the multiple cloning site of the promoter-less pG L2- 
enhancer vector. This vector contains the luciferase cDNA and a multiple 
cloning site at 5’ to the cDNA (without promoter) and is generally used to 
determine the efficiency of putative genomic promoter regions to drive the 
transcription of the luciferase gene. Using the method reported in chapter 
2.2.7, recombinant clones were selected and the DNA partially sequenced 
to further verify the presence of the right insert and to determine the 
orientation. One of the clones tested containing the sense orientation 
inserted fragment has been chosen.
In p53-defective cells, the 10,735 bp-genomic region did not reveal any 
transcriptional promoter functionality. Nevertheless, it has been tested if 
p53 could induce this putative promoter region by co-transfecting an 
expression vector containing the human p53 cDNA with the construct 
containing the luciferase gene under the control of the human DRAGO 
fragment of 10,735 bp as described in chapter 2.3. However p53 did not 
induce the transcriptional activation of the 10,735-bp fragment.
140
4.3 Isolation of p53 responsive region
Since the entire 10,735-bp region did not respond to p53 induction, a 
smaller DNA fragment was then isolated from the 10,735 bp genomic 
region by using the Kpn\ restriction site located 214 bp upstream to the 
first exon of the genomic region and in the multiple cloning site of the 
pGL2 vector, in which the same region is subcloned. The digestion with 
the Kpn\ restriction enzymes of the 10,735-pGL2 construct resulted in the 
deletion of a DNA fragment of about 7,000 bp from the 10 ,735-bp  
genomic region. The 3’-end of remaining 3,761-bp fragment (which will 
be referred as the 3.8-kb fragment) was still functionally linked to the 
reporter gene luciferase and thus the 5’-end has been re-ligated to the 
vector to have a new construct. The 3.8-kb fragment (Fig. 4.1 A) which 
consists of the initial non coding part of the DRAGO gene (exon 1), a 
genomic intronic region 3’ to this non coding part and a sequence stretch 
contiguous to exon-1 5 -en d , has been subjected to investigation for its 
transcription promoter activity. In p53-defective cells, the transcription of 
the reporter gene could not be detected. However, in cells where p53 
functionality had been restored (as described in the previous section) the 
promoter activity of the 3.8-kb fragment was two-fold higher than in its 
absence (Fig. 4.1B) which is consistent with the results of the experiments 
carried out in isogenic models differing for p53 expression (see  
Introduction chapter 1.7). The observed p53 regulation has been 
compared to the transcriptional activation induced by p53 on another 
promoter fragment isolated from the human p21 gene and known to be
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Figure 4.1
Panel A. Schematic representation of the 3.8-Kb fragment obtained by 
digesting the construct pGL2-10,735-bp with Kpn\ restriction enzyme. 
One of the sites of cleavage is contained in the 10,735-bp fragment and 
upstream the exon 1. The other was contained in the pGL-2 MCS. The 
symbol >< indicates the position of the restriction site.
Panel B. Levels of luciferase expression upon the 3.8-Kb fragment 
induction either in the presence (blue column) or in the absence (red 
column) of p53 in p53-defective Saos-2 cells (see chapter 2.3). Whenever 
p53 functionality had been restored, the promoter activity of 3.8-Kb was 
increased by 2 fold. As a positive control, the level of induction of the p21 
promoter by p53 was considered.
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activated by p53, which was obtained from Dr. Carol Prives, Columbia. 
University, NY.
4.4 Analysis of putative p53 responsive elements
The 3.8-kb fragment revealed to putatively contain p53 responsive 
elements, even though the transcriptional activation induced by p53 was 
lower than that observed with a well known p53-responsive promoter 
gene like p21. Furthermore, the luciferase assay showed that in the 
absence of p53, the 3.8-kb fragment exhibited no promoter functionality. 
The fragment was then investigated for the presence of a promoter region 
predictable by bioinformatics. For this purpose, the Promoterlnspector 
program from Genomatix Software GmbH was used which find a good 
match with a theoretical promoter region comprised between base 1 and 
792 of the 3.8-kb.
On the basis of these indications, a region starting from base 1 of the 3 .8 -  
kb and base 964 bp was further isolated by PCR amplification using a set 
of primers designed in order to introduce a Xho\ restriction enzyme site of 
cleavage (as reported in chapter 2.3-2.4) at the 3’-end of the fragment 
amplified. The 964-bp fragment, obtained by PCR amplification using the 
10,735-bp region as template DNA, showed a Kpn\ restriction site at the 
5’-end (which was the same used to isolate the 3.8-kb fragment and 
present in the sequence itself) and a Xho\ restriction site, introduced by 
PCR. The fragment was then subcloned in the multiple cloning site of the 
pGL2 vector after digestion of both the plasmid and the PCR fragment with
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Kpn I and Xho\ restriction enzymes. After checking the right insertion by 
sequencing, the 964-bp-pGL2 construct was analysed for the promoter 
activity.
In p53-defective cells, it showed by itself a promoter activity but, when p53 
functionality was restored, the 964-bp fragment revealed no increase in 
the promoter activity (Fig 4.2).
Considering that the 3.8-kb fragment resulted to be responsive to p53, the 
analysis was then focussed on the remaining 2.5 kb. The fragment was 
isolated by PCR amplification using a set of primers designed to introduce 
a Xho\ restriction site at the 5’-end whereas a Hind\\\ restriction site at the 
3’ end was indeed present in the sequence itself. Once amplified and 
digested, the PCR fragment was then subcloned in the pGL2 vector for 
gene-reporter assays. The 2.5-kb fragment showed a promoter activity 
similar to that observed with the 3.8-Kb fragment in the absence of p53 
(Fig 4.3).
The 3.8-kb was then analysed for the presence of the canonical 
consensus DNA-binding sequence, RRRCWWGYYY, recognised by p53. 
The search has been performed with the PROMOTION program that has 
been developed by Dr. Riccardo Bonomi from the Molecular 
Pharmacology Laboratory of Mario Negri Institute. Considering that the 
variability and degeneracy of the p53 binding motif complicates their 
identification, the search for consensus sequences has been focused on 
the core sequence, CWWG. The score of the alignment between the 
nucleotide stretch and the promoter region under investigation has been
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Figure 4.2
Panel A. schematic representation of the 964-bp fragment, obtained by 
PCR amplification followed by restriction with Kpn\ and Xho\ enzymes (the 
Xho\ restriction site was introduced by PCR). The primers are represented 
as red arrows. The Xho\ restriction site which is carried by the downstream 
primers is indicated.
Panel B. Levels of induction of the 964-bp promoter by p53 was evaluated 
in Saos-2 cells. In the presence of p53, the promoter activity did not 
increase as compared to the luciferase activity of the empty vector (pGL2) 
in the presence of p53.
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Panel A. Schematic representation of the 2.5-Kb fragment which was 
obtained by PCR amplification followed by restriction with Xho\ and HindlW 
enzymes (the Xho\ site was introduced by the upstream primer).
Panel B. The promoter activity of the 2.5-Kb fragment was evaluated in 
Saos-2 cells in the presence or in the absence of p53. The level of 
induction of the luciferase expression by p53 was similar to that measured 
with the 3.8-Kb promoter.
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set equal to 100, which means that only the exact matches between the 
consensus motif CWWG and the promoter sequence have been taken into 
consideration. As discussed in the introduction chapter, the binding motif 
RRRCWWGYYY is commonly repeated in two pairs, with a spacer region 
between the two sequences that consists of a number of nucleotides that 
can vary from 0 to approximately 20 bp. The matches were screened on 
the basis of their relative distance from each other and considered only 
whenever they fit with the above mentioned criterion. In figure 4.4 the 
putative binding sites recognised by p53 are highlighted showing that, 
although the binding pattern can deviate from the consensus 
RRRCWWGYYY, the number of sites can be reiterated into clusters. In 
figure 4.5, a diagram showing DRAGO putative p53 BS and those of some 
known p53 target genes has been reported, revealing no evident 
similarities with DRAGO p53 BS and those present in the genes reported. 
In particular, p53 responsive elements of the BTG2 gene have also been 
reported, since this gene shares with DRAGO the feature of being inducible 
by DNp73a (see Chapter 1.5.1).
4.5 Role of p73 in gene transcription
Considering that p73 can bind to the motives originally identified as p53- 
binding site within the promoter and the first intronic sequence of its 
downstream genes and that the regions isolated responded to p53 less 
than expected, the same regions were analysed for their ability to 
transcriptionally activate DRAGO in the presence of p73. The experiments
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Figure 4.4
Sequence of the 3.8-Kb fragment. Putative binding sites of p53 are 
highlighted.
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Binding site RRRCWW WGYYY RRRCW W WGYYYW W
Bax tcACA AGTTa G AGACA TGTCC
p21 5’ site GAACA TGTCC CAACA TGTTg
p21 3’ site GAAgA AGaCT GGGCA TGTCT
mdm2 gGtCA AGTTg GGACA cGTCC
Noxa AGGCT TGTCC CGGCA AGTTg
BTG2 BS1 AGACA TaCCC AG GAAgA TGTTC
BTG2 BS2 AcGCA TGTTC AGGCA TGCaT
BTG2 BS3 AGGCg AGgCC G GGGCc TGCCC
BTG2 BS5 GGcCc TGCCT GGACA TGCCa
Scotin BS1 tAACg AGTaC TCCTGGGCA GtGCA AGTTC
Scotin BS2 GGcCT TGTTa G GAACTt TGTCC
Scotin BS3 cAGCc TGTgT GTACCCTAG GAGC TGTTa
Scotin BS4 GAGCc AGggT GAGCA GTTa
Scotin BS5 GAGCA GTTa CCTGGAGGT GGtCT TGgTC
PUMA BS1 ctcCT TGCCT T GGGCT AGgCC
PUMA BS2 ctGCA AGTCC TGaCT TGTCC
DRAGO BS1 AGACA AGggC ACGCGGGGCCT cGcGT AGaCC
DRAGO BS2 GGGCT TGCgC TGGGGCA GGGCT gGCTT
DRAGO BS3 cAtCT AGTgg AGGCT AGTag
DRAGO BS4 cttCT AGTTg AGACCCAAACC AAACA AGTTa
DRAGO BS5 GccCA TGTCa CATAGGTA tctCA TGgTg
DRAGO BS6 ctACT AGaTT ATA ctGCT AGTTT
DRAGO BS7 AGACT TGgTT T tAcCA TGTTg
DRAGO BS8 AcACT TGTCC ATTTCCCACATAA AAACT TGgCT
DRAGO BS9 AAACA AGTga ACTGTGGAGAATGAAGCAGAAGCAGAA ccACT TGCCa
DRAGO BS10 ATACA TGaag TGAGTTATTAAGCTCCTGAAA tGACA TGCTa
DRAGO BS11 ctcCT AGTTg AAGC tGACA AGCag
DRAGO BS12 AGtCT TGTTa GAGGGTGTTC GctCA AGCag
Binding site WGYYY RRRCW WGYYY RRRCW
w w
BTG2 BS4 cTGaa AAAcg C TGCCC GGGgA
BTG2 BS4’ AGTCC GGGCA G AGCCC GAGCA
BTG2 BS6 AGTTT tcACT C ccCTT AGGCA
BTG2 BS6’ TGCATa AGGaA GG TtCTC cGACT
Figure 4.5
Diagram showing p53 canonical binding sites (HH orientation) of some 
p53 target genes and DRAGO responsive elements. In the lower raws, 
BTG2 binding sites in the TT orientation have been reported. The 
alignment does not reveal any evident similarities between DRAGO 
putative p53 binding sites with those of other p53 target genes here 
reported.
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were performed as those described when p53 promoter activation has 
been studied. The first region to be analysed has been the 3.8-kb which 
showed a slightly stronger promoter activity in the presence of p73 
compared to the induction level driven by p53. Similarly, the evaluation of 
the role of p73 has been extended to the 2.5-kb region which contains 
more putative consensus binding sequences than the 964-bp promoter. 
The 2.5-kb region showed a slight increase of transcriptional activation in 
response to p73 compared to p53.
As mentioned in the introduction chapter (1.6.1) different isoforms of p73 
are generated by alternative splicing of p73 gene. The full length protein, 
which has been used in the experiments carried out with the 3.8-kb  
fragment, is defined as alpha p73 (p73a), and, at least, 4 C-terminal 
isoforms (beta-p73(3, gamma-p73y, delta-p735 and epsilon-p73s) have 
been described so far. Since these isoforms can have different 
transcriptional activation potency (289, 334), the fragment of 2.5 Kb was 
used to test the specific activity of the different p73 isoforms. A typical 
experiment is reported in figure 4.6 showing the ability of different p73 
isoforms to activate the promoter region and revealing that p73 is a 
stronger activator of the promoter fragment than p53. Among different p73 
isoforms, beta and gamma isoforms are the strongest, being able to 
induce an increase of about 5 -6  fold. In parallel, experiments have been 
performed with the p21 promoter in the same conditions as those used for 
the 2.5-Kb fragment. The smallest 964 bp fragment did not respond to 
any of the p73 isoforms as observed previously for p53.
150
8
>*
:i 7
n 6
G>
2 5 
o 4
3
o 3
5
n  2 
o
“  1
p53 p73a p73p p73y p735
j i m  i  i i
p53 p73a p73p p73y p735
2.5-Kb p21
Figure 4.6
Activity of the 2.5-Kb fragment linked to the luciferase gene evaluated in 
Saos-2 cells cotransfected with different isoforms of p73 and p53. The 
level of the activation of the 2.5-Kb fragment was compared with that of 
the p21 promoter fragment.
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4.6 Fragments retaining promoter activity
The localisation of the putative p53 binding site has given the possibility to 
create a series of constructs derived from the 2.5-Kb fragment-pGL2, in 
order to better investigate the promoter activity of the region in presence of 
p53 and p73.
Five constructs have been generated by restriction with several enzymes 
the cleavage site of which were present in the constructs. The constructs 
obtained were Smal, Pstl, PH3, HP4 and SP5 (Fig. 4.7A). The Smal and 
Pstl, constructs have been obtained by digesting with either Smal or Psfl 
restriction enzymes respectively. The cleavage of the 2.5-Kb fragment- 
pGL2 by Smal restriction enzymes resulted in the deletion of about 1.6 Kb 
from the construct. The remaining 6.8-Kb fragment has been purified from 
the agarose gel, on which the restriction reaction was loaded, and re­
ligated. Similarly, the restriction reaction of the same promoter construct 
with the Psfl enzyme generated two fragments of 680 bp and 7.8 Kb, the 
last of which, purified from the agarose gel, was re-ligated. The remaining 
constructs, PH3, HP4 and SP5, were obtained after restriction with Psfl 
and Hindi 11 (PH3), Hindlll and Pvull (HP4) and Smal and Psfl (SP5), 
respectively. The double reaction with Psfl and Hindlll enzymes, 
generated three different fragments of 7 Kb, 730 bp and 680 bp 
respectively. The Pvull and Hindlll enzymes cleaved the promoter 
construct into 2 fragments of 7.5 kb and 990 bp. The digestion with Smal 
and Psfl restriction enzymes generated two fragments of 6.5 Kb, 3.3 Kb
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length
3,761 bp 3.8 -Kb
964 bp 964 -bp
2,500 bp 2.5 -Kb
939 bp Smal
1,815 bp Pstl
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Figure 4.7
Panel A. Schematic representation of the Smal, Pstl, PH3, HP4 and SP5 
fragments generated by restriction of the 2.5-Kb promoter. 3.8-Kb and 
964-bp promoter fragments are represented. The position of the putative 
p53 binding motives is also represented on 3.8-Kb fragment-bar as 
vertical segments.
Panel B. Agarose gel electrophoresis of the restriction reactions of the 
pGL2-2.5-kb construct. Lanes 1 and 5: 1 Kb DNA molecular marker; lane 
4 and 6: 100-bp plus DNA molecular marker; lane 2: pG L2-2.5-kb  
construct digested by Smal enzyme; lane 3: restriction with Pst\ enzyme; 
lane 6: Psfl and Hind\\\ double digestion; lane 7: HindlW and Pvu\\\ lane 8: 
Smal and Psfl.
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and 1.2 Kb. In all the cases described the reactions were loaded on an 
agarose gel to allow the separation of the different fragments (Fig. 4.7B) 
and the purification of the desired ones. Particularly, the longest fragments 
were purified to be re-ligated. Since the extremities of each fragment were 
sticky and not compatible, being digested by enzymes recognising 
different consensus sequences, they were refilled to make them blunt to 
allow subsequent re-ligation of the generated fragments. Each promoter 
construct obtained have been verified by sequencing.
Those deletions of the 2.5-Kb sequence retained a promoter activity 
responsive to p73, particularly to the beta and gamma isoforms, while the 
p53-dependent luciferase activity was almost abolished (Fig. 4.8). The 
SP5 fragment (577 base pairs) was particularly responsive to p73 gamma 
as reported in figure 4.8. In figure 4.9 a schema of the degree of 
responsiveness to p53 and p73 isoforms are illustrated.
4.7 Role of DNp73
To further study the role of p73 in DRAGO transactivation, the ability of the 
transactivation domain deficient isoform DN-p73 to block p73 promoter 
activation has been evaluated. The 2.5-Kb promoter-luciferase construct 
has been co-transfected with the p73 and DNp73 expression plasmids. 
The p21-luciferase construct has been used as a control. As expected, 
transactivation of p21 promoter by p73 tended to decrease in the presence 
of DNp73, whereas the transactivation of the 2.5-Kb fragment-pGL2
154
Smal
If) 4
p73a p73p p73y p735
PH3
Pstl
;>  2,5 
-*—<Oas
0 2
inco0)1.5
>+—O 
= 1
0>
■■£=0,5ra
0a: o
p53
HP4
p73a p73p p73y p735
^9
' >'■s 8 0 7 
0
60
^ 5 y 4
<U 3 
>
20 
0  1 ct o
0 6 
0
55 5
p53 p73a p73p p73y p735 p53 p73a p73p p73y p735
>^25 SP5
o
0  20
0in
2 1 5
o
= 10
0>
_0
0
p53 p73a p73p p73y p738
Figure 4.8
Luciferase activity of the 2.5-kb derived fragments in Saos-2 cells 
cotransfected with p53 and with different isoforms of p73.
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10,735 bp
Fragment
length
Exon 1
RESPONSE TO
P53 P73ct P73P P73Y
3,761 bp + nd nd
964 bp - - - -
2,500 bp 2.5 -Kb + + + + + + +
939 bp Smal + + + + + + +
1,815 bp Pstl - + / - + / -
1,215 bp PH3 - + / - + + + + + +
1,650 bp HP4 - + / - + + + + + +
602 bp SP5 m  _ + / - + + + + + + +
Figure 4.9
Summary of the response of the 3.8-Kb fragment and of the deleted 
mutants derived from it, to p53, p73a, p73p and p73y. On the 3.8-Kb  
promoter bar, p53 binding motives are represented as vertical segments
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construct, by means of the different p73 isoforms increased with the 
presence DNp73 as reported in figure 4.10. Nevertheless, the increase of 
DNp73 amounts determined a concentration-dependent increase in 
luciferase activity, which suggests a cooperation between p73 and DNp73 
in transactivating the 2.5-Kb construct (Fig. 4.11). Conversely, the same 
effect was not observed with the p21 promoter which was indeed 
downregulated as the DNp73 amounts increased (Fig. 4.12). DNp73 per 
se is also able to transactivate 2.5-Kb fragment-luciferase construct when 
transfected in the absence of p53 or p73. This effect was not observed 
when the p21 promoter sequence was used.
4.8 Discussion
The results presented in this chapter confirm that there is a strict 
relationship between p53 and DRAGO, having isolated a region which is 
likely to be bound by p53 which in turn would induce the expression of the 
gene. Moreover, the present experiments clearly indicate that the DRAGO 
might be more efficiently transactivated by p73 than by p53. In general, 
p53 is a stronger transactivator than p73. There are examples in the 
literature, however, showing that certain genes respond better to p73 than 
to p53 (i.e p57, ADA) (335, 336).
The different TA p73 isoforms showed a different transactivation efficiency 
in inducing DRAGO. Particularly, the beta and gamma isoforms seem to 
be the strongest activators of the gene in the experiments carried out with 
the different fragments derived from the 3.8-Kb promoter fragment, even
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Figure 4.10
Effect of DNp73 contransfected with different p73 isoforms on the activity 
of the 2.5-Kb promoter and p21 promoter.
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Figure 4.11
DN-p73 cooperation with p73a, p73p, p73y, p738 in transactivation of 2 .5 -  
Kb fragment-luciferase construct. Increasing concentrations of DN-p73 
was cotransfected with a fixed amount of p73 isoforms. The first column 
shows induction of 2.5 Kb fragment by DN-p73 alone.
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Figure 4.12
DN-p73 repression of transcription activity of p73a and p73y on p21- 
luciferase promoter. Increasing concentration of DN-p73 were used in co­
transfection experiments with p73a and p73y.
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when the p53 activity was completely abolished. Moreover, these 
experimental analyses support the hypothesis that the role of DNp73 is not 
merely to antagonise the p73 isoforms or p53 transcriptional activation of 
their target genes. As discussed in the introduction chapter, several 
evidences reported in the literature support the idea that DNP73 act on 
p53 or p73 isoforms either as a dominant negative, thus exerting an 
antagonising effect or as a co-operator, therefore acting in a synergistic 
manner with the same transcriptional factor.
These observations gain more interests when the sequence of those 
fragments retaining the promoter activity is considered. The 2.5-Kb  
fragments is in fact characterised by the presence of numerous putative 
p53 consensus binding sequences. Those sequences present several 
mismatches in respect to the canonical RRRCWWGYYY sequence, which 
are consistent with the degenerate nature of the p53 binding site, that are 
critical for regulatory control since it allows diversity and flexibility in timing 
and levels in response to cellular signals. However, those binding 
sequences are reiterated into clusters, which should stabilise binding and 
mediate expression likewise in the MDM2 and p21 genes.
However, these encouraging results need to be confirmed by other 
experimental approaches to better verify that these sequences are really 
functionally bound by p53 and p73 isoforms. Experiments such as either 
the EMSA (electrophoretic mobility shift assay) or ChIP (chromatin 
immunoprecipitation) have been planned to be carried out in the future. 
Another simple and efficient approach could be the introduction of site-
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specific mutations in DNA sequences that are considered to be the 
consensus binding elements for p53 and p73 different isoforms.
The sequences showing stronger activity in response to p53 and 
especially to p73 are mostly located in the first intron, similarly to what 
observed for several other p53/p73 target genes (i.e MDM2, KILLER/DR5, 
DR4, CD95 (Fas/APO-1) receptor) (138, 139, 337-339). As previously 
mentioned, the molecular structure of DRAGO gene revealed the 
presence of two introns of considerable length implying a probable 
involvement of these sequences in the regulation of the gene expression. 
This could also suggest the presence of binding motives for other 
transcription factors but most likely of other binding motives for p53 and its 
family members. These points will be studied in the future by using 
bioinformatics tools together with the experimental tests on longer 
genomic sequences.
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CHAPTER 5 
MUTATIONAL ANALYSIS
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5.1 Introduction
As discussed in introduction chapters, cancer development takes 
advantage from mutations or, in general, alterations in genes especially 
those responsible for cellular growth control. P53 is a paradigmatic 
example. As “cancer gene” it has been found to be mutated in almost half 
of the tumors (see chapter 1.4). On the basis of this consideration, 
possible mutations in DRAGO gene exons have been searched by 
performing the SSCP analysis and DNA sequencing.
5.2 SSCP analysis
SSCP analysis permits to evidentiate even a point mutation occurring on a 
single strand of a gene of interest. Mutations in a gene are in fact 
responsible to a different electrophoresis profile if compared to that of a 
non mutated one. The presence of DNA mutations in the gene has been 
investigated in exons 1, 2, 3, 4 and 5 which were amplified by PCR from 
genomic DNA extracted from 12 human cancer cell lines of different origin 
and used for SSCP analysis. In figure 5.1 a representative SSCP gel of 
not mutated fragments has been reported. Fragments with a suspected 
mutation (see figure 5.2 as an example) were subjected to direct DNA 
sequencing. In figure 5.3 (panel A) the sequence of the exon 1 of SK O V-3  
cells has been reported. The perfect alignment between the sequence of 
interest (indicated as query and corresponding to exon 1 from SKO V-3
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cells) and the DRAGO cDNA has also been showed in panel B of figure 
5.3. As reported in chapter 3.2, the first exon of DRAGO cDNA spans 
nucleotides 1-188. In the table 5.1, the 12 human cancer cell lines 
investigated have been reported. The PCR fragments with suspect 
mutations which have been sequenced are indicated. Nevertheless, for 
each exon, even if putatively not mutated on the basis of the SSCP  
analysis, random PCR fragments have been chosen for sequencing. In 
any cases, the alignment of either the suspected mutated or the putative 
not mutated exons with the genebank DNA sequence of DRAGO revealed 
no DNA mutations among the cell lines tested.
As DRAGO gene resulted to be not mutated in the panel of human cell 
lines which represent an in vitro model, then the search for mutations have 
been address to clinical samples. Genomic DNA was therefore purified 
from human tumor biopsies and investigated to verify if some mutations 
could be found. The analysed samples included ovarian cancer, colon 
cancer, endometrial cancer and leukemia. Among the tumor samples 
investigated, no mutations could be detected on the basis of the SSCP  
analysis (Fig. 5.4) and no more tumor samples have been studied. Since 
the overexpression of DRAGO upon drug treatment induces the arrest of 
cellular growth as it will be discussed further in the result chapter, it has 
been investigated if the gene is mutated in cell lines resistant to drugs 
acting by different mechanisms. For this purpose DRAGO has been 
examined for mutations by direct sequencing of the exons 1 -5  obtained by 
PCR amplification of the genomic DNA isolated from human cancer cell
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Figure 5.1
Representative SSCP gel (see 2.5) PCR fragments corresponding to the 
exon 5 in the 12 cell lines tested (cell lines are indicated with a letter: see 
table 5.1 to identify cell lines and the corresponding origin). Fragments did 
not show altered migration suggesting that they were not mutated.
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Figure 5.2
Representative SSCP gel (see 2.5) of PCR fragments corresponding to 
the exon 1 in 12 cell lines tested (cell lines are indicated with a letter: see 
table 5.1 to identify cell lines and the corresponding origin). The fragment 
with suspect mutation has been highlighted.
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A>Exon1_SKOV-3
CGCTGCAGCCGTCGCTACCGCCGCGTTCTATTCTCCGAAGCCGGCG
ACCGCCCCACCTCCTCCCTCCCTCCCGCCCGCTTCCTCTGCCCACA
GCGCCGGCCAGAGCGAGCTAGACAAGGGCACGCGGGGCCTCGCC
TAGACCCGAGAAGACTGCGGGCGCGCGCAAGCGGCGGCGTGGAA
GCTGTGAGCGCCCCCATCCCGGAGGTCTCCGCCGGCTCCCGGGTG
AGTANNNNN
B
Query= exon1_SKOV-3
Subject= Homo sapiens mRNA for KIAA0247 gene
>  g i 1 1 6 6 5 7 6 2 | d b j | D 8 7 4 3 4 . 1 1 Hom o s a p i e n s  m RNA f o r  K IA A 0 2 4 7  g e n e ,  p a r t i a l  c d s
L e n g t h = 5 3 3 8
S c o r e  =  3 8 1  b i t s  ( 1 9 2 ) ,  E x p e c t  =  6 e - 1 0 3
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S t r a n d = P l u s / P l u s
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Figure 5.3
Panel A: Sequence of PCR fragment amplified from genomic DNA 
extracted from SKOV-3 cells and corresponding to exon 1 of DRAGO 
cDNA.
Panel B: Blast result between the sequence of exon 1 (panel A) and 
nucleotide sequence of DRAGO cDNA (gi: 1665762) deposited in 
genebank has been reported. Exon 1 from SKOV-3 cells which seemed to 
be mutated on the basis of SSCP analysis, perfectly matched with 
DRAGO cDNA.
3 5 C C G A A G C C G G C G A C C G C C C C A C C TC C TC C C T C C C TC C C G C C C G C TT C C TC TG C C C A C A G C  9 4
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1  C C G A A G C C G G C G A C C G C C C C A C C TC C TC C C TC C C TC C C G C C C G C TTC C TC TG C C C A C A G C  6  0
9 5  G CCG G CCA G A G C G A G C TA G A CAA G G G CAC G C G G G G C CTC G C CTA G A CC CG AG AAG AC TG C 1 5 4
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
6 1  G CCG G CCA G A G C G A G C TA G A CAA G G G CAC G C G G G G C CTC G C CTA G A CC CG AG AAG AC TG C 1 2  0
1 5 5  G GG CG CG CG CAAG CG G C G G CG TG G AA G C TG TG A G C G C CC CC ATC CC G G AG G TC TCC G C CG  2 1 4
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
1 2 1  G GG CG CG CG CAAG CG G C G G CG TG G AA G C TG TG A G C G C CC CC ATC CC G G AG G TC TCC G C CG  1 8 0
2 1 5  G CTC CC G G  2 2 2
l l l l l l l l
1 8 1  G CTC CC G G  1 8 8
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Cell line Origin Exon 1 Exon 2 Exon 3 Exon 4 Exon 5
A: SW620 Colon normal normal sequenced normal normal
B: SW626 Ovary normal sequenced normal normal normal
C: IGROV Ovary normal normal normal normal sequenced
D: SKOV-3 Ovary
?
sequenced normal normal
?
sequenced normal
F: DU145 Prostate normal normal normal normal normal
G: REH ALL normal normal normal normal normal
H: ALLOPO ALL normal normal normal normal normal
I: TOM ALL normal normal normal normal normal
L: U20S Osteosarcoma normal normal normal normal normal
M: SAOS Osteosarcoma normal normal normal normal normal
N: OEM T-Leukemia normal normal normal normal normal
0: HL60 T-Leukemia normal normal normal normal normal
Table 5.1
Summary of SSCP analysis.
The first two columns report the 12 cell lines used in this study and their 
origin, respectively. Exons 1 -5  were PCR amplified and analysed. 
Fragments with suspect mutations (indicated with a question mark ?) were 
sequenced as reported in the table. Additional PCR fragments with normal 
electrophoresis pattern were selected and sequenced in order to verify 
they were not mutated.
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lines of different origin resistant to cisplatin (A2780/cp70), taxol 
(1A9PTX22), etoposide (CEM-VM1) or doxorubicin (LoVo/DX). However, 
each of the fragments analysed perfectly matched with the genebank DNA 
sequence of DRAGO. Examples of some sequences of exons derived 
from drug resistant cell line DNA are reported in figure 5.5.
5.3 Discussion
Altogether these results strongly support the idea that DRAGO seems to 
be not mutated in human cancer cell lines sensitive or resistant to 
cytotoxic treatments. The same observations has been confirmed in 
clinical samples of human tumors where mutations have not been found 
among the limited number of the analysed samples. Considering that the 
human cell lines are more frequently mutated than the corresponding 
clinical cancers, it is unlikely that human tumors could be mutated in 
genes that are not altered in the nucleotide sequence in cell lines. For 
these reasons the analysis for searching mutations in DRAGO gene has 
not been extended to other clinical samples of human tumors. These data, 
therefore suggest that DRAGO is not frequently mutated and are in line 
with what observed for other p53 downstream genes, like p21 (340), which 
has not been found mutated in human tumor samples. On the other hand, 
as p53 is frequently mutated in human tumors, it is not strictly necessary 
that its downstream effector genes are non-functional being its inactivation 
enough to de-regulate cellular growth or death thus leading to cancer 
inception, as widely discussed in the Introduction chapter.
170
MW 1 2 3 4 5 6 7 8 9 10 11 12
\ / / / \  \  \
-
- s *  a t .  .. ' ' .
MW 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 MW
v g ^ w  lj  LJ U U '- »  'ov-i'W  w  WJt
*  I
I *
s mr~x f  ,i **** pf
-
Figure 5.4
SSCP analysis on DNA samples derived from ovarian (3 cases, indicated 
as I, II, III), colon, endometrial cancers and leukaemia. Lane 1-3, exon 1 
of I, II, III ovarian cancers respectively; lane 4 -6 , exon 2 of I, II, III ovarian 
cancers; lane 7-9 , exon 3 of I, II, III ovarian cancers; lane 10-12, exon 4 
of I, II, III ovarian cancers; lane 13-15, exon 5 of I, II, III ovarian cancers; 
lane 16-20, exons 1-5 of colon cancer; lane 21-25, exons 1 -5  
endometrial cancer; lane 26-30, exons 1-5 leukemia. Among human 
cancers analysed no mutations were detected.
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Query exon 1 of CEM-VM1 cell lines
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Figure 5.5
Representative PCR amplified exons sequences from drug resistant cell 
lines. The exon 4 sequence is in the reverse sense. The reported 
sequences show perfect match with the cDNA sequence (gi: 1665762) 
deposited in the genbank.
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CHAPTER 6 
CHARACTERISATION OF THE 
FUNCTION OF THE DRAGO GENE
173
6.1 Introduction
As outlined in the previous chapter, the analysis of either the cDNA 
sequence or the primary aminoacid sequence did not reveal any similarity 
to known domains that could help to hypothesise any functional role of the 
protein or its subcellular localisation. Moreover, as reported in the 
introduction chapter, DRAGO mRNA has been found ubiquitously 
expressed at very low level. The strategy that has been undertaken was to 
study any biochemical and morphological modifications induced by 
DRAGO overexpression in both eukaryotic and prokaryotic (bacterial) cells 
in either transient or stable transfections. Another effort here reported 
regarded the functional analysis of domains at either the N H 2- or C O O H - 
terminus of the protein coded by DRAGO.
6.2 Effects of gene overexpression in eukaryotic cells
The effects of gene overexpression were evaluated in cells carrying 
constructs in which the isolated cDNA was functionally linked to a strong 
viral promoter. The complete cDNA (5,338 bp) and the coding region 
(nucleotides 269-1,180) were used for vector assembly. The full length 
cDNA sequence was excised from pBS plasmid (see 1.7) by restriction 
with Hind\\\ and Kpn\ enzymes and inserted into PCDNA3 digested with the 
same enzymes. The coding region was indeed inserted into the 
pCDNA3HA expression vectors which was prepared from pCDNA3 by
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insertion of the HA tag coding sequence. The latter was excised from a 
vector available in the laboratory by restriction with the Kpn\ and Xho\ 
enzymes used to digest the PCDNA3 vector as well. Whereas the coding 
portion of DRAGO cDNA was amplified by PCR using a set of primers 
designed to introduce the sequences for Xho\ and Xba\ restriction sites at 
the 5’ and 3’, respectively. After digestion with the above mentioned 
enzymes, the coding region was then sub-cloned in frame with the HA 
sequence, after restriction of the pCDNA3HA with the same enzymes. 
Each construct was automatically sequenced to verify its correct assembly 
and transfected into A2780 ovarian cancer cell lines. Fifteen days later, 
the colonies were stained with crystal violet, washed and photographed. 
Figure 6.1 shows the photographs of a plate in which A2780 cells were 
transfected with the full-length cDNA (B) or with vector PCDNA3 alone (A) 
and flasks were the A2780 cells were transfected with the coding 
sequence subcloned in the pCDNA3HA vector (D) or with the vector 
alone (C). In both cases, no colonies were detected in DRAGO transfected 
cells (B and D), whereas a large number of colonies was present in the 
culture transfected with vectors alone (A and C). The overexpression of 
the complete cDNA (5,338 bp) or its 1,180 bp fragment (coding region) 
prevented therefore colony formation. This effect was observed not only in 
A2780 cells (ovary carcinoma), but also in SaoS2 and U 20S  lines (human 
osteosarcoma) cell lines and in murine fibroblasts Swiss 3T3 cells. Failure 
to isolate stable clones was probably due to the strong growth- 
suppressing effect following gene-overexpression.
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Figure 6.1
Effect of the overexpression of DRAGO on A2780 and SKOV-3 cells 
stably transfected with the full length DRAGO cDNA (B) or the coding 
region (D). A and C are respectively the A2780 and SKOV-3 cells 
transfected with the vector alone
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6.3 Morphologic modification in contrast phase microscopy
Morphologic changes following gene overexpression were evaluated in 
fibroblast 3T3 cells transiently transfected with the construct PCDNA3HA- 
DRAGO, used for the stable transfection experiments. The morphological 
effects have been analysed within a sfiort time (24 and 48 hours) from 
transfection by contrast phase microscopy. The overexpression of DRAGO 
caused a series of dramatic morphological changes in the transfected cells 
which were characterised by the presence of several cytoplasmic 
vacuoles. In some cases the cell membranes appeared disrupted and the 
vacuole content was extra-cellularly released (Fig. 6.2). Transfection with 
the vectors alone was not associated with any evident morphologic 
alteration.
6.4 Analysis of functional domains: deletion mutants
The results reported in the chapter 6.2 explain why it is impossible to study 
the gene-induced changes in phenotype in stable transfected clones 
because of the intrinsic growth inhibition ability of the gene itself. 
Therefore, the phenotypic changes induced by the cDNA overexpression 
were evaluated using specific deletion mutants. The aim of these studies 
was to identify regions of the protein encoded by the gene which could be 
responsible for the growth suppressive activity.
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Figure 6.2
Evaluation of morphological effects by contrast phase microscopy in 
fibroblast 3T3 cells transiently transfected with DRAGO.
Panel A: 3T3 fibroblasts transfected with the vector (pCDNA3HA) as 
control.
Panel B: 3T3 fibroblasts transfected with the coding region of DRAGO 
(pCDNA3HA-DRAGO)
Panel C: an enlargement of the photograph in panel B showing the 
presence of several vacuoles inside the cell and the release of cytosolic 
material outside the broken plasmatic membrane.
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6.4.1 Analysis of deletion mutants in prokaryotic cells
The entire coding region of the DRAGO was subcloned in the pG EX-3X  
vector used for the expression of the protein in bacteria, in particular in the 
E. coli strain. With this vector, the coding sequence for the protein of 
interest is subcloned in frame with the GST tag. The resulting GST-fused 
proteins can be easily isolated and purified from bacteria. At the 3’ of the 
cDNA coding the GST enzyme there is a protease-specific recognition 
site which can be cleaved by appropriate protease (the factor Xa protease) 
to release the desired protein from the fusion product for subsequent 
studies (sequence identification, cristallography etc). The full length coding 
region has been PCR amplified using the pBS-DRAGO construct as a 
template and primers designed to introduce the cleavage site for BamH\ 
and EcoR\ at the 5’ and 3’ end of the PCR fragment respectively. The 
PCR fragment was subcloned in the pGEM-T plasmid for the TA cloning 
and verified by DNA sequencing. Then the construct has been digested 
with the BamHl and Ecofil restriction enzymes to get a fragment with the 
suitable extremities to be subcloned in the pG EX-3X vector. The first 
methionine used to synthetise the protein is the one present in the GST  
tag. The gene methionine has been removed so that all the constructs 
start from aminoacid 2.
Starting from the entire 303 aminoacid sequence, progressive deletions 
were designed either at N -  or C-terminus (Fig. 6.3). similarly as the full 
length coding region, the deletion mutants were generated by PCR using
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as a template the coding sequence subcloned in the pG EX-3X vector and 
primers spanning the desired region, containing sequences recognised by 
the same restriction enzymes used for the full length coding region 
subcloning in the pG EX-3X vector (BamHl and EcoRl). Different N- 
terminus deletion mutants produced were:
N1: 12-303 aa cDNA construct: 893 bp 11 aminoacids deleted
N2: 23-303 aa cDNA construct: 860 bp 22 aminoacids deleted
N3: 35-303 aa cDNA construct: 824 bp 34 aminoacids deleted
N4: 49-303 aa cDNA construct: 782 bp 48 aminoacids deleted
N5: 60-303 aa cDNA construct: 749 bp 59 aminoacids deleted
N6 : 74-303 aa cDNA construct: 707 bp 73 aminoacids deleted
Similarly, different C-terminus deletion mutants have been generated:
C 1: 2-290 aa cDNA construct: 884 bp 13 aminoacids deleted
C 2: 2-275 aa cDNA construct: 839 bp 28 aminoacids deleted
C 3: 2-260 aa cDNA construct: 794 bp 43 aminoacids deleted
C 4: 2-245 aa cDNA construct: 749 bp 58 aminoacids deleted
C 5: 2-230 aa cDNA construct: 704 bp 73 aminoacids deleted
C 6 : 2-215 aa cDNA construct: 659 bp 8 8  aminoacids deleted
The PCR products (Fig. 6.4) were then processed similarly as the full 
length coding region has been subcloned in the pG EX-3X vector (with the 
same procedure to subclone in the pGEX-3X vector the full length coding 
region. In summary they were subcloned in the pGEM-T to be digested 
with the BamHl and Ecoftl restriction enzymes to get the deleted 
fragments with the suitable extremities to be subcloned in the pG EX-3X
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WffiffimGST-DRAGO
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230 aa
Figure 6.3
Progressive deletions at N - and C-terminus of the coding region of 
DRAGO generated deletion mutants which were subcloned in frame with 
the GST-tag in the pGEX-3X vector to be expressed in bacteria
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Figure 6.4
Panel A: PCR fragments corresponding to the N -  and C-terminus deleted 
DRAGO cDNAs. Correspondence with the expected molecular weight was 
verified with the molecular weight marker (M1 and M2) ladder in each gel. 
Panel B: pGEX-3X constructs were verified by restriction with EcoR\ and 
BamHl enzymes which caused the excision of the deleted cDNA from the 
plasmid vector. Lane 1: pGEX-N1, lane 2: pGEX-N3; lane 3: pGEX-N4, 
lane 4: pGEX-N5; lane 5: pG EX-N 6 ; lane 6 : pGEX-DRAGO; lane 7: 
pGEX-N2; from lane 8  to13: pGEX-C1 to pG EX-C 6 ; M1: 1 KB DNA 
ladder molecular marker; M2: 100 bp DNA ladder plus molecular marker.
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vector. The first methionine used to synthesise the protein is the one 
present in the GST tag as for the pGEX-DRAGO.
The GST constructs, after confirmation by sequencing, have been used to 
transform XL1-blue bacteria and their presence verified by standard 
molecular biology technique. The bacteria expressing the different 
constructs were induced with IPTG to stimulate the production of the 
peptides encoded by the DNA sequence inserted in the vector. After 4-6 
hours following induction, the bacteria were harvested, lysed and the 
proteins loaded onto SDS polyacryilamide gels. These evidentiated the 
exogenous proteins, present in relatively higher amounts, which, starting 
from the first deletion for the C-terminus (Fig. 6.5A) and form the third for 
the N-terminus, show a progressive reduction in molecular weight. This 
result was also confirmed by Western blotting (Fig. 6.5B), using 
monoclonal antibody against DRAGO (see next section). It is interesting to 
underline that even bacteria did not produce the full length protein coded 
by DRAGO cDNA fused to the GST tag (Fig 6.5).
Taking advantage of the GST tag, the purification of the N- and C-terminal 
deleted proteins produced by bacteria has been carried out by using a 
glutathione-bound matrix to sequester the GST-fusion proteins. The 
structure of glutathione is in fact complementary to the G^lutathione-S- 
Transferase-binding site. Therefore, fusion proteins binding to the matrix 
are retained by the matrix and then isolated from the other proteins 
present in the lysates. Unfortunately, no GST-fused protein has been 
recovered from the bacteria. The exogenous GST-fusion proteins were
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Figure 6.5
N - and C -  terminal deletion mutants expressed by bacteria upon 
induction.
Panel A: SDS-PAGE of cellular lysates obtained from bacteria expressing 
C-terminal deleted proteins. Exogenous proteins were present in relatively 
higher amounts as revealed after Coomassie blue staining of the gel (see 
section 2 .1 0 .1 ).
Panel B: N-terminal deleted proteins from bacterial extracts were detected 
by Western Blotting, using monoclonal antibody against DRAGO.
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Figure 6.6
SDS-PAGE of different eluates and aliquots of supernatant and bacterial 
pellet saved during the purification of GST-fusion proteins exogenously 
expressed by bacteria, as reported in chapter 3.9. Lane 1: eluate 
corresponding to G S T-N 6  fusion protein purified from bacterial cells which 
were induced to produce it. Lane 2: aliquot of bacterial cell pellet from 
G ST-N 6  bacterial culture. Lane 3: aliquot of the eluate corresponding to 
purification of GST from pGEX-3X transformed bacterial cells. Lane 4: 
aliquot of first wash of the GSH-bound matrix after binding to G S T -  
carrying proteins. Lane 5: aliquots of supernatant flowed through the 
GSH-bound matrix. Lane 6 : aliquot of bacterial cell pellet from GST-C1  
bacterial culture.
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Figure 6.7
SDS-PAGE of purified GST and GST-SB after Coomassie Blue staining. 
Numbers on the left refers to the molecular weight marker (MW).
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retained in the insoluble material after bacterial lysis, as observed when 
bacteria debris have been loaded on SDS polyacrylamide gels (Fig. 6 .6 ). 
These proteins tended to accumulate in the inclusion bodies, thus making 
their purification and subsequent cleavage from the GST tag for 
sequencing difficult.
6.4.1.1 Production of monoclonal antibodies
Monoclonal antibodies against DRAGO have been generated in 
collaboration with ARETA INTERNATIONAL biotech (Gerenzano, Varese- 
Italy). Since the purification of all the deleted mutants, fused to the GST 
protein produced by bacteria, was not successful, as antigen a smaller 
peptide (SB) corresponding to the last 82 aminoacids at the C-terminus of 
DRAGO has been produced and purified. The nucleotide fragment coding 
the 82 aminoacids has been PCR amplified using the pGEX-DRAGO  
construct as a template. The upstream primer was designed to introduce 
the sequence recognised by BamHl restriction enzyme. The downstream 
primer was the primer with the EcoRl site designed for the PCR  
amplification of the full length coding sequence. The PCR fragment 
obtained was then loaded on an agarose gel, purified and subcloned on 
the pGEM-T vector. It was then digested with the appropriate enzymes 
and subcloned in the pGEX-3X vector. The construct has been confirmed 
by sequencing and transferred into bacteria. The bacteria were then 
induced to produce the GST-SB peptide similarly as done with the N- 
terminus and C-terminus deleted mutants. The purification of the peptide
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has been carried out using the GSH-matrix. The elution has been checked 
on a SDS polyacrylamide gel, confirming the presence of the SB eluate 
(Fig. 6.7). The purified SB-GST peptide has been then used as antigen for 
the production of monoclonal antibodies.
6.4.2 Analysis o f deletion mutants in eukaryotic cells
In parallel analogous PCR products have been subcloned in the PCDNA3- 
HA expression plasmid which was previously generated by inserting the 
HA tag sequence in the commercially available PCDNA3 plasmid. The HA 
tag is a short aminoacid sequence which can be recognised in cell by 
specific antibodies. The advantage of this tag is that the short sequence is 
unlikely to interfere with the structure and function of the protein to be 
studied. The deletion mutants generated by PCR had Xho\ and Xba\ 
sequences inserted at the 5 ’ and 3’ by ad hoc designed primers and 
necessary for the subcloning in the pCDNA3HA vector. The PCR amplified 
fragments (Fig. 6 .8 ) were processed similarly to those inserted in the 
pG EX-3X vector, therefore, after having been inserted in the pGEM-T 
easy vector, they were digested with the appropriate restriction enzymes 
and subcloned in the pCDNA3HA vector. The HA tags constructs (Fig. 6.9) 
were verified by sequencing and transfected in eukaryotic cells. Taking 
advantage of a neomycin resistance gene present in the same plasmid 
used for subcloning, clones growing in neomycin were isolated and further 
characterised. In particular, so far two clones have been obtained in 
SKOV-3 ovarian cancer cells, i.e. the C2 and the C6  deletion mutants.
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pCDNA3-H A  (5.4 Kb)
PCR fragments exicesed
Figure 6.8
Panel A. PCR fragments corresponding to N - and C -  terminal deleted 
cDNAs fragments of DRAGO. M1: 100-bp DNA ladder plus. Lane 1-6: 
N1-N6 PCR fragments, lanes 7 and 13 correspond to the blank PCR 
reactions (reaction without template to verify that the amplification was 
specific). Lanes 8-12 and 14: C 1-C 6 PCR fragments.
Panel B. HA constructs were verified by double restriction with Xho\ and 
Xba\ enzymes. The empty vector (pCDNA3HA, 5.4 kb about) and the 
cDNA deleted fragments are pointed with arrows.
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Figure 6.9
Progressive deletions at N - and C -  terminus of the coding region of 
DRAGO generating deletion mutants which were subcloned in frame with 
the HA tag in the pCDNA3 vector to be expressed in eukaryotic systems.
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The growth of these clones were followed for different in vitro passages. At 
each passage total RNA was extracted and after several passages all the 
RNAs collected loaded on agarose gel, blotted and hybridised with a 32P- 
labeled probe generated from a gene fragment (C6 ). The results showed 
that both C2 and C6  deletion mutants could be evidentiated at RNA level. 
After 8  passages in vitro both clones retained the expression of C2 and C6  
(Fig 6.10). Among the clones able to grow in neomycin, those stably 
transfected with the empty vector and the PCDNA3HA-DRAGO constructs 
were also isolated. However, as reported in the Northern blot, clones 
carrying the PCDNA3-DRAGO construct did not express the gene at RNA 
level. This is consistent with the results previously discussed in the chapter 
6.2, where the overexpression of the full length DRAGO prevented colony 
formation.
In parallel, three SKOV-3 clones transiently expressing the N-terminus 
deletion mutants N3, N4, N6 , were investigated. The analysis was 
addressed to those deleted mutants selected on the basis of the results 
obtained when bacteria were induced to express the N-terminal deletion 
mutants. N3-construct transiently transfected cells expressed the deleted 
gene at RNA level after few passages following transfection, as confirmed 
by Northern blotting using the exon 3 as a probe (Fig 6.11 A). However, 
stably expressing clones isolated for their resistance to the antibiotic 
neomycin did not retain any detectable expression at RNA level (Fig. 
6.11B).
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Figure 6.10
Panel A: Northern blot showing the expression of DRAGO deletion 
mutants in clones derived from SKOV-3 cells which were retained after 8 
passages. Total RNA was extracted from C2 and C6 cellular clones and 
from cellular clones derived from cells transfected with pCDNA3H A - 
DRAGO (D) which grew in the presence of neomycin. Total RNA was then 
separated on agarose gel (panel B) and transferred to a nylon filter. The 
blot was hybridised with a DRAGO cDNA probe.
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Figure 6.11
Northern blot to detect the expression of N-terminus deletion mutants (N3, 
N4 and N6) in either transiently (panel A) or stably (panel B) expressing 
SKOV-3 clones.
Panel A. Total RNA was extracted from SKOV-3 cells transiently 
transfected with pCDNA3HA-N3 (N3), pCDNA3HA-N4 (N4), pCDNA3H A - 
N6 (N6), pCDNA3HA (H) and pCDNA3HA-DRAGO (D); W T represents 
wild-type SKOV-3 which were not transfected. N3 and N4 cells expressed 
the corresponding deleted DRAGO at RNA level. Total RNA, separated on 
agarose gel (lower part) was transferred onto a nylon filter (upper part). 
Cells transfected with the vector carrying the full length coding region of 
DRAGO (lane D) were able to grow in the presence of the neomycin but 
they did not expressed the protein at the RNA level.
Panel B. Stable clones isolated from transiently expressing N3 and N4 
cells did not retain the expression of the corresponding N-deleted mutants 
at the RNA level.
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6.4.3 Activity of peptides
On the basis of the previously reported results, the removal of the last 28 
aminoacids from the DRAGO protein, resulted in a truncated protein whose 
expression was tolerated by the cell. This suggests that the last 28 
aminoacids play an important role in the DRAGO growth suppressive activity. 
To test whether this assumption was reasonable, a peptide corresponding to 
the 28 aminoacids (DSENSDIQSLLSLTSEEYTDDIPLLKEA) deleted from 
the C2 mutants has been synthesised. A peptide comprising the 13 
aminoacids (EEYTDDIPLLKEA) deleted from the C1 mutants has been also 
synthesised. Eukaryotic cellular clones stably expressing the C1 mutants 
were not able to grow. Therefore the deletion of the last 13 aminoacids 
should not be able to abrogate the growth inhibitory effect that was observed 
when full length DRAGO is expressed. The activity of the peptides were 
evaluated against either p53 +/+ or p53 - I -  HCT-116 cells which were 
treated with different concentrations of either the 13 aminoacid or the 28 
aminoacid peptide. An unrelated peptide from the human endothelin has 
been used as a negative control. The cells were treated for 48 hours then 
washed and stained with crystal violet. The effect of the treatment did not 
reveal any particular toxic effect on cellular growth related to the tested 
peptide (Fig. 6.12). Increasing further the concentration of the peptide, a toxic 
effect was observed, which was, however, not necessarily related to the 
specific effect of the peptide. In fact, a similar toxic level was found when a 
DRAGO unrelated peptide was used at a specific concentrations (Fig.6.13).
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Figure 6.12
Activity of peptides HE, 13 AA and 28 AA against HCT-116 p53 (+/+) 
(panel A) and HCT-116 p53 ( - / - )  (panel B). Peptides were added to the 
cells 24 hours after seeding (at 60,000/ml) at different concentrations as 
indicated. Cells were stained with crystal violet 72 hours after treatment.
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Figure 6.13
Activity of peptides HE, 13 AA and 28 AA against HCT-116 p53 (+/+) 
(panel A) and HCT-116 p53 ( - / - )  (panel B). Cells were seeded at 
60,000/ml, and treated 24 hours after seeding with the indicated 
concentrations of peptides and stained 72 hours after treatment with 
crystal violet.
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6.5 Discussion
The results reported in this chapter indicate that when overexpressed, 
DRAGO has a strong inhibitory effect on cellular growth, preventing any 
colony formation of stably DRAGO expressing cellular clones. For this 
reason any experiment aimed at assessing the morphological and 
biochemical modifications induced by the overexpression of the full length 
gene had to be carried out in transiently transfected cells. The observation 
of morphological modifications in contrast phase microscopy evidentiated 
that the overexpression of the gene caused the formation of many 
vacuoles in the cytosolic compartment. This morphological effect due to 
the overexpression of DRAGO was not associated to the activation of any 
extrinsic or intrinsic apoptotic pathways (see chapter 1.5.3). Nonetheless 
the mechanisms of death in cells expressing high level of the protein 
coded by DRAGO gene is discussed in this thesis being the object of still 
ongoing studies.
The analysis of deletion mutants has been focused to identify possible 
functional domains of the protein which might be responsible for the 
growth suppression effects. The analysis has been also extended to 
bacterial cells in order to purify and isolate the proteins for subsequent 
studies. Otherwise, any effort of purification from bacteria of the deleted 
proteins failed. The collected evidences suggest that the exogenous 
proteins might accumulate in the inclusion body probably due to their 
hydrophobicity. Another important observation is that bacteria expected to
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produce the full length protein retained the ability to overcome the effect of 
the antibiotic ampicillin used for the selection of positive clones, without 
producing any protein. This suggests that the full length protein is toxic on 
cellular growth of prokaryotes as observed in eukaryotic cells. Sometimes, 
clones transfected with the full length DRAGO were able to grow in the 
presence of neomycin, but they did not retain the corresponding cDNA 
expression at RNA level meaning that those clones were able to “skip” the 
synthesis of the protein which would inhibit their growth. Taken together all 
the results collected with the deletion mutants expressed in eukaryotic 
hosts, indicate that the last 28 aminoacids were crucial for the death/grow 
arrest effects of the entire gene. This evidence was supported by the fact 
that the SKOV-3 stably expressing the C2 deleted cDNA retained the 
expression for several passages without any significant morphological 
change suggesting that the last 28 aminoacids deleted starting from the 
C-terminus were necessary to the inhibitory effect of the entire gene. 
Nevertheless, the treatment with the peptides corresponding to the 
aminoacids deleted in the C2 and C1 constructs did not reveal any 
suppressive effect on cellular growth. This observation suggests that those 
peptides, particularly the one with 28 aminoacids, might not have any 
toxicity per se, but its deletion could interfere with the conformational 
structure of the protein or its stability, thus compromising its activity. 
Alternatively, the C-terminus could be important for the interactions with 
other proteins.
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CHAPTER 7 
THE COMPUTATIONAL ANALYSIS 
OF THE PROTEIN
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7.1 Introduction
The aminoacid sequence of the protein coded by DRAGO gene did not 
resemble any protein with known function. In the following section, the 
computational prediction of the conformation of the protein has been 
reported. The theoretical analysis of the primary aminoacid sequence has 
been then supported by a set of experiments aimed at the determination of 
the subcellular localisation of the protein itself. To determine the 
subcellular localisation of the protein two strategies have been 
undertaken. First, immunofluorescence experiments have been performed 
on transiently expressing N3 clones, the characterisation of which has 
been discussed in the chapter 6.4.2. The second strategy was addressed 
at the use of intrinsically fluorescent protein like the GFP protein fused in 
frame to one of the deleted mutants which the cell tolerates when it is 
overexpressed. For this purpose a pEGFPC1-C2 construct has been 
generated.
7.2 In vitro synthesis of DRAGO protein
As mentioned in introduction chapter (see chapter 1.7), the full length 
cDNA of DRAGO putatively codes for a protein of 303 aminoacids. The 
full-length cDNA subcloned in the pBS vector has been used as a 
template for the in-vitro synthesis of the putative protein coded by the 
cDNA. A polypeptide was produced with an apparent molecular
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weight, calculated by SDS-PAGE, of 25-33 kDa (Fig. 7.1). This 
molecular weight is consistent with the structure of the polypeptide 
and with the predicted molecular weight (32 kDa) calculated on the 
basis of the number (303) of aminoacids and the primary sequence of 
the protein deducible from the cDNA sequence.
7.3 Conformational prediction of DRAGO protein and 
computational analysis
The aminoacid sequence has been computationally analysed using 
bioinformatic tools available from the web in order to identify the 
similarity with domains of protein with known function. The submission 
of the primary aminoacid sequence into the CDD database (341) from 
the NCBI website and into others PROSITE (from the ExPASy 
website), InterPro, UniProt, Smart or Pfam databases reveals high 
similarity (about 94%) with the protein region comprised between 
aminoacids 40 and 104 with the complement control protein (CCP) 
domain, also known as short consensus repeats (SCRs) or SUSHI 
repeats. The CCP modules contain approximately 60 amino acid 
residues and have been identified in several complement and adhesion 
proteins. By using the TMHMM database (Fig. 7.2A), the presence of 
putative transmembrane domain, particularly transmembrane helixes, 
have been predicted to be located between the aminoacid 13 and 35 and 
between the aminoacids 120 and 142.
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Figure 7.1
SDS-PAGE of protein product synthesised in vitro using DRAGO coding 
sequence as template, as discussed in section 2.11. The apparent 
molecular weight (MW) around 25-33 kDa of the polypeptide, revealed by 
Coomassie blue staining, is consistent with the aminoacid sequence of the 
DRAGO protein.
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Figure 7.2
Panel A. DRAGO as a membrane-associated protein by informatics 
modelling. Two transmembrane domains located between the aminoacid 
13 and 35 and between the aminoacids 120 and 142 were predicted by 
TMHMM database.
Panel B. Hypothetic conformational structure of DRAGO protein was 
derived by computationally prediction
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On the basis of this database, the N-terminal region which comprises the 
aminoacids 1-12 and the C-terminus portion of the protein (aminoacids 
143-303) are predicted to be located inside the cellular region that the 
membrane, where the protein is linked, contains. The remaining protein 
region (aminoacids 36-119) is predicted to stand in the outside region of 
the membrane. The prediction of transmembrane domains has been 
confirmed by other databases, such as prosite and swiss-prot/tremble. 
Altogether these results have led to draw a hypothetic conformational 
structure of the protein as shown in figure 7.2B.
7.4 Subcellular localisation of the protein
7.4.1 Immunofluorescence on the N3 clone
The experiments reported in this section were aimed at evaluating the 
subcellular localisation of the DRAGO protein, by using the 
immunofluorescence technique taking advantage of the monoclonal 
antibodies generated against the C-terminus peptide SB of 82 
aminoacids. The expression of DRAGO full length protein resulted to be 
growth suppressive as widely discussed in the previous section. The 
experiments were performed on SKOV-3 clones transiently expressing 
N3-deleted DRAGO, the expression of which was characterised and 
verified by Northern blot (see section 6.4.2, figure 6.11). 
Immunofluorescence revealed an intracellular localisation of the truncated 
protein. The fluorescence seemed to localise in correspondence of
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membrane structures, supporting the theoretical and computational 
prediction of the transmembrane domains of the protein. Moreover, 
whenever the cells were not permeabilised, the signal was absent or 
homogeneous: this observation suggests that at least the portion of the 
protein recognised by the antibody is localised intracellularly (Fig. 7.3).
7.4.2 Intracellular localisation o f GFP-C2 protein
Another approach aimed at subcellularly localising the protein was to 
create a fusion protein intrinsically fluorescent such as the GFP. Among 
the deleted mutants stably expressed by the cells, the C2 is the one which 
has the smaller deletion, therefore the GFP-C2 fusion protein can be 
considered as a good tool to get information regarding the intracellular 
localisation of the wild-type protein with good approximation. With this 
purpose, the pEGFP-C1 vector which carries the GFP coding region, was 
used. The coding region of the C2 deletion mutant was subcloned in frame 
to the C-terminus of the GFP coding region. The C2 deleted was PCR 
amplified using the construct of pEGFP-C1-DRAGO as a template which 
was previously generated in the laboratory. To generate the construct, the 
coding sequence of DRAGO was PCR amplified using as a template the 
DRAGO cDNA subcloned in the pBS and primers designed to insert the 
sequence for the HindlU and Kpnl restriction enzymes respectively at the 
5’ and 3’ end. Once amplified, the PCR product was inserted in the 
pG EM -T vector, digested with the appropriate enzymes and subcloned in 
the pEGFP-C1 vector.
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PERMEABILISED NOT PERMEABILISED
Figure 7.3
Immunofluorescence experiments on SKOV-3 clones transiently 
expressing the N3-deleted DRAGO. In permeabilised cells, fluorescence 
localised in correspondence of membrane structures; conversely, if cells 
were not permeabilised, the signal was absent or barely detectable.
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The final construct containing the DRAGO and GFP cDNA was verified by 
sequencing. For PCR amplification of C2, the upstream primer was the 
same which had been used for the sucloning of the DRAGO coding region 
in the same vector. The downstream primer was the same used when the 
C2 deleted mutant has been generated to be subcloned in the PCDNA3HA 
vector and introducing a Xba\ site at the 3’ end of the amplified fragment. 
The PCR product was inserted in the pG EM -T vector, digested with the 
appropriate enzymes and subcloned in the pEGFP-C1 vector. The final 
construct containing the C2 deleted DRAGO and GFP cDNA was verified 
by sequencing. SKOV-3 cells were transfected with the construct and 
cellular clones resistant to neomycin were selected and checked for the 
stable expression of the G FP-C2 construct by Northern blot (Fig. 7.4). 
This clone was then investigated by fluorescence microscope, revealing 
and confirming the fluorescent localisation corresponding probably to 
membrane structures, whereas the cells transfected with the vector alone 
resulted to be uniformly fluorescent (Fig. 7.5).
7.5 Discussion
The protein coded by the cDNA has been confirmed to be of about 25-33 
KDa as that predicted on the basis of the cDNA sequence. The aminoacid 
sequence of the DRAGO protein, predicted on the basis of the cDNA 
sequence, did not reveal any particular motif, indicative of possible cellular 
localisation and function.
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Figure 7.4
Northern Blot showing the expression of the deleted DRAGO mutants C2 
(lane 3) in stably transfected SKOV-3 clones. Total RNA was extracted 
from cells transfected with the vector pEGFP-C1 (lane 1), with pEG FP- 
C1-DRAGO construct (lane 2) and from pEGFPC1-C2 clone (lane 3). 
Total RNA was then separated on agarose gel (panel B) and transferred to 
a nylon filter. The blot was hybridised with the DRAGO exon 3 probe 
(panel A).
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pEGFP-C1 pEGFP-C1-C2
Figure 7.5
Analysis under fluorescence microscope of a SKOV-3 clone stable 
expressing the GFP-C2 fusion protein. The fluorescence localised in 
correspondence of membrane structures, whereas the cells transfected 
with the vector alone (pEG FP-C I, left panel) resulted to be uniformly 
fluorescent.
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However, the bioinformatic analysis of the primary sequence, made it 
possible to predict that the protein coded by DRAGO gene presumably is 
a transmembrane protein. The theoretical prediction was then supported 
the immunofluorescence experiment on N3 transiently expressing clones, 
showing that the fluorescence seemed to be mostly localised in the 
membrane. With the immunofluorescence experiments the stably 
expressing C2 clones were not used since they lacked of the C-terminal 
portion against which the antibodies were generated. However, the N3 
clones used in those experiments expressed the cDNA relative to the 
deleted mutant as confirmed by Northern blot. To support the results 
collected so far, the GFP-C2 stably expressing clones were analysed. With 
this clone the fluorescence was found to be associated to the intracellular 
membrane. In both cases, the localisation of deleted mutants instead of 
the wild-type protein was observed. This fact is linked to the strong growth 
inhibitory effect of the full length protein whether overexpressed by the 
cell. It has also to be underlined that the N3 deleted mutant which lacks of 
one of the two theoretical transmembrane domains, seems to retain the 
membrane-bound localisation.
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CHAPTER 8 
ANALYSIS OF THE EVOLUTIONARY 
CONSERVATION OF DRAGO
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8.1 Introduction
In the introduction chapter (1.7.2), the isolation of the mouse cDNA coding 
the murine analogue of DRAGO was reported. The comparison between 
human and mouse sequences showed a high similarity both at nucleotide 
and aminoacid level. The striking percentage, more than 80%, of the 
homology has suggested to investigate the level of conservation of the 
protein and the corresponding coding region sequences among different 
organisms. Therefore, the aminoacid sequence of the human DRAGO 
protein was compared with those available from the sequence databases.
8.2 Search for sequence homology
The search for homologies between the protein sequence of DRAGO and 
proteins deduced by the available cDNA sequences deposited in the 
databases was carried out by using the BLASTP program at the NCBI 
databases. A significant and interestingly high similarity has been found 
with mammals, such as chimpanzee (Pan troglodytes), dog (Canis 
familiaris), mouse (Mus musculus), bovines (Bos taurus). With those 
mammals the identity exceeds 85%. In figure 8.1 the alignment between 
those mammals and DRAGO protein has been reported. In the same 
region, the proteins aligned were almost identical.
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Figure 8.1
Alignment between the sequence of human DRAGO protein (Homo 
sapiens) and those from other mammals which exhibited identity higher 
than 85%. Higher consensus sequences (>90% of identity) are in red 
colour. Low consensus sequences (>50% of identity) are in blue.
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Figure 8.2
Alignment between the sequence of human DRAGO protein (Homo 
sapiens) and those from vertebrates (zebrafish, puffer and Xenopus). 
Identity higher than 90% (high consensus)s are indicated in red colour. 
Low consensus (identity higher than 50%) are in blue.
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Similarities has also been found with other mammals such as rats (Rattus 
norvegicus), macaque (Macaca fascicularis) orangutan (Pongo 
pygmaeus). Similarities currently extended to all vertebrates for which 
genomic data is available. Significant similarities, higher than 70% have 
been found with cocks (Gallus gallus) and more than 50% with zebrafish 
(Danio rerio) and Xenopus leavis. Similarities have also to be underlined 
with puffer (Takifugus rubripes, Tetraodon nigroviridis). In figure 8.2 the 
alignment with these vertebrates (except for the Gailus gallus) is reported 
showing some identities between the sequences.
8.3 Discussion
In this short section, the attention has been focused on the striking high 
similarities that DRAGO protein shares with gene products from genomes 
of mammals. Surprisingly, high levels of similarities have also been found 
with vertebrates such as cocks and fishes. The similarities found between 
the human DRAGO protein with proteins of phylogenetically distant 
organisms revealed an evolutionary conservation of the gene which could 
suggest an important functional role of the gene. Furthemore, due to the 
difficulties in generating cellular systems expressing DRAGO, the finding 
that simple organisms such as zebrafish share significant homologies with 
humans for DRAGO certainly provide an alternative for investigating the 
function of DRAGO protein.
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CHAPTER 9 
GENERATION AND CHARACTERISATION 
OF DRAGO KO MICE
217
9.1 Introduction
As mentioned in the Introduction chapter, DRAGO expression is induced 
upon cytotoxic treatments. In order to investigate the role of DRAGO in 
determining the response to treatment, and the function of the gene 
product coding by DRAGO, one of the selected strategy was the 
development of cellular model systems lacking the gene, which could be 
morphologically and biologically compared with the isogenic counterparts 
expressing the wild-type protein. For this purposes, the development of a 
DRAGO-null mouse line have been conducted in collaboration with 
Genoway (Lyone-France) in the laboratory directed by Sandrine Millet. 
The generation of the KO mice lacking DRAGO gene was not carried out 
by eliminating the ATG site which avoids the risk of expression of 
truncated form of the protein. The strategy pursued for the generation of 
the KO mouse line was to delete most of the coding region comprised in 
exon 3, 4 and 5, to avoid the risk of alternative splicing. This is consistent 
with two previously reported observations. The first is based on the 
assumption that the murine gene structure is similar to the human which is 
supported by the high similarity of the mouse DRAGO cDNA with the 
human at a nucleotide and aminoacid level. Therefore, consequently to 
this assumption, it is highly probable the presence of two long introns 
between the first and second exons and between the second and third 
exons, containing cryptic ATG which could give rise to isoforms of the 
protein by alternative splicing. A mouse genomic region comprising most
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of the coding region of DRAGO was therefore isolated from a mouse 
genomic library for the targeting vector construction. Once the KO mice 
have been generated the MEF cell coltures have been isolated and 
characterised.
9.2 Isolation of mouse DRAGO genomic sequence
Analogously to human genomic PAC clone, to isolate the genomic clones 
comprising DRAGO gene from mouse genome, a mouse genomic PAC 
library spotted in duplicate in seven different filters, obtained through the 
UK-HGMP-RC was used. These filters contain genomic DNA clones and 
can be hybridised with different probes derived from the mouse DRAGO 
cDNA to isolate the genomic sequence of interest.
For the purpose of this study, considering the high similarity between the 
human and the mouse cDNA, a fragment of the human cDNA, 
corresponding to the C-terminus deleted cDNA C6 (see chapter 6.4.2) has 
been used in order to allow the isolation of a genomic region which is likely 
to contain most of the entire cDNA sequence. On the whole set of seven 
filters (see figure 9.1 as an example), the use of this cDNA probe led to 
the identification of four positive clones which, once univocally identified 
through the coordinates of the filters have been requested to the UK- 
HGMP-RC. The four positive clones (458-D3, 394-M24, 577-C4, 662-F21) 
thus obtained were grown in LB media and the DNA was isolated from the 
overnight culture using the procedures described in the Materials and
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Figure 9.1
Screening of the RPCI mouse genomic PAC library 21.
The figure shows a representative autoradiography obtained from a filter 
containing the genomic DNA that was probed with a 32P-labelled human 
DRAGO cDNA C6 fragment. Each clone is spotted in double on the filter. 
The arrow points the DRAGO positive clone (458-D3) which has been 
selected based on this screening.
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Methods chapter (chapter 2.8). The isolated DNA was then digested with 
BamH\, EcoR\ and Hind\\\ restriction enzymes and half of it loaded on 
0.8% agarose gels to separate the fragments of different length. Figure 
9.2A, shows fragments of the most representative clone (458-D3) digested 
with the restriction enzymes. The gel was blotted overnight to nylon filter 
and hybridised with 3 probes corresponding to the human exon 1, human 
exon 3 and human exon 5 to identify the restriction fragments of the 
genomic sequence which presumably contained exon 3, 4 and 5. The 
results of the hybridisation are shown in figure 9.2B, from which one can 
deduce that few digested fragments gave positive hybridisation and hence 
contained the sequence of DRAGO used to hybridise. From these 
experiments a DNA fragment of approximately 20-23 Kb obtained from 
clone 458-D3 after digestion with EcoR\, which seemed to give positive 
hybridisation with both exon 3 and 5, was isolated for further 
characterisation. This DNA fragment was in fact subcloned in the EcoR\ 
site contained in the multiple cloning site of the pBS plasmid. The DNA 
inserted was then sequenced using the primer T7, the sequence of which 
was upstream the multiple cloning site contained in the plasmid. The 
obtained sequence (of 696 bp-figure 9.3A) was aligned and matched with 
the mouse genomic sequences present in the NCBI gene bank database. 
A complete overlap was found with a genomic sequence located upstream 
to and partially overlap the exon 3 of DRAGO cDNA sequence (Fig. 9.3B). 
The mouse PAC fragment isolated presumably contained exon 3, 4 and 5. 
Therefore the further 10 kb starting from the T7 primer of the 20-23 kb
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Figure 9.2
Southern Blot from the genomic 458-D 3 clone from the RPCI mouse PAC 
library 21. Panel A. Ethidium bromide staining of the gel. DNA isolated 
from the clone was digested with BamH\ (B) Ecoftl (E) and Hind\\\ (H), 
resolved on agarose gel. M1 is the A DNA/H/ndlM marker 2, M2 is the 1 Kb 
DNA molecular weight marker. Panel B. Autoradiography of the gel 
transferred to a nylon membrane and hybridized with 32P-labelled DRAGO  
probes containing exons 1, 3 and 5 probes. Numbers on the left are 
derived from M1 molecular weight markers. The arrow point to the 23-Kb  
fragment of the DRAGO clone digested with EcoRI isolated for further 
study.
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Figure 9.3
Partial sequence of the 23-Kb EcoRI fragment isolated from the 458-D 3  
mouse genomic clone and subcloned in the Ecoftl site of pBluescript SK II 
vector. The sequence, obtained using the T7 primer of the plasmid (panel 
A), partially overlap the exon 3 of DRAGO cDNA sequence as 
schematically depicted in panel B. Starting from the T7 primer the further 
10 Kb of the 23-Kb Ecoftl fragment were sequenced, revealing to 
comprise exons 3 -5  and to share high level of homology with human 
exons sequences.
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EcoRl fragment were sequenced. By sequence alignment, a high level 
homology to human exons 3, 4 and 5 sequences within the EcoRl 
fragment was found, consistently with previously observation. But the 
interesting thing was that even the intronic regions were very close 
between the two species.
9.3 Targeting vector construction
For the construction of the targeting vector for the replacement of the 
region comprising exon 3 to 5, the first step was the construction of the 
Neo cassette for selection of the further positive events of recombination. 
This was performed by inserting the FRT linker at the 3’ of the NEO gene 
and consequently the loxP-FRT linker upstream the NEO-FRT. The loxP 
and FRT are sites for specific recombinases. The second step was the 
insertion of the selection cassette in the intronic region upstream the 
region to delete, that is the intron 2. For this purpose the DNA from mouse 
PAC genomic clone 458-D3 was digested by several restriction enzymes 
(BamHl, EcoRl, HindlU, Kpnl, Pstl, Seal, SpeI, Xbal and Xhol). After 
Southern blot analysis using the exon 3 probe (Fig. 9.4A), a smaller 2 Kb 
Pstl fragment has been subcloned in pZErO-2 (invitrogen) vector and 
sequenced, revealing to contain mostly the intronic region upstream the 
exon 3. The selection cassette was therefore inserted in the unique M e l 
site present in intron 2 of the Pstl fragment (Fig. 9.4B). The second step 
was aimed at the insertion of the second LoxP site for specific 
recombinase in the long homology arm, downstream to the exon 5.
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Figure 9.4
Targeting vector construction.
Panel A. Southern blot analysis of the mouse PAC genomic clone 458-D 3. 
DNA extracted from the clone was digested with BamH I (lane 1), EcoR I 
(lane 2), Hind III (lane 3), Kpn I (lane 4), Pst I (lane 5), Sac I (lane 6), Spe I 
(lane 7), Xba I (lane 8) and Xho I (lane 9), separated on agarose gel, 
blotted onto a nylon filter and hybridised with human DRAGO exon 3 
fragment. A 2 Kb Pst I fragment was isolated and subcloned in pZErO-2  
vector. Panel B. the selection cassette was inserted in the unique Mfe I site 
upstream of exon 3 in the Pst I fragment. Panel C. the loxP site was 
inserted in the Thill I site downstream the exon 5. Panel D. the selection 
cassette was excised from the Pst\ fragment by EcoR\/Ssp\ digestion and 
ligated to the EcoRI/EcoRV fragment to get the targeting vector.
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Two loxP sites, oriented in same sense for efficient Cre excision, were 
inserted in the Tth1111 site, downstream the exon 5 (Fig. 9.4C). The final 
construct was confirmed by sequencing.
The final step was the extraction of the selection cassette from the Pst\ 
fragment in which it was subcloned by EcoRUSspl digestion and ligated to 
the EcoRl/EcoFN fragment containing the other loxP site. The right 
orientation of the constructs were checked by DNA sequencing. The 
resulting targeting vector is represented in figure 9.4D.
9.4 Generation of KO mice
ES cells were then electroporeted with the final construct and positive 
clones selected were screened for homologous recombination event by 
PCR and Southern blot. Positive ES cell clones were electroporeted with a 
Cre-expressing plasmid to carry out an in vitro Cre-mediated deletion of 
the targeted region. Positive Cre-excision events specifically at the 
targeted locus were then screened by PCR and Southern blot. This in-vitro 
Cre-mediated deletion of the targeted region in ES cell clones transiently 
expressing the Cre recombinase could isolate only one clone which 
underwent to a complete Cre-mediated excision. This clone was then 
injected into 42 C57BL/6 blastocysts and reimplanted into 3 CD1 pseudo­
pregnant females giving 1 male chimera at 100% and 1 male chimera at 
90% chimerism among 12 pups. Those male chimeras were then crossed 
with 2 wild-type C57BL/6 females each, giving rise to two heterozygous 
female carrying the floxed allele (with the recombinase specific sites).
226
These females were bred with a male mouse expressing ubiquitously CRE 
recombinase under control of CMV promoter. Similarly the male 100% 
chimera was crossed with 2 female mice expressing ubiquitously CRE 
recombinase under control of CMV promoter. The F1 generation resulted 
to be partially Cre-excised DRAGO animals. Among them, the animals 
with 100% of Cre-mediated excision event were bred with Cre-expressing 
mice. The second breeding (F2) gave rise to HE DRAGO KO animals, 
showing a 100% of Cre-mediated deletion of DRAGO targeted region. 
These were crossed (F3) to generate KO mice. F3 animals were 
genotyped by PCR and Southern Blotting. Representative results of the 
screening are shown in figure 9.5.
9.5 DRAGO-null mice status
Homozygously deleted mice are viable and fertile. The male/female ratio is 
in the expected proportion from breeding of HE mice. Macroscopically they 
do not present alterations. As an indication of the healthy status of the 
homozygous (HO) KO mice their weight has been measured and 
compared to that of W T or HE KO mice and shown in figure 9.6.
9.6 Isolation of MEF and growth rate characterisation
Embryo fibroblast cultures were prepared from 12-15 day embryos derived 
from either DRAGO HO KO crosses or W T mice crosses. Nine hundred 
thousand cells were plated in T75 culture flasks and were passaged at
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Figure 9.5.
Panel A. Screening by PCR of the animals generated by HE breeding (F3), 
using GW722/GW723 primers, to identify the allele with the Cre-mediated 
excision of DRAGO exon 3 to 5. The band 10-Kb corresponding to the wt 
allele is often absent due to the competition of the more efficient amplification 
of the 3.6 Kb band. Results obtained are illustrated for 14 animals (lanes 2 to 
15). Lanes 1 and 16 are the negative and the positive (wt DNA) controls 
respectively. The HE versus HO genotyping were obtained by Southern 
Blotting (Panel B). The genomic DNA digested by EcoN\ was hybridised with 
a 3’ probe designed by Genoway, in order to screen the wt allele (10.4 Kb 
band) and the allele with the excision of DRAGO exons 3 to 5 (4.1 K band). 
Results obtained are illustrated for 12 only animals (lanes 17 to 18). Lane 29 
is the wt DNA. MW is the molecular weight. Representative HO animals are 
highlighted by an asterisk.
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Figure 9.6
Body weight of KO HO male and female mice, generated from HO x HO 
breeding., and of wild-type, KO HO and HE mice derived from HE x HE 
breeding.
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Figure 9.7
Growth curve of DRG-/- and DRG+/+ MEFs cultures at different 
passages.
Panel A. Growth curve of DRG-/- (□) compared to DRG+/+ (A)  at 
culturing passage 3. The DRG-/- cells (doubling time 29.43 hours) divided 
twice and half as rapid as DRG+/+ cells
Panel B. Growth curve of DRG-/- (□) at culturing passage 57 compared to 
DRG+/+ (A)  at culturing passage 65. At late passages, wild-type and KO 
HO cells grew similarly with a doubling time around 12 hours.
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these densities every 3 days. After the first passage in vitro both 
DRAGO.HO KO and W T MEF were cryopreserved. For studies of early 
passage embryo fibroblasts, comparative growth rates was defined with 
cells at passage 3. The results indicated that DRAGO - / -  cells grew more 
rapidly that DRAGO +/+ cells. The cell doubling times, calculated from 
early time points of this curve were 29, 43 hours for the DRAGO - / -  and 
79 hours for the wild-type cells meaning that at early passages, the HO 
KO MEF divided twice and a half as fast as the W T (Fig. 9.7A). After few 
passages the growth rate dramatically dropped down till around the 
passage 20 when both DRAGO - / -  and DRAGO +/+ MEF cell lines 
spontaneously immortalised. At late passages (65P for the W T and 58P 
for HO KO embryo fibroblast) the W T MEF grew similarly to KO HO cells 
with a doubling time around 12 hour and 14 hour respectively for W T and 
HO KO cells (Fig 9.7B).
9.7 Response of MEF to UV and X rays
Both DRAGO - / -  and DRAGO +/+, plated on six-well plates were treated 
with either UV or X  rays at different doses. Seventy-two hours after 
treatment, plates were washed and stained with crystal violet evidencing 
that both W T and HO KO cells responded to treatments with no 
differences. The response to UV and X rays have been reported as a 
growth curve relative to controls (untreated cells) in figure 9.8. These 
results were confirmed by other experiments conducted with different 
doses.
231
UV treatment
1,2
o
fe iou
£ 0,8 <l)>■■p
■2 0,6
0,4
0,2
o 0
X-ray treatment
o ’
o 1 o
a
a> 0,8 
S 0,6
o 0,4
D)
»-TO
D 0,2
0 2,5 5 7,5 10
Figure 9.8
UV (upper panel) and X rays (lower panel) treatments. Response of 
DRG+/+ MEF (•) and DRG-/- MEF (■) has been expressed as cellular 
growth relative to control (untreated) cells.
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9.8 Response of MEF to drug treatment
MEFs were treated with several drugs, most of them were tested on 
different cells lines showing to induce the increase of DRAGO gene 
expression. Plated on 24-well plates, both DRAGO - / -  and DRAGO +/+ 
MEFs were treated 24 hours after seeding with 5-FU, OPT, DDP, DX, 
PS341, taxol and VP-16. Seventy-two hours after treatment, cells were 
washed and stained with crystal violet. The treatment with DX, DDP, OPT, 
and etoposide (VP-16) induced a different response in the MEF cultured 
cells showing that the DRAGO - / -  cells were more resistant than the W T  
MEF to drug treatment as represented in figure 9.9. The other drug 
treatment determined a similar response in both MEF cultured cell lines. 
As reported in the introduction chapter, in HCT-116 cell line DRAGO 
expression is induced by almost strong drug treatment, meaning that the 
concentrations and time able to induce the gene expression were often 
higher than the GI50 calculated for each drug used. In particular, 5-FU and 
taxol determined an increased in the expression of DRAGO in the HCT- 
116 cell line whether added to the cells at particularly high doses for long 
time (see table 1.1). Therefore, the observation discussed here are 
consistent with the real time data reported in the introduction chapter. It is 
possible that to detect a different response to 5-FU and taxol in W T and 
HO KO MEFs it is necessary to treat the cells with higher doses tested so 
far but possibly too toxic for the cells.
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Figure 9.9
MEF response to drug treatments. DRG+/+ (first two rows of each plate) 
and D R G -/- (last two rows) cells were treated with the indicated 
concentration of drug for 72 hours. Staining with crystal violet was 
performed at the end of the treatment.
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9.9 Apoptosis of MEF by DAPI/sulphorhodamine staining
In order to understand how the DRAGO-null MEFs are relatively resistant 
to drug treatment, both DRAGO +/+ and DRAGO - / -  nuclei have been 
stained with DAPI/sulphorhodamine in order to evaluate whether cells 
underwent to apoptosis following treatment. MEFs cells were then treated 
with etoposide (VP-16), DX and OPT. Two concentrations were chosen at 
which in the previously described experiments the highest differences 
between the two cell lines in response to the treatment were observed. At 
either 24 or 48 hours of treatment cells were stained and photographed at 
fluorescence microscope. As represented in figures 9.10-9.11, DRAGO -  
/ -  MEFs very rarely showed fragmentation of the nuclei, which is a 
characterising feature of the apoptotic cells as discussed in the 
introduction chapter 1.5.3. Conversely, 50% of the nuclei of the DRAGO  
+/+ cells resulted to be apoptotic. This effect is observable in W T cells 
after treatment with VP-16 and DX as shown in figures 9.10-9.11. This 
finding strengthens the hypothesis that DRAGO induced upon drug 
treatment could drive the cell to respond to stress by activating pathways 
leading to apoptosis.
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Figure 9.10
DAPI/sulphorhodamine staining of MEF DRG+/+ (upper panel) and D R G -/-  
(lower panel) after treatment with V P -1 6  5 pM for 24 hours (left panel) 
compared to the corresponding untreated cells.
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Figure 9.11
DAPI/sulphorhodamine staining of MEF DRG+/+ (upper panel) and D R G -/-  
(lower panel) after treatment with doxorubicin 0.5 pM for 24 hours (left 
panel) compared to the corresponding untreated cells.
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9.10 Discussion
The determination of the cellular function of DRAGO gene protein product 
was certainly challenging for the difficulties encountered related to the fact 
that its expression was associated to a strong growth suppressive effect. 
With the generation of KO mice, most of the hypothesis derived from 
previous results could be proven. DRAGO-null mice, generated in 
collaboration with Genoway, are viable, fertile and do not present any 
macroscopically evident alteration. No experiments on mice to assess the 
response to genotoxic insults such as X rays or drug treatment have been 
conducted as yet although they have been planned to be carried out in the 
near future.
The experiments for the evaluation of the genotoxic insults, such as X and 
UV radiation or drug treatment were performed on mouse embryo 
fibroblast cultured cells isolated from either DRAGO +/+ or DRAGO - / -  
mice. Those cells show a similar response to UV and X rays treatment. 
While there was no indications regarding the influence of X rays on 
DRAGO induction, by real time PCR no increase in the expression level of 
DRAGO was measured in cells treated with UV radiation (see introduction 
chapter 1.7.1). Therefore, at least for the UV radiation, MEF response to 
treatment is consistent with the experimentally collected data reported in 
the introduction chapter.
Conversely, upon drug treatment DRAGO - / -  cells were in general less 
sensitive than the DRAGO +/+ cells. Moreover, the W T DRAGO MEFs
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showed to undergo to apoptosis in contrast to the DRAGO-null cells which 
less frequently had nuclei fragmentation. This ultimate observation 
strengthens the hypothesis that DRAGO gene, when induced in cells upon 
stresses and DNA damage could activate a series of steps ultimately 
leading to cellular death by apoptosis.
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CHAPTER 10 
GENERAL DISCUSSION
The overall aim of the present thesis was the characterisation of a new 
gene named DRAGO (DRugs Activated Gene Overexpressed) identified 
as a p53-inducible gene by differential expression analysis in cells 
following genotoxic insults. The hypothesis that DRAGO is a 
transcriptional target for p53 apoptosis control conferred particular 
relevance to this work. Being DRAGO a previously uncharacterised gene, 
the establishment of DRAGO as a mediator of p53-dependent apoptosis 
could add a novel aspect to the understanding of the mechanism by which 
p53 physiologically controls cell death, the essential function for its tumor 
suppressor activity.
The newly identified gene sequenced matched with a cDNA cloned 
sequence (named KIAA0247) that had been submitted to Genbank 
databases, but the function of the gene product was unknown. From 
tissues expression analyses, the gene was found to be ubiquitously 
expressed at a very low level. From preliminary experimental results 
collected in my lab, the gene was overexpressed to treatment with DNA 
damaging agents, at doses and times of treatment were significantly 
higher than the drugs GI50 established for administered drugs (see table
1.1). Moreover upon stress, the expression of DRAGO was induced after 
24 hours following treatment. This evidence suggested that DRAGO could 
be considered as a late rather than immediate p53-dependent gene 
activated in response to treatment.
The characterisation of this newly identified gene started with the 
description of the molecular organisation of the gene. The full cDNA of
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5,338 bp had already been isolated and sequenced by colleagues of the 
Molecular Pharmacology Laboratory of the Department of Oncology at the 
Mario Negri institute. As reported in chapter 3.2, the 5,338-bp cDNA is the 
result of the junction of 6 exons. The coding region of the putative 303- 
aminoacid protein, deduced from the nucleotide sequence, is comprised 
between exon 2 and the first 26 bases of exon 6. What has to be 
underlined is the peculiar gene structure, which is characterised by the 
first two very long introns, about 45-48 kb long, and by the presence of a 
4-kb 3’UTR. The unusual length of those regions could imply an 
involvement in the regulation of the gene at post- 
transcriptional/translational levels. The 3’UTR-sequence in fact contains 
several AU and CU-rich regions which are known to be involved in the 
degradation/stability of mRNA. Moreover, a recently collected observation 
in my lab, highlights the presence in the same region of sequences which 
can be specifically bound by at least two miRNAs. As reported in the 
literature, the miRNAs are small regulatory non-coding RNAs of 19-28 nt 
in length, which are derived from double-stranded RNA (dsRNA) and can 
induce gene silencing (post-transcriptional or transcriptional) through 
specific base-pairing with target molecules in a number of eukaryotes 
(from nematodes, plant, mammals). It would be interesting, therefore, to 
evaluate the expression of a reporter gene which is measurable like 
luciferase, fused to the DRAGO 3’UTR, after treatment with the miRNAs, 
the specific target regions of which were identified. This experiment, 
together with the discovery of putative proteins determining the stability of
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the mRNA, are some of those planned to be done on the basis of the 
results of the studies presented here.
As already discussed, in chapter 3.4, the intronic region might contain 
cryptic ATGs which, by alternative splicing, could give rise to isoforms of 
the protein. These isoforms could be putatively expressed also in a tissue- 
specific fashion, therefore the above mentioned intronic region might also 
include cis-regulatory element together with binding site for tissue-specific 
transcription factors. It has to be underlined that there is a unique 
polyadenylation signal, ATTAAA, located at 20 bp upstream of the stop 
codon. Therefore, the putative isoforms which share the same stop codon, 
would have another promoter likely comprised in the above mentioned 
intronic regions. In the chapter 4.2 to 4.7, the analysis of a theoretical 
promoter region of the gene is reported. The data indicate that p53 
transcriptionally controls DRAGO expression, consistently with the results 
so far collected, even though for the putative promoter regions isolated, 
p53 only weakly induced the gene. The interesting findings reported here 
regard p73 and its isoforms, particularly p73p and y, which induce DRAGO  
more efficiently than p53. As already discussed, other genes are better 
activated by p73 than p53. Nevertheless, DRAGO could represent an 
additional downstream gene of both p73 and p53. The fact that DNp73 
acts in a synergising manner with p53 and p73 different isoforms to induce 
DRAGO expression adds complexity to the numerous mechanisms so far 
hypothesised to control the expression of the gene. The promoter analysis 
is not complete and needs to be supported with experimental tests aimed
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at defining the DRAGO regulatory regions bound by p53 and p73 
isoforms. It is also particularly important to verify whether the sequences 
tested for promoter activity are really those controlling DRAGO  
transcription. Therefore the analysis of intronic region should define the 
binding motif for transcription factors implicated for instance in tissue 
specific expression of DRAGO, but in particular for p73 isoforms and p53. 
The search for putative p53, p73 and its isoforms responsive elements 
should also be address to the 7-Kb sequence, which is located upstream 
to the 3.8-kb region and is part of the isolated 10,735-bp fragment (see 
Fig. 4.1). The sequential portions of the 7-Kb region should also be 
analysed with the luciferase assay.
On the basis of the observed better induction of DRAGO gene by p73 (and 
its isoforms) than p53, it would be also interesting measuring by real-time 
PCR the induction of DRAGO at the mRNA level in p 7 3 -/-  cells after 
treatments with drugs (i.e 5-FU and Taxol) which are able to induce 
DRAGO mRNA in p53+/+ and not in p 5 3 -/-  (as reported in chapter 1.7.1). 
As reported in chapter 5.2, DRAGO was not found to be mutated in any of 
the experimental systems tested, including tumor cell lines sensitive or 
resistant to anticancer drugs, and clinical human samples. This result is 
not surprising considering that p53 is frequently mutated in human cancer, 
thus not necessarily meaning that it requires additional mutations of its 
downstream effectors. It is also to note that the gene might not be mutated 
because it can be down-regulated at the mRNA level, as widely discussed 
above.
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In chapter 6, the functional role of the DRAGO gene has been investigated 
in in vitro systems represented by cultured cell lines of different origin 
(bacterial, human and murine). The data obtained on the effect of ectopic 
overexpression of DRAGO indicate that the gene has a strong inhibitory 
effect on cellular growth, preventing the formation of stably expressing 
cellular clones. At a morphological level, the overexpression of the gene, 
under the control of a strong viral promoter, induces the formation of a 
large number of vacuoles to cause the disruption of the membrane leading 
to the extracellular release of cytosolic material. It is important to stress 
that whenever overexpressed under the control of a strong constitutive 
promoter, the level of induction is probably much higher than to the 
induction level measured by real time PCR following a genotoxic insult. 
Threfore, the morphological alteration induced by overexpression of the 
transfected DRAGO might not be modelling the physiological situation. It is 
important to verify if DRAGO gene product whenever expressed after DNA 
damage localises in vesicles thus leading to the membrane desruption. 
Moreover, it has also to be formally proved that the morphological effects 
observed are really due to the overexpression of the gene by double 
staining the cells to verify that the plasmid has entered the cells, even if all 
the results would suggest this. The results reported in chapter 6.4, 
however, indicate that probably the protein conformation or stability is 
strictly required for the growth suppressive activity. Cells, in fact, can 
tolerate the expression of mutant proteins lacking a few aminoacids 
deleted from the C-terminus. Since the peptides corresponding to those
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aminoacids, on the basis of the results reported here, seem not to affect 
cellular growth, it is possible that the deletion of the same aminoacids 
could determine a loss of the toxic effect by compromising the stability or 
the correct folding of the protein. However, to prove that the peptides have 
no suppressive effects on cells after treatment, it is necessary to show that 
the peptides have indeed entered the cells, by either doing a fusion 
peptide with the tat epitope (which is known to favour the entrance of 
peptides into the cells) or co-transfecting small amounts of FITC fusion 
peptides to monitor if peptides have entered the cells by fluorescence.
The computational analysis of the aminoacid sequence deduced from the 
cDNA of the protein (chapter 7) reveals that the DRAGO protein is likely a 
transmembrane protein. The theoretical prediction has been supported by 
experimental evidences reported in chapter 7.4 where it has been seen 
that the protein localises to membrane structures. However it is unclear in 
which membrane of the cell the protein positions itself. It is to note that the 
immunofluorescence experiments showing the localisation to membranes 
of the protein were performed on deleted proteins generated as reported 
in chapter 6. The deletion mutants were generated by progressive 
deletions from the N-terminus and C-terminus in order to preserve at least 
one of the two transmembrane domains to verify the protein can localise at 
the membrane. However, it is important to detect the wt protein by 
immunofluorescence, too, in order to support the hypothesis that DRAGO  
is really a membrane-bound protein.
The generation of DRAGO-null mice would help in answering most of the
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unsolved questions identified so far. The fact that KO mice are viable, 
macroscopically normal and fertile, suggests that DRAGO is unlikely to 
play a crucial role in development. Embryo fibroblasts cultured cells 
isolated from KO and W T mice embryos would be important in vitro 
experimental systems. The results reported in chapter 9 finally 
demonstrated that the absence of the DRAGO gene, as in D R A G O -/-  
MEFs, renders the cells relatively resistant to several anticancer agents, 
with different mechanisms of action, by suppressing the ability of the cells 
to undergo apoptotic death. In contrast, W T MEFs were relatively sensitive 
to the anticancer agents used to treat KO MEFs, dying by apoptosis 
(chapters 9.8 and 9.9). These results lead to important conclusions. First, 
DRAGO is a newly identified p53/p73 target gene involved in the control of 
growth and apoptosis. These observations are also supported by DNA 
microarray analyses of p53 target genes involved in apoptosis (342, 343) 
revealing that KIAA0247/DRAGO was one of the apoptotic genes 
activated in a p53-dependent fashion.
Second, DRAGO is a gene induced after high doses of anticancer drugs, 
suggesting that only when cells are subjected to irreparable genotoxic 
damage is DRAGO induced to execute the suicide of the damaged cells. It 
is also important to underline the necessity to confirm the direct role of 
DRAGO on the drug treatment induced apoptosis by knock down of the 
gene in DRAGO+/+ cells with the use of synthetic siRNA (small-interfering 
RNA) duplexes against DRAGO, to observe if cells acquire resistance to 
DNA damage and still undergo apoptosis. Similarly to miRNAs, siRNAs
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are regulatory non-coding short RNAs derived from dsRNAs, which, 
through perfect basepairings with a sequence in the target mRNA, induce 
the cleavage of the target mRNA, thus silencing the corresponding gene 
expression at a post-transcriptional level. The isolated D R A G O -/- and 
DRAGO +/+ MEFs cultured cells would be useful for immunofluorescence 
experiments aimed at investigating the subcellular localisation of the 
protein by using a specific staining to distinguished the different cellular 
compartments. Other experiments planned to be performed on the basis 
of this work includes the physiological and pathological response to drug 
and radiation treatments of sensitive tissues, such as thymus, spleen and 
small intestinal epithelium. With this work the functional role of DRAGO 
protein has been initiated and further studies identified to explore more 
fully the specific mechanisms in which DRAGO is involved in the apoptotic 
response. This important issue remains to be solved with future 
experiments taking advantage of the DRAGO-null mouse line generated. 
Nevertheless, DRAGO might be considered a novel potential target for the 
development of new therapeutic anticancer agents.
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CHAPTER 12 
APPENDICES
12.1 List of abbreviations
3-MeAde 3-methyladenine
53BP1 p53 binding protein 1
5-FU  5-fluorouracil
AD activator domain
AIF apoptosis inducing factor
ALL acute lymphoblastic leukaemia
APAF-1 apoptotic protease-activating factor 1
AT annealing temperature
ATM ataxia-telangectasia mutated gene
ATR ATM-related gene
ATRIP ATR-interacting protein
AUR K Aurora kinase
BAI-1 brain-specific angiogenesis inhibitor 1
BER base-excision repair
bFGF basic fibroblast growth factor
BH Bcl-2 homology
BLM Bloom syndrome protein
bp base pair
BRCA1 breast cancer 1
CAK CDK-activating kinase
CDK cyclin-dependent kinases
CFU colony forming unit
clAP1 cellular inhibitor of apoptosis protein 1
CK casein kinase
CMV cytomegalo virus
CPT campthotecin
dam DNA adenine methylation
DBD DNA-binding domain
dcm DNA cytosine methylation
DD death domain
DDP cisplatinum
DIABLO direct lAP-binding protein with low pi
DISC death-inducing-signalling-complex
DMSO dimethyl sulfoxide I
DNA Deoxyribonucleic acid
DNA-PK DNA-dependent protein kinase
dNTPs nucleotides
DR death receptor
DRAGO DRugs Activated Gene Overexpressed
DSB double-strand breaks
dsRNA double-stranded RNA
DX doxorubicin
EndoG endonucleases G
ER endoplasmatic reticulum
GFP green fluorescent protein
GI50 growth inhibitory concentration by 50%
GST Glutathione S-transferase
H2AX Histone-2A family, member X
HAT histone acetyl-transferase
HAUSP herpesvirus associated ubiquitin-specific protease
HD AC histone deacetylase
HE heterozygous
HEBS HEPES-Buffered Saline
HH head-to-head
HJ Holliday junctions
HO homozygous
HPV human papillomavirus
HR Homologous recombination
HT head-to-tail
Htr2A high temperature requirement A2
IAP inhibitors of apoptosis proteins
IPTG isopropyl (3-D-thiogalactoside
IR ionizing radiation
JNK Jun N-terminal kinase
Kb kilobase pair
KO knock-out
LB Luria-Bertani
maspin mammary serine protease inhibitor
MCS multiple cloning site
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MDC1 mediator of DNA damage chekpoint 1
MDM2 mouse double minute 2
MEF mouse embryo fibroblasts
MMR mismatch repair
MPG 3-MeAde DNA-glycosylase gene
mRNA messanger ribonucleic acid
MSH2 MutS homologue-2
NBS1 Nijmegen breakage syndrome-1
NER nucleotide-excision repair
NES nuclear exportation signal
NHEJ Non-Homologous End-Joining
NLS nuclear localization signal
NO nitric oxide
OD oligomerization domain
P/CAF p300/CBP-associated HAT
p53BS p53 binding site
p53RE p53 responsive element
PAC1 pro-apoptotic phosphate
PAGE polyacrylamide gel electrophoresis
P A M plasminogen activator inhibitor 1
pBS pBluescript-SKII+
PBS phosphatase buffer saline
PCR polymerase chain reaction
PERP p53 apoptosis effector related to PM P-22
PI phosphatidylinositol
PI3K phosphatidylinositol 3- kinase
PIDD p53-induced protein with a death domain
PIG p53-induced gene
PIKK PI3K-like protein kinases
PIP2 phosphatidylinositol 4,5-bisphosphate
PIP3 phosphatidylinositol 3,4,5-triphosphate
PKC protein casein C
PML promyelocytic leukaemia
PRD proline-rich region
PUMA p53 up-regulated modulator of apoptosis
RNA ribonucleic acid
ROS reactive oxygen species
RPA replication protein A
RTS Rothmund-Thomson syndrome
SAM domain sterile alpha motive domain
SCE sister chromatid exchange
SDS sodium dodecyl sulphate
Smac second mitochondria-derived activator of caspases
SMC1 structural maintenance of chromosomes 1
SSCP single strand conformation polymorphism
ssDNA single-strand DNA
TA domain transactivation domain
TAF TBP-associated factor
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TBP TATA box-binding protein
TD tetramerization domain
TNF-R tumor necrosis factor receptor
TRAIL TNF-related apoptosis-inducing ligand
TSP-1 thrombospondin-1
TT tail-to-tail
UK-HGMP-RC UK Human Genome Mapping Project Resource Centre
USP ubiquitin-specific protease
UTR untranslated region
UV ultra violet
UV-DDB UV-damage DNA-binding proteins
WRN Werner Syndrome protein
W T wild-type
XIAP x-linked inhibitor of apoptosis protein
XPC xeroderma pigmentosum complementation group C
YY1 Yi Yang 1
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